
<html lang="en"     class="pb-page"  data-request-id="586fe728-d26a-4bae-a95c-63bdce32caad"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-23;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.0c00797"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery and Early Clinical Development of Isobutyl 1-[8-Methoxy-5-(1-oxo-3H-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxylate (LEO 39652), a Novel “Dual-Soft” PDE4 Inhibitor for Topical Treatment of Atopic Dermatitis" /></meta><meta name="dc.Creator" content="Jens  Larsen" /></meta><meta name="dc.Creator" content="Maja  Lambert" /></meta><meta name="dc.Creator" content="Henrik  Pettersson" /></meta><meta name="dc.Creator" content="Thomas  Vifian" /></meta><meta name="dc.Creator" content="Mogens  Larsen" /></meta><meta name="dc.Creator" content="Anna  Ollerstam" /></meta><meta name="dc.Creator" content="Pontus  Hegardt" /></meta><meta name="dc.Creator" content="Cecilia  Eskilsson" /></meta><meta name="dc.Creator" content="Steen  Laursen" /></meta><meta name="dc.Creator" content="Anders  Soehoel" /></meta><meta name="dc.Creator" content="Tine  Skak-Nielsen" /></meta><meta name="dc.Creator" content="Lene M.  Hansen" /></meta><meta name="dc.Creator" content="Nina Ø.  Knudsen" /></meta><meta name="dc.Creator" content="Stefan  Eirefelt" /></meta><meta name="dc.Creator" content="Morten D.  Sørensen" /></meta><meta name="dc.Creator" content="Tatiana G.  Stilou" /></meta><meta name="dc.Creator" content="Simon F.  Nielsen" /></meta><meta name="dc.Description" content="We describe the design of a novel PDE4 scaffold and the exploration of the dual-soft concept to reduce systemic side effects via rapid elimination: introducing ester functionalities that can be ina..." /></meta><meta name="Description" content="We describe the design of a novel PDE4 scaffold and the exploration of the dual-soft concept to reduce systemic side effects via rapid elimination: introducing ester functionalities that can be ina..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 15, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00797" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00797" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00797" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00797" /></link>
        
    
    

<title>Discovery and Early Clinical Development of Isobutyl 1-[8-Methoxy-5-(1-oxo-3H-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxylate (LEO 39652), a Novel “Dual-Soft” PDE4 Inhibitor for Topical Treatment of Atopic Dermatitis | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00797" /></meta><meta property="og:title" content="Discovery and Early Clinical Development of Isobutyl 1-[8-Methoxy-5-(1-oxo-3H-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxylate (LEO 39652), a Novel “Dual-Soft” PDE4 Inhibitor for Topical Treatment of Atopic Dermatitis" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0020.jpeg" /></meta><meta property="og:description" content="We describe the design of a novel PDE4 scaffold and the exploration of the dual-soft concept to reduce systemic side effects via rapid elimination: introducing ester functionalities that can be inactivated in blood as well as by the liver (dual-soft) while being stable in human skin. Compound 40 was selected as a clinical candidate as it was potent and rapidly degraded by blood and liver to inactive metabolites and because in preclinical studies it showed high exposure at the target organ: the skin. Preclinical and clinical data are presented confirming the value of the dual-soft concept in reducing systemic exposure." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00797"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00797">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00797&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00797&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00797&amp;href=/doi/10.1021/acs.jmedchem.0c00797" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 14502-14521</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01480" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.0c00978" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and Early Clinical Development of Isobutyl 1-[8-Methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylate (LEO 39652), a Novel “Dual-Soft” PDE4 Inhibitor for Topical Treatment of Atopic Dermatitis</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Jens Larsen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jens Larsen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Design, LEO Pharma Global Research & Development, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jens++Larsen">Jens Larsen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maja Lambert</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maja Lambert</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Design, LEO Pharma Global Research & Development, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maja++Lambert">Maja Lambert</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Henrik Pettersson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Henrik Pettersson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Design, LEO Pharma Global Research & Development, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Henrik++Pettersson">Henrik Pettersson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thomas Vifian</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas Vifian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Design, LEO Pharma Global Research & Development, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas++Vifian">Thomas Vifian</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mogens Larsen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mogens Larsen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Design, LEO Pharma Global Research & Development, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mogens++Larsen">Mogens Larsen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anna Ollerstam</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anna Ollerstam</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Skin Research, LEO Pharma Global Research & Development, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anna++Ollerstam">Anna Ollerstam</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pontus Hegardt</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pontus Hegardt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Clinical Operations Projects, LEO Pharma Global Research & Development, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pontus++Hegardt">Pontus Hegardt</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cecilia Eskilsson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cecilia Eskilsson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Preclinical Development, LEO Pharma Global Research & Development, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cecilia++Eskilsson">Cecilia Eskilsson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Steen Laursen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steen Laursen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Preclinical Development, LEO Pharma Global Research & Development, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steen++Laursen">Steen Laursen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anders Soehoel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anders Soehoel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Clinical Pharmacology, LEO Pharma Global Research & Development, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anders++Soehoel">Anders Soehoel</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tine Skak-Nielsen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tine Skak-Nielsen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Skin Research, LEO Pharma Global Research & Development, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tine++Skak-Nielsen">Tine Skak-Nielsen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lene M. Hansen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lene M. Hansen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Early Formulation and Analytics, LEO Pharma Global Research & Development, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lene+M.++Hansen">Lene M. Hansen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nina Ø. Knudsen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nina Ø. Knudsen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Early Formulation and Analytics, LEO Pharma Global Research & Development, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nina+%C3%98.++Knudsen">Nina Ø. Knudsen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stefan Eirefelt</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stefan Eirefelt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Design, LEO Pharma Global Research & Development, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stefan++Eirefelt">Stefan Eirefelt</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Morten D. Sørensen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Morten D. Sørensen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Design, LEO Pharma Global Research & Development, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Morten+D.++S%C3%B8rensen">Morten D. Sørensen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tatiana G. Stilou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tatiana G. Stilou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Skin Research, LEO Pharma Global Research & Development, 2750 Ballerup, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tatiana+G.++Stilou">Tatiana G. Stilou</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Simon F. Nielsen</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Simon F. Nielsen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Design, LEO Pharma Global Research & Development, 2750 Ballerup, Denmark</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 0045 2551 8760. E-mail: <a href="/cdn-cgi/l/email-protection#0271646c6669426e676d2f726a63706f632c616d6f"><span class="__cf_email__" data-cfemail="c5b6a3aba1ae85a9a0aae8b5ada4b7a8a4eba6aaa8">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Simon+F.++Nielsen">Simon F. Nielsen</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8263-4469" title="Orcid link">http://orcid.org/0000-0001-8263-4469</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00797&amp;href=/doi/10.1021%2Facs.jmedchem.0c00797" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 14502–14521</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 15, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>18 May 2020</li><li><span class="item_label"><b>Published</b> online</span>15 October 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00797" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00797</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D14502%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJens%2BLarsen%252C%2BMaja%2BLambert%252C%2BHenrik%2BPettersson%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D23%26contentID%3Dacs.jmedchem.0c00797%26title%3DDiscovery%2Band%2BEarly%2BClinical%2BDevelopment%2Bof%2BIsobutyl%2B1-%255B8-Methoxy-5-%25281-oxo-3H-isobenzofuran-5-yl%2529-%255B1%252C2%252C4%255Dtriazolo%255B1%252C5-a%255Dpyridin-2-yl%255Dcyclopropanecarboxylate%2B%2528LEO%2B39652%2529%252C%2Ba%2BNovel%2B%25E2%2580%259CDual-Soft%25E2%2580%259D%2BPDE4%2BInhibitor%2Bfor%2BTopical%2BTreatment%2Bof%2BAtopic%2BDermatitis%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D14521%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00797"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1538</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">2</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00797" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and Early Clinical Development of Isobutyl 1-[8-Methoxy-5-(1-oxo-3H-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxylate (LEO 39652), a Novel “Dual-Soft” PDE4 Inhibitor for Topical Treatment of Atopic Dermatitis&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jens&quot;,&quot;last_name&quot;:&quot;Larsen&quot;},{&quot;first_name&quot;:&quot;Maja&quot;,&quot;last_name&quot;:&quot;Lambert&quot;},{&quot;first_name&quot;:&quot;Henrik&quot;,&quot;last_name&quot;:&quot;Pettersson&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;Vifian&quot;},{&quot;first_name&quot;:&quot;Mogens&quot;,&quot;last_name&quot;:&quot;Larsen&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;Ollerstam&quot;},{&quot;first_name&quot;:&quot;Pontus&quot;,&quot;last_name&quot;:&quot;Hegardt&quot;},{&quot;first_name&quot;:&quot;Cecilia&quot;,&quot;last_name&quot;:&quot;Eskilsson&quot;},{&quot;first_name&quot;:&quot;Steen&quot;,&quot;last_name&quot;:&quot;Laursen&quot;},{&quot;first_name&quot;:&quot;Anders&quot;,&quot;last_name&quot;:&quot;Soehoel&quot;},{&quot;first_name&quot;:&quot;Tine&quot;,&quot;last_name&quot;:&quot;Skak-Nielsen&quot;},{&quot;first_name&quot;:&quot;Lene&quot;,&quot;last_name&quot;:&quot;M. Hansen&quot;},{&quot;first_name&quot;:&quot;Nina&quot;,&quot;last_name&quot;:&quot;Ø. Knudsen&quot;},{&quot;first_name&quot;:&quot;Stefan&quot;,&quot;last_name&quot;:&quot;Eirefelt&quot;},{&quot;first_name&quot;:&quot;Morten&quot;,&quot;last_name&quot;:&quot;D. Sørensen&quot;},{&quot;first_name&quot;:&quot;Tatiana&quot;,&quot;last_name&quot;:&quot;G. Stilou&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;F. Nielsen&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;14502-14521&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00797&quot;},&quot;abstract&quot;:&quot;We describe the design of a novel PDE4 scaffold and the exploration of the dual-soft concept to reduce systemic side effects via rapid elimination: introducing ester functionalities that can be inactivated in blood as well as by the liver (dual-soft) while being stable in human skin. Compound 40 was selected as a clinical candidate as it was potent and rapidly degraded by blood and liver to inactive metabolites and because in preclinical studies it showed high exposure at the target organ: the skin. Preclinical and clinical data are presented confirming the value of the dual-soft concept in reducing systemic exposure.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00797&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00797" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00797&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00797" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00797&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00797" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00797&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00797&amp;href=/doi/10.1021/acs.jmedchem.0c00797" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00797" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00797" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00797%26sid%3Dliteratum%253Aachs%26pmid%3D33054196%26genre%3Darticle%26aulast%3DLarsen%26date%3D2020%26atitle%3DDiscovery%2Band%2BEarly%2BClinical%2BDevelopment%2Bof%2BIsobutyl%2B1-%255B8-Methoxy-5-%25281-oxo-3H-isobenzofuran-5-yl%2529-%255B1%252C2%252C4%255Dtriazolo%255B1%252C5-a%255Dpyridin-2-yl%255Dcyclopropanecarboxylate%2B%2528LEO%2B39652%2529%252C%2Ba%2BNovel%2B%25E2%2580%259CDual-Soft%25E2%2580%259D%2BPDE4%2BInhibitor%2Bfor%2BTopical%2BTreatment%2Bof%2BAtopic%2BDermatitis%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D23%26spage%3D14502%26epage%3D14521%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292178" title="Organic compounds">Organic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=292143" title="Metabolism">Metabolism</a>,</li><li><a href="/action/doSearch?ConceptID=291675" title="Stability">Stability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/jmcmar.2020.63.issue-23/20201210/jmcmar.2020.63.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00797&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We describe the design of a novel PDE4 scaffold and the exploration of the dual-soft concept to reduce systemic side effects via rapid elimination: introducing ester functionalities that can be inactivated in blood as well as by the liver (dual-soft) while being stable in human skin. Compound <b>40</b> was selected as a clinical candidate as it was potent and rapidly degraded by blood and liver to inactive metabolites and because in preclinical studies it showed high exposure at the target organ: the skin. Preclinical and clinical data are presented confirming the value of the dual-soft concept in reducing systemic exposure.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07357" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07357" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by eczematous lesions and intense itching.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Skin barrier dysfunction and immune cell activation participate in the complex pathophysiology of AD. The immune activation in AD lesions is dominated by Th2 cytokines (IL4, IL5, IL13) and Th22 (IL22), but the Th1 and Th17 cytokines also play a role in more chronic AD.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The disease is most prevalent during early infancy and childhood, with a prevalence of up to 20% of children and 3% in adults. Limited topical treatment options exist, namely, topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). Both TCSs and TCIs are coupled to some side effects. Only recently crisaborole<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> was approved as the first topical PDE4 treatment for mild to moderate AD. The enzyme phosphodiesterase (PDE) 4 is found in most immune cells, and it breaks down the secondary messenger cyclic adenosine monophosphate (cAMP). PDE4 inhibitors induce increased levels of cAMP in leukocytes which are associated with suppression of a number of proinflammatory cytokines and other inflammatory mediators such as prostaglandin E2.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Increased PDE activity has been observed in leukocyte preparation of patients with AD,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and this further emphasizes the relevance of pharmacological PDE4 intervention in AD.</div><div class="NLM_p">We aimed to develop a topical treatment for severe AD. Topical treatment of severe atopic dermatitis frequently requires application of drug to more than 30% of the body surface, the total applied dose being much higher than what is usually used for oral dosing. As the atopic dermatitis skin barrier is highly compromised, it is probable that a significant proportion of the drug will be absorbed.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> This could lead to significant systemic exposure of the applied compound and potential adverse effects such as nausea, vomiting, and diarrhea observed after systemic treatment with PDE4 inhibitors.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_p">Previously we described the discovery of <b>1</b> (see <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), a “soft”<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> PDE4 inhibitor designed to achieve high local skin concentrations but low systemic exposure upon topical application due to a high hepatic clearance.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> The compound was proven to be efficacious in AD patients,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> but nevertheless, the clinical development of <b>1</b> was discontinued in part due to safety concerns related to the systemic exposure of metabolites of the candidate drug. In most patients <b>1</b> was rapidly converted to inactive metabolites as predicted, but unfortunately in some individuals a different metabolic pathway was observed resulting in high levels of an active pyridine <i>N</i>-oxide metabolite.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Examples of PDE4 inhibitors known prior to the discovery of the new triazolopyridine scaffold described in this paper.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00797&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">This publication describes our effort to further reduce the systemic exposure upon topical administration and mitigate the risk of producing active metabolites, an exercise that should minimize the risk of PDE4-mediated systemic side effects. We set out to design “dual-soft” PDE4 inhibitors, i.e., compounds with even higher systemic clearance than that of <b>1</b>, driven by extrahepatic as well as hepatic metabolism of the drug.</div><div class="NLM_p">The approach was to take advantage of esterase-mediated extrahepatic compound degradation in, for example, blood. The major classes of human esterases are the carboxylesterases (CES1 and CES2), paraoxonases (PON1, PON2, and PON3), butyrylcholinesterase (BChE), and acetylcholineesterase (AChE).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Despite the fact that tissue distribution in humans is not fully described for all esterases, some differences in esterase expression in for instance skin versus blood have been reported.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Therefore, it was speculated that it should be possible to identify ester-containing compounds suitable for topical delivery,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> compounds that would be sufficiently stable in skin to provide the desired pharmacological effect but at the same time rapidly degraded both in blood and by the liver. The dual elimination mechanism should ensure very fast clearance and at the same time mitigate the risk of interpersonal variations in drug levels due to polymorphism in esterases (and other metabolizing enzymes).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> By applying this dual elimination strategy, we anticipated that the systemic levels of parent and potential active metabolites would be minimized.</div><div class="NLM_p">In this paper we report the discovery of a novel series of PDE4 inhibitors and our efforts to maximize the systemic clearance of these, using screening models of human skin and blood stability together with stability in human liver microsomes to guide the design.</div><div class="NLM_p">Ultimately, compound <b>40</b> was selected as a clinical development candidate, and in this paper, we report an in-depth characterization of its metabolism and pharmacokinetic profile as well as the early clinical data obtained with this compound.</div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0019.gif" alt="" id="GRAPHIC-d7e376-autogenerated" /></img></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36518" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36518" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Scaffold Exploration: Focus on <i>in Vitro</i> Potency</h3><div class="NLM_p">During the lead optimization campaign that led to the nomination of our first topical PDE4 clinical development candidate <b>1</b>, we also explored chemical scaffolds with the trialkoxyphenyl top-part replaced by a triazolopyridine core as exemplified by compounds <b>2</b> and <b>3</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> We learned that for these keto-linked triazolopyridine compounds the cyclopropyl group of compound <b>3</b> is very important for PDE4 inhibition. Indeed, we believe that it occupies the same “lipophilic pocket” in PDE4 as the cyclopropyl of roflumilast <b>4</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Overlay of roflumilast and compound <b>3</b> docked in the roflumilast structure <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XOQ">1XOQ</a>.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Compound <b>3</b> was docked in the enol form previously described for compound <b>1</b>.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The figure was made using Maestro, Schrödinger, LLC, New York, NY, 2019.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00797&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The catalytic binding pocket of the PDE4 enzyme contains two metal ions, which previously have been shown to be crucial for design of PDE4 inhibitors. The compounds shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> are all examples of that, as they are believed to gain significant affinity via water mediated interactions between their pyridine nitrogens and one of these two metals ions (see <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Binding mode of roflumilast taken from <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XOQ">1XOQ</a>.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Shown are the water molecules coordinating the Mg<sup>2+</sup> metal ion and the water mediated interactions with the pyridine nitrogen of Roflumilast. The figure was made using Maestro, Schrödinger, LLC, New York, NY, 2019.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00797&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Thus, it came as no surprise that removing this water meditated interaction by substituting the pyridine ring with a phenyl led to reduced potency. The potency of the phenyl-substituted analogue of <b>1</b> dropped 10-fold compared to that of <b>1</b> (data not shown). In contrast, in our search for a new, simplified scaffold we were pleasantly surprised that <b>5</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), despite removal of the chlorines, keto linker and no option for interaction with the metal atoms, still showed promising potency. It should be noted that the phenyl group in the simpler compound <b>5</b> most likely will not occupy the same position as the pyridine ring of <b>1</b>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structure–Activity Relationship of Early Triazolopyridine Compounds<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0010.gif" alt="" id="GRAPHIC-d7e493-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0011.gif" alt="" id="gr10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">All data represent an average of <i>n</i> ≥ 3 test occasions; standard deviations are as shown.</p></div></div><div></div></div><div class="NLM_p">On the basis of the interactions observed for roflumilast in the crystal structure, we hypothesized that introduction of a hydrogen bond acceptor in compound <b>5</b> could improve potency by reestablishing interactions with the metal ion. Pleasingly, introduction of an acetyl group in the 3-position of the lower aromatic ring supported this hypothesis, with <b>6</b> being more than 40 times more potent compared to <b>5</b>. On the basis of this finding, we decided to further explore the triazolopyridine scaffold.</div><div class="NLM_p">Interestingly a very steep potency SAR was revealed when we evaluated analogues with different substitutions on the lower aromatic ring. For instance, as exemplified by compounds <b>7</b> and <b>8</b>, increased bulk around the carbonyl in the 3-position is not tolerated. Changing the attachment point of the acetyl group from the 3- to the 4-position gave compound, <b>9</b>, with potency comparable to the unsubstituted phenyl analogue <b>5</b>. Again an increased size of the keto substituent reduced the PDE4 activity even further (<b>10</b> and <b>11</b> vs <b>9</b>).</div><div class="NLM_p">A key finding was the importance of the orientation of the carbonyl group. Compound <b>12</b> with the carbonyl group pointing upward is significantly weaker PDE4 inhibitor than <b>6</b>, whereas <b>13</b> with the carbonyl orientation downward apparently locks the conformation in a much more favorable manner, consistent with a good fit for <b>13</b> to a pharmacophore model based on the docked conformation of <b>3</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). In contrast, no conformation of <b>12</b> is able to fit the pharmacophore.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Fit of <b>13</b> (shown in green) to five-point pharmacophore model based on the docked binding model of <b>3</b> (shown in orange). The pharmacophore model and fit were done with Phase, Schrödinger Inc. The figure was made using Maestro, Schrödinger, LLC, New York, NY, 2019.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00797&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition, the regioisomeric cyclic ketone <b>14</b> possessed PDE4 inhibition comparable to that of both <b>6</b> and <b>13</b>, again highlighting the importance of both size and orientation of the keto group. We assumed that these compounds interact with the target via the carbonyl lone pairs, and to further explore and substantiate this hypothesis, the nitrile substituted analogue <b>15</b> was synthesized. The cyano nitrogen lone pair of <b>15</b> should in principle be able to pick up a similar interaction as achieved by the carbonyl lone pairs of <b>6</b>, <b>13</b>, and <b>14</b>. As comparable potencies were observed, we assume they all make similar interactions.</div><div class="NLM_p">A wider range of substituents on the lower aromatic ring were evaluated, but in general, other than those analogues presented in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, they led to significantly reduced <i>in vitro</i> potency.</div><div class="NLM_p last">Having identified a new scaffold and explored possible substitution points on the bottom ring, our attention focused on the top part of the molecule. Modeling, as well as in house SAR previously generated on the keto-linked scaffold series shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, had taught us that substituents are not allowed on the two unsubstituted positions on the left-hand side of the upper aromatic ring. Likewise, we had learned that a methoxy group seems to be one of the most preferred substituents on top. Hence substitution appeared to be tolerated only in the 1-postion of the cyclopropylpropyl ring. Many substituents were evaluated, and during this exercise secondary amides with the carbonyl directly attached to the cyclopropyl ring revealed themselves as some of the most interesting analogues as exemplified by <b>16</b>, with 10 times greater potency than the unsubstituted analogue <b>15</b>.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Optimization of Skin and Blood Stability</h3><div class="NLM_p">Having established an understanding of the potency SAR, the attention was shifted toward the <i>in vitro</i> PK of the compounds, focusing in particular on optimizing the balance between blood instability and skin stability. We employed an empirical screening approach rather than utilizing individual recombinant esterases.</div><div class="NLM_p">For investigation of the instability in blood we measured degradation in freshly drawn human whole blood. As 90% of the upper part of human skin (the epidermis) consists of keratinocytes, we rationalized that stability of compounds in keratinocyte suspensions could function as a primary human skin stability assay.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The chemical stability was also evaluated as certain classes of the ester-containing compounds turned out to be chemically unstable under assay/physiological conditions.</div><div class="NLM_p">For “soft” and “dual-soft” compounds to be attractive the main metabolite(s) must have a significantly lower PDE4 activity than the parent as only this will minimize the risk of potential, systemic, target-related side effects. This may be difficult to achieve for non-ester “soft” compounds as liver metabolism often results in small changes and the metabolites can sometimes be as active or even more active than the parent compound (as seen for the pyridine <i>N</i>-oxide of compound <b>1</b>).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> By utilization of ester cleavage, inactive metabolites are intuitively easier to obtain as ester cleavage results in a significant change in properties (size, polarity, and charge) of the compound. Despite this, loss of activity is not guaranteed and we made a thorough evaluation of the ester metabolites (alcohols or acids) along with the parent ester-containing molecules. Our preferred profile was to achieve at least a 10-fold decrease in potency upon hydrolysis.</div><div class="NLM_p last">Considering the SAR of the newly discovered scaffold, we deemed that two regions seemed amenable for introduction of a “dual-soft spot”: esters with the carbonyl attached directly to the lower aromatic ring and esters linked to the cyclopropyl group.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Strategy A: Esters in the Lower Part of the Molecule</h3><div class="NLM_p">Due to the steep SAR described above, we decided to evaluate only methyl esters and lactones with the carbonyl directly attached to either the 3- or 4-position of the lower aromatic ring. On the basis of modeling, it was reasonable to assume that lactones would mimic the cyclic ketones and that the interaction of the carbonyl group with the target should be kept. Similarly, for the methyl esters we expected to obtain potency somewhat between that of the methyl and ethyl ketones.</div><div class="NLM_p"><i>The 3-Position.</i> The 3-substituted methyl ester <b>17</b> was, as predicted, not the most potent compound, but addition of small lipophilic amides at the cyclopropyl ring did increase the PDE4 activity to an acceptable level, as illustrated with the isobutylamide substituted analogues, <b>18</b> shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. The putative acid metabolites were significantly less potent then the parent ester. Unfortunately compounds from this scaffold series with a variety of amide substituents turned out to be too stable in human whole blood.<named-content content-type="anchor" rid="tbl3" type="simple"></named-content></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Esters on the Lower Aromatic Ring<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0012.gif" alt="" id="GRAPHIC-d7e677-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0013.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">All data represent an average of <i>n</i> ≥ 3 test occasions; standard deviations are as shown.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Number in parentheses is the IC<sub>50</sub> of the putative metabolite formed upon hydrolysis.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last"><i>In vitro</i> clearance is determined in human liver microsomes, and degradation half-life is determined in fresh human whole blood and human epidermal keratinocytes.</p></div></div><div></div></div><div class="NLM_p">The lactone <b>19</b> showed a similar effect to the methyl ester, being significantly less potent than the cyclic ketone <b>13</b>. Apparently, the extra oxygen makes an unfavorable interaction with the target. On the positive side, <b>19</b> did meet our primary criteria for both skin stability and whole blood instability. Furthermore, hydrolysis of the lactone led to a metabolite with reduced PDE4 activity. Again, substitution with small lipophilic amides at the cyclopropyl ring, as illustrated with <b>20</b>, reestablished the lost PDE4 activity, but unfortunately, it also increased the whole blood stability. Further optimization attempts did not lead to compounds with the desired <i>in vitro</i> profile.</div><div class="NLM_p"><i>The 4-Position.</i> In line with the SAR of compounds <b>9</b>–<b>11</b>, compounds <b>21</b> and <b>22</b> with the methyl ester in the 4-position had rather poor PDE4 activity. In addition, the putative acid metabolites formed upon hydrolysis were found to be even more potent than the parent esters in the biochemical enzyme assay. Consequently the 4-substituted ester series was abandoned.</div><div class="NLM_p last">The properties of the lactone <b>23</b> did appear rather attractive. The compound was equipotent with the corresponding carbocyclic analogue <b>14</b>, and in contrast to lactones with the carbonyl in the 3-position (<b>19</b> and <b>20</b>), the extra oxygen in the ring was well tolerated. It was rapidly degraded both in whole blood and by the liver and was stable in our primary skin stability assay, and an acceptable decrease in PDE4 activity was observed upon hydrolysis. A range of analogues substituted in most cases with lipophilic amide functionalities, as exemplified by compound <b>24</b>, were as expected highly potent and, as desired, highly unstable in whole blood as well. The potency shifts observed upon hydrolysis were acceptable, but most importantly, the introduction of the amide functionality disappointingly led to an unacceptable and quite surprising poor performance in our primary skin stability assay. Thus, in the end we did not manage to identify any potential candidates from this series, balancing blood and HLM instability with keratinocyte stability proving too challenging. Compound <b>23</b> appeared to be the most promising compound, but lower than desired HLM clearance in the end disqualified the compound.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Strategy B: Esters in the Upper Part of the Molecule</h3><div class="NLM_p">The second option we explored was to introduce an ester in the upper right-hand side of the molecule. Two subseries were evaluated, the “alcohol” and the “acid” series (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Structure–Activity Relationships in the “Alcohol” and “Acid” Series</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0014.gif" alt="" id="GRAPHIC-d7e772-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0015.gif" alt="" id="gr12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">All data represent an average of <i>n</i> ≥ 3 test occasions; standard deviations are as shown.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last"><i>In vitro</i> clearance is determined in human liver microsomes, and degradation half-life is determined in fresh human whole blood and human epidermal keratinocytes.</p></div></div><div></div></div><div class="NLM_p">In the “alcohol” series, esters were based on the three potential alcohol metabolites <b>25</b>–<b>27</b>. From a potency perspective the most promising metabolite appeared to be <b>25</b>, being only moderately potent against PDE4 and even less potent in the cell-based assay. Further extension of the chain resulted in alcohols (<b>26</b>, <b>27</b>) with higher than desired PDE4 inhibitor activity, and we were not able to optimize the potency of the corresponding esters to achieve the >10-fold difference that we had defined as our minimum target criteria (data not shown). Consequently, we focused on ester derivatives of <b>25</b> using both aliphatic and heteroaromatic acids. They all showed properties similar to those of ester <b>28</b>. They were potent, had high liver instability, and were degraded reasonable quickly in blood but had very low stability in human keratinocytes. It is speculated that esters from the “alcohol series” may be degraded by a different esterase compared to the other compounds described in this paper and that this esterase is present in both skin and blood at significant levels.</div><div class="NLM_p">We abandoned the “alcohol series” and focused our attention toward the “acids”. Optimization of this series also started with an evaluation of the potential metabolites, and again, in line with what we observed with the “alcohols” the acid metabolites became more potent the further the polar (acid) functionality was away from the aromatic ring. On the basis of the known PDE4 crystal structures, extending the polar functionality places it closer to the solvent front of catalytic enzyme pocket. Consequently, analogues with the carboxylic acid attached directly to the cyclopropyl group (<b>29</b>) and to a slighter extent the ones having a methylene spacer (<b>30</b>) seemed the most appealing to us from a potency point of view. The ethylene linked metabolite <b>31</b> was on the other hand considered less useful as the metabolite per se was quite active and the prepared esters were only moderately more potent than the acid <b>31</b> (data not shown).</div><div class="NLM_p">Several ester derivatives of acid <b>29</b>, like compound <b>32</b>, were synthesized. In general, these compounds were potent; they had adequate skin stability and rapid turnover in HLM but were simply too slowly degraded in blood.</div><div class="NLM_p">Making esters of acid <b>30</b> resulted in compounds with profiles quite like that of <b>32</b>, the main difference being an undesired and unexpected increase in HLM stability as well as a reduced potency shift observed upon ester hydrolysis.</div><div class="NLM_p">In conclusion, esters with the carbonyl directly attached to the cyclopropyl group held the most promise with regard to parent potency, the potency shift upon hydrolysis, skin stability, and hepatic instability, but they lacked the desired whole blood instability.</div><div class="NLM_p last">Concluding on “strategy A” and “strategy B”, we found it quite challenging to balance all of the desired properties in one molecule, in particular, the need for high skin stability and blood instability.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Strategy C: Esters in Both Parts of the Molecule</h3><div class="NLM_p">The “alcohol series” and the analogues exemplified by compound <b>24</b> were discarded due to unacceptable skin instability. For the rest of the compounds described so far, the main issue was too slow degradation in blood. In a final attempt to obtain compounds with the desired <i>in vitro</i> PK and potency profile, we went all in, incorporating two ester functionalities in the molecules. The 3,4-lactone, exemplified by compound <b>23</b>, was identified as the most promising from “strategy A”, and it was therefore chosen as the preferred bottom part, as we hoped it would ensure both potency and blood instability. Combining this with a carboxylic ester directly attached to the cyclopropyl group, we explored the impact of varying the ester alkyl group. (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Diester Analogues in the Triazolopyridine Scaffold</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0016.gif" alt="" id="GRAPHIC-d7e872-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0017.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">All data represent an average of <i>n</i> ≥ 3 test occasions; standard deviations are as shown.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last"><i>In vitro</i> clearance is determined in human liver microsomes, and degradation half-life is determined in fresh human whole blood and human epidermal keratinocytes.</p></div></div><div></div></div><div class="NLM_p">Even the simplest alkyl esters turned out to be active in this series. An increase in the size of the substituent going from methyl (<b>33</b>) to ethyl (<b>34</b>) to <i>n</i>-propyl (<b>35</b>) gradually increased potency against PDE4, and larger lipophilic substituents like cyclopentyl (<b>43</b>), cyclohexyl (<b>44</b>), and cycloheptyl (<b>45</b>) resulted in even more potent but perhaps also overall less attractive compounds. Esters with branched butyl substituents (<b>37</b>–<b>40</b>) balanced the <i>in vitro</i> potency and PK properties quite elegantly, whereas the closely related <i>n</i>-butyl and cyclobutyl ester analogues (<b>41</b> and <b>42</b>) did not perform as well in our primary skin stability assay. Finally, substituents with moderate polarity also seemed to be well tolerated with respect to both <i>in vitro</i> PK and potency, compounds <b>46</b>–<b>52</b> containing either an ether or alcohol functionality being representative examples. As polarity increased, a corresponding decrease in liver metabolism was observed, although we still considered it acceptable for a soft compound. In general compounds from this series were all rapidly degraded in blood as well as by the liver, and fortunately most of the compounds appeared to be stable in our human keratinocytes assay.</div><div class="NLM_p">On the basis of these data, three compounds, <b>38</b>, <b>40</b>, and <b>49</b>, were selected for further profiling toward a potential candidate selection. The profiling included <i>in vivo</i> efficacy observed in the mouse CHROXA model<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> as well as a more thorough PK and safety evaluation. Parent compounds and putative metabolites were synthesized and tested for off-target effects and in particular for metabolism and PK. Unexpectedly, compound <b>38</b> appeared to be phototoxic <i>in vitro</i> (3T3 assay), a property incompatible with topical dosing, and compound <b>49</b> exhibited genotoxicity in the GreenScreen<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> in the absence of S9.</div><div class="NLM_p">The profiling of compound <b>40</b> did not identify any particular safety concerns. Selectivity screening against PDE1–11 was performed for the parent compound as well as all possible metabolites (<b>50</b>, <b>53</b>, <b>54</b>, <b>55</b>, <b>72</b>). All compounds were highly selective against PDE4, and <b>40</b> showed no significant difference in inhibition of the four PDE4 isoforms (A, 1.2 nM; B, 1.2 nM; C, 3.0 nM; D, 3.8 nM). No significant signals were observed in a broad panel screen (kinases, GPCR, ion channels, and phosphatases). The emetic potential was evaluated in ferrets. Due to the extremely fast degradation in ferrets also, low exposure of <b>40</b> was observed. The iv dosing of 0.25 mg/kg provided the highest exposure (30 nM), and no signals of emesis were observed. Compound <b>40</b> was therefore selected as a clinical development candidate. An in-depth discussion of the data generated on this compound is provided in the sections below, while its basic potency and HLM, whole blood, and keratinocyte stabilities are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> along with those of its putative metabolites.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Structure–Activity Relationship of LEO 39652 (<b>40</b>) and Its Putative Metabolites</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0018.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">All data represent an average of <i>n</i> ≥ 3 test occasions; standard deviations are as shown.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last"><i>In vitro</i> clearance is determined in human liver microsomes, and degradation half-life is determined in fresh human whole blood and human epidermal keratinocytes.</p></div></div><div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Confirmation of Binding Mode</h3><div class="NLM_p">To obtain further insight into its binding mode, a crystal structure of <b>40</b> complexed to PDE4D was obtained (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). As expected, the lactone coordinates with one of metal ions, while the triazolopyridine core positions the methoxy and cyclopropyl groups of <b>40</b> in the expected lipophilic pockets. For the cyclopropyl this is determined by residues Phe414, Met431, and Phe446. In addition, the isobutyl group forms hydrophobic interactions with Met347 and Ile450. Overall, the observed binding mode is very similar (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B) to that previously observed for the binding of an analogue of LEO 29102 (<b>1</b>).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Crystal structure of <b>40</b> (shown in magenta) complexed with PDE4D solved to 1.6 Å. Key residues are shown in ball-and-stick representation. Residue numbering is as in ref <a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a>. (B) Overlay of <b>40</b> with the previously determined binding mode of an analogue (shown in green) of LEO 29102 (<b>1</b>).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The figure was made using Maestro, Schrödinger, LLC, New York, NY, 2019.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00797&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Chemistry</h3><div class="NLM_p">The compounds described in this paper can be obtained following the synthetic sequences outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a></div><figure id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Preparation of the Triazolopyridine Scaffold Series<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00797&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 10% Pd/C, 3 atm of H<sub>2</sub>, EtOH, rt, 91%; (b) <i>O</i>-(4-nitrobenzoyl)hydroxylamine or <i>O</i>-mesitylensulfonylhydroxylamine, DCM, rt, 88–91%; (c) aldehyde, dioxane, 90 °C, 76% (R = H), 88% (R = COOEt), 47% (R = CH<sub>2</sub>O-TBDPS); (d) TBAF, THF, rt, 79%; (e) NIS, BF<sub>3</sub>·2H<sub>2</sub>O, 84% (R = H), 77% (R = COOEt); 52% (R = CH<sub>2</sub>OH); (f) aq LiOH, dioxane, rt, 98%; (g) MsCl, Et<sub>3</sub>N, DCM, 0 °C, 91%; (h) NaCN, DMF, 80 °C, 66%; (i) HCl, MeOH, 70 °C, 81%; (j) LiOH, THF–MeOH–water, 50 °C, 69%; (k) dimethyl malonate, NaH, toluene, 110 °C, 68%; (l) 6 N HCl, 100 °C, 68%; (m) Sn<sub>2</sub>Me<sub>6</sub>, (PPh<sub>3</sub>)<sub>2</sub>Pd(OAc)<sub>2</sub>, toluene, 100 °C, 100%; (n) Ar–Br, Pd(PPh<sub>3</sub>)<sub>4</sub>, toluene, 100 °C; (o) Ar-B(OR)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, aq K<sub>2</sub>CO<sub>3</sub>, DME, 80 °C or Ar-B(OR)<sub>2</sub>, Pd<sub>2</sub> dba<sub>3</sub>, PCy<sub>3</sub>, K<sub>3</sub>PO<sub>4</sub>, dioxane–water, 110–145 °C; (p) BH<sub>3</sub>·THF, THF, 0 °C to rt; (q) R′OH, EDAC·HCl, DMAP, DCM, rt or R′NH<sub>2</sub>, HATU or PYBROP, Et<sub>3</sub>N, DMF, rt; (r) R″COCl, DIPEA, DCE, rt.</p></p></figure><div class="NLM_p">First, nitropyridine <b>56</b> was reduced under classic Pd/C-catalyzed hydrogenation conditions to the amine-pyridine <b>57</b>, which was then N-aminated at the pyridine nitrogen using either <i>O</i>-(4-nitrobenzoyl)hydroxylamine or <i>in situ</i> generated <i>O</i>-mesitylensulfonylhydroxylamine. The obtained 4-nitrobenzoate (<b>58</b>) or 2,4,6-trimethylbenzenesulfonate (<b>59</b>) 1,2-diamino-3-methoxypyridinium salts are thermally unstable. Thus, preferably, immediately after isolation they were reacted with the aldehyde of choice to form the key triazolopyridine core (<b>60</b>–<b>62</b>). The aldehydes are either commercially available or obtained in a few steps from readily available starting materials. NIS/BF<sub>3</sub>·2H<sub>2</sub>O-mediated iodination and, if required, classic deprotection reactions provided the 5-iodo-substiuted building blocks (<b>63</b>–<b>65</b>), which can then be coupled with the lower aromatic ring of interest using either Stille or, more commonly, classic Suzuki methodology. Mesylation of <b>63</b> followed by alkylation, decarboxylation, and/or hydrolysis allowed us to access the 5-iodo-substiuted building blocks <b>66</b> and <b>67</b> required to generate the metabolites of the “acid series”, <b>30</b> and <b>31</b>. A subsequent BH<sub>3</sub>·THF mediated reduction of these produced the “alcohol series” metabolite counterparts <b>26</b> and <b>27</b>. The esters and amides presented in this paper were in most cases synthesized with the aid of standard coupling reagents like EDAC and HATU, respectively.</div><div class="NLM_p">After <b>40</b> was nominated as clinical development candidate, a chemistry optimization effort led to the synthesis shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, allowing us to access multikilogram quantities of <b>40</b> with excellent purity (>99%) in six steps with an overall yield of 13%.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><figure id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of the Clinical PDE4 Inhibitor <b>40</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00797&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 5% Pd/C, 3 atm of H<sub>2</sub>, EtOAc–MeOH, rt, 97%; (b) HOSA, DBU, MeOH, 40 °C; (c) dimethyl cyclopropane-1,1-dicarboxylate, DBU, MeOH, 65 °C; (d) aq NaOH, rt; (e) aq H<sub>2</sub>SO<sub>4</sub>, rt, 49%; (f) NBS, DMF–MeCN, 60 °C, 66%; (g) bis(pinacolato)diborane, Pd(dppf)Cl<sub>2</sub>, KOAc, dioxane, 90 °C, 76%; (h) Pd(dppf)Cl<sub>2</sub>, Et<sub>3</sub>N, dioxane–water, 80 °C; (i) aq citric acid, rt, 69%; (j) iso-BuI, K<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C, 81%.</p></p></figure><div class="NLM_p last">With the optimized procedure column chromatography and isolation of energy rich 1,2-diamino-3-methoxypyridinium intermediates are no longer required. The aldehyde and the preferred N-amination reagent <i>O</i>-(4-nitrobenzoyl) hydroxylamine used in the original synthesis of <b>40</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) are (just like <b>57</b>) commercially available. However, to keep the synthesis cost-efficient, we did produce both reagents in three steps from cheap, readily available starting materials.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Thus, in practice the optimization effort did shorten the reaction sequence with eight steps.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Systemic PK and Metabolism</h3><div class="NLM_p">The “dual-soft” design strategy added extra complexity to understanding both the dermal and systemic PK and metabolism due to the two ester moieties in <b>40</b> which are hydrolyzed first in blood and subsequently by the liver and other extrahepatic tissues expressing esterases. Therefore, stability and metabolism of <b>40</b> and the putative hydrolytic metabolites <b>53</b>, <b>54</b>, and <b>55</b> were investigated in human, rat, minipig, and monkey blood as well as cryopreserved hepatocytes with the purpose of identifying preclinical species with a suitable exposure and metabolism profile of <b>40</b> for preclinical safety studies as well as making predictions of human PK.</div><div class="NLM_p">The half-life of <b>40</b> in blood was found to be short in all species evaluated, ranging from 2 to 19 min (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. <i>In Vitro</i> Stability in Human, Minipig, Monkey, and Rat Whole Blood</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center"><i>t</i><sub>1/2</sub> (min)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">human WB</th><th class="colsep0 rowsep0" align="center">monkey WB</th><th class="colsep0 rowsep0" align="center">minipig WB</th><th class="colsep0 rowsep0" align="center">rat WB</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="left">>60</td><td class="colsep0 rowsep0" align="left">>60</td><td class="colsep0 rowsep0" align="left">>60</td><td class="colsep0 rowsep0" align="left">34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="left">>60</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">>60</td><td class="colsep0 rowsep0" align="left">>60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>55</b></td><td class="colsep0 rowsep0" align="left">>60</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">>60</td><td class="colsep0 rowsep0" align="left">>60</td></tr></tbody></table></div></div><div class="NLM_p">Metabolite identification studies revealed a clear difference in the degradation pathways in blood <i>in vitro</i>, as lactone hydrolysis of <b>40</b> rapidly forms <b>53</b> in human and monkey blood, whereas in rat blood the isobutyl ester is rapidly hydrolyzed leading to complete transformation to <b>54</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). In minipig blood formation of both <b>53</b> and <b>54</b> occurs. In addition, it was found that the monoacid <b>53</b> is stable in human, minipig, and monkey blood whereas in rat blood it is hydrolyzed to diacid <b>55</b>. Both <b>54</b> and <b>55</b> are stable in blood from all species.</div><figure id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Metabolites Formed <i>in Vitro</i> in Human, Minipig, Monkey, and Rat Whole Blood</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00797&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The observed species difference in blood stability fits well with previously described difference in expression of CES1 which has been reported to hydrolyze esters with a large and bulky acyl group and small alcohol. CES1 is highly expressed in rat blood, and carboxyl esterases are known to be absent in both human and monkey blood.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> The expression levels in minipig blood are to the best of our knowledge unknown.</div><div class="NLM_p">In addition to rapid metabolism in blood, rapid metabolism by the liver was expected. Metabolite identification studies of <b>40</b> and <b>53</b> (the only metabolite formed in human whole blood) were performed in human, monkey, minipig, and rat hepatocytes using UPLC/TOF-MS analysis. MS-based structure elucidation followed by comparison to synthetic standards showed that for <b>40</b>, the expected metabolites <b>53</b>, <b>54</b>, and <b>55</b> were found in all species. In addition, two major oxidative metabolites were identified in human and monkey hepatocytes, where hydroxylation in the 2-position of the isobutyl side chain led to the formation of <b>50</b> and its lactone-hydrolyzed counterpart, <b>72</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). Compound <b>50</b> is PDE4 active (IC<sub>50</sub> = 15 nM) and requires attention in relation to toxicological qualification and levels obtained in human studies. Furthermore, as shown in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a> the lactone hydrolysis from <b>40</b> to <b>53</b> was found to be reversible in hepatocytes.</div><figure id="sch4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Proposed Metabolic Pathway in Human, Monkey, Minipig, and Rat Hepatocytes</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00797&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The stability of <b>40</b> was investigated in human, minipig, and rat hepatocytes (monkey not tested) and confirmed the expected high hepatic turnover in all species (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). On the basis of the low hepatocyte stability, <b>40</b> would be expected to have a human <i>in vivo</i> hepatic clearance close to 100% of LBF, and with additional extrahepatic clearance driven by esterases, this should give a total clearance greatly in excess of LBF. The monoacid metabolite formed in human blood, <b>53</b>, is further metabolized by the liver in all species, whereas <b>54</b> and <b>55</b> have low to medium turnover.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. <i>In Vitro</i> Stability in Human, Minipig, and Rat Hepatocytes<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">CL<sub>H</sub> (mL min<sup>–1</sup> kg<sup>–1</sup>)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">human Hep</th><th class="colsep0 rowsep0" align="center" char=".">minipig Hep</th><th class="colsep0 rowsep0" align="center" char=".">rat Hep</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="char" char=".">>26</td><td class="colsep0 rowsep0" align="char" char=".">>63</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">21</td><td class="colsep0 rowsep0" align="char" char=".">51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="char" char=".">5.2</td><td class="colsep0 rowsep0" align="char" char="."><11</td><td class="colsep0 rowsep0" align="char" char="."><19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>55</b></td><td class="colsep0 rowsep0" align="char" char="."><5.2</td><td class="colsep0 rowsep0" align="char" char="."><10</td><td class="colsep0 rowsep0" align="char" char=".">33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">>26</td><td class="colsep0 rowsep0" align="char" char=".">63</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>72</b></td><td class="colsep0 rowsep0" align="char" char=".">7.1</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">53</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Predicted hepatic clearance (CL<sub>H</sub>) from hepatocytes calculated using the well stirred model. For calculations, liver blood flow used in human, minipig, and rat were 20, 28, and 80 mL min<sup>–1</sup> kg<sup>–1</sup>, respectively.</p></div></div></div><div class="NLM_p">PK studies of <b>40</b> in rat, minipig, and monkey after intravenous administration were performed and confirmed a very rapid elimination of <b>40</b> in all three species (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). Total clearance exceeded liver blood flow 5- to 10-fold in all species, thereby confirming a substantial contribution from extrahepatic metabolism. On the basis of these results, clearance in man was predicted to be 110 mL min<sup>–1</sup> kg<sup>–1</sup> using allometric scaling of total clearance, which would lead to very rapid elimination once <b>40</b> enters systemic circulation and thereby ensuring the low systemic levels needed to avoid any side effects mediated by PDE4 inhibition.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. <i>In Vivo</i> Clearance and Metabolite Profile Observed after Intravenous Administration of <b>40</b> in Rat, Minipig, and Cynomolgus Monkey</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="4" align="center"><i>in vivo</i> clearance of <b>40</b> (mL min<sup>–1</sup> kg<sup>–1</sup>)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">human</th><th class="colsep0 rowsep0" align="center">monkey</th><th class="colsep0 rowsep0" align="center">minipig</th><th class="colsep0 rowsep0" align="center">rat</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">110 (predicted)</td><td class="colsep0 rowsep0" align="left">300 (<i>n</i> = 4)</td><td class="colsep0 rowsep0" align="left">200 (<i>n</i> = 4)</td><td class="colsep0 rowsep0" align="left">930 (<i>n</i> = 3)</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="5" align="center">systemic exposure after single dose of <b>40</b></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">human</th><th class="colsep0 rowsep0" align="center">monkey</th><th class="colsep0 rowsep0" align="center">minipig</th><th class="colsep0 rowsep0" align="center">rat</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">ratio to total AUC (%)<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">ratio to total AUC (%)<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">ratio to total AUC (%)<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">ratio to total AUC (%)<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">36</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">45</td><td class="colsep0 rowsep0" align="left">55</td><td class="colsep0 rowsep0" align="left">55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>55</b></td><td class="colsep0 rowsep0" align="left">71</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="left"><LLOQ</td><td class="colsep0 rowsep0" align="left">0.1</td><td class="colsep0 rowsep0" align="left"><LLOQ</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>72</b></td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left"><LLOQ</td><td class="colsep0 rowsep0" align="left">nd</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">Data from clinical study after topical administration.</p></div><div class="footnote" id="t8fn2"><sup><sup>b</sup></sup><p class="last">Preclinical <i>in vivo</i> studies with intravenous administration (rat) or intravenous infusion (minipig and monkey).</p></div></div></div><div class="NLM_p">Parent <b>40</b> and the metabolites observed <i>in vitro</i> were quantified <i>in vivo</i> in monkey, minipig, and rat intravenous infusion studies. All three species showed <b>53</b>, <b>54</b>, and <b>55</b> as major metabolites, with <b>53</b> and <b>55</b> accounting for >65% of AUC. <b>50</b> and <b>72</b>, which were observed as major <i>in vitro</i> metabolites in human and monkey hepatocytes, turned out to be circulating only in monkey (at low levels), and they were not quantifiable in minipig and rat.</div><div class="NLM_p last">The dual elimination mechanism by liver and extrahepatic esterases, combined with the species differences in both blood and liver, made prediction of the <i>in vivo</i> metabolite profile uncertain. Therefore <i>in vivo</i> pharmacokinetics and metabolite profiles were investigated thoroughly and early in the preclinical development. To ensure all human metabolites were safety tested, it was decided to use monkey in our preclinical safety studies.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Dermal PK and Metabolism</h3><div class="NLM_p">As described previously, human epidermal keratinocytes, which comprise ∼90% of the viable epidermis, were used as a screening model for compound optimization, and <b>40</b> turned out to be fully stable under the assay conditions used. Thus, it was not expected to see significant metabolism of <b>40</b> in the skin.<named-content content-type="anchor" rid="tbl9" type="simple"></named-content></div><div class="NLM_p">To confirm sufficient stability and distribution in the skin, <b>40</b> was evaluated <i>in vivo</i> in female Göttingen minipigs and compared to <b>1</b> to support selection of clinical formulation. <b>40</b> and <b>1</b> were dosed in monoglyceride cream at concentrations of 0.1 and 0.25% (both efficacious doses of <b>1</b>) at 24, 4, 1, and 0.5 h prior to biopsy sampling. The biopsy concentrations and dermal PK profile of <b>40</b> appear similar to <b>1</b> at both doses with total drug concentrations 24 h after dosing of 17 μM (0.1%) and 24 μM (0.25%) for <b>40</b> and 14 μM (0.1%) and 26 μM (0.25%) for <b>1</b> (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>). On the basis of these numbers, full target engagement over 24 h should be achieved with both compounds. While metabolism in the pig skin does occur, metabolites constitute ≤25% of the total drug related exposure at 24 h, suggesting that skin metabolism should not prevent <b>40</b> from achieving an efficacious concentration in the skin.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Skin Biopsy Concentrations of <b>1</b>, <b>40</b>, and Metabolites <b>53</b>, <b>54</b>, and <b>55</b> at 24 h after Dermal Application in Monoglyceride Cream Formulation in Göttingen Minipigs (<i>n</i> = 2)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">skin biopsy concentration (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">metabolite</th><th class="colsep0 rowsep0" align="center" char=".">monoglyceride cream (0.25%)</th><th class="colsep0 rowsep0" align="center" char=".">monoglyceride cream (0.10%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">26</td><td class="colsep0 rowsep0" align="char" char=".">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">24</td><td class="colsep0 rowsep0" align="char" char=".">17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="char" char="."><0.1</td><td class="colsep0 rowsep0" align="char" char="."><0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>55</b></td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">3</td></tr></tbody></table></div></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Clinical Results</h3><div class="NLM_p">On the basis of the preclinical PK, safety and efficacy profile, it was decided to enter <b>40</b> in a phase 1 safety and PK study with topical administration of increasing body surface areas (5–20%) of patients with atopic dermatitis. The compound was suspended 0.25% in a lipid cream designed treatment of atopic dermatitis.</div><div class="NLM_p">The PK profile after dermal administration of <b>40</b> is shown in <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>. We observed very low systemic exposure of the PDE4 active parent molecule (<b>40</b>), and at the same time we observed significantly higher levels of the inactive metabolites <b>53</b>, <b>54</b>, and <b>55</b>. In fact, the <i>C</i><sub>max</sub> of the major metabolite, <b>55</b>, was 30 times higher than the <i>C</i><sub>max</sub> of the parent, compound <b>40</b>. In addition, the observed human metabolite profile after topical dosing was similar to that seen in the cynomolgus monkey after subcutaneous dosing, supporting our choice of tox species. The levels of the active hydroxylated metabolite (<b>50</b>) were extremely low/not detectable. Overall the human PK profile proves that the concept of a “dual-soft” PDE4 inhibitor was successful, and we do not foresee any PDE4-related systemic side effects after topical application.</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Pharmacokinetic Profile Observed after Dermal Application of <b>40</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center"><i>C</i><sub>max</sub> (ng/mL)</th><th class="rowsep1 colsep0" colspan="2" align="center">AUC<sub>0–24</sub> (ng·h/mL)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">PDE4 active</th><th class="colsep0 rowsep0" align="center">cyno monkey<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">human<a class="ref internalNav" href="#t10fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">cyno monkey<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">human<a class="ref internalNav" href="#t10fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">yes</td><td class="colsep0 rowsep0" align="left">46.0</td><td class="colsep0 rowsep0" align="left">0.0659</td><td class="colsep0 rowsep0" align="left">21.8</td><td class="colsep0 rowsep0" align="left">0.458</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="left">no</td><td class="colsep0 rowsep0" align="left">749</td><td class="colsep0 rowsep0" align="left">0.299</td><td class="colsep0 rowsep0" align="left">932</td><td class="colsep0 rowsep0" align="left">4.18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="left">no</td><td class="colsep0 rowsep0" align="left">71.7</td><td class="colsep0 rowsep0" align="left">0.355</td><td class="colsep0 rowsep0" align="left">208</td><td class="colsep0 rowsep0" align="left">5.18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>55</b></td><td class="colsep0 rowsep0" align="left">no</td><td class="colsep0 rowsep0" align="left">407</td><td class="colsep0 rowsep0" align="left">1.89</td><td class="colsep0 rowsep0" align="left">1296</td><td class="colsep0 rowsep0" align="left">24.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="left">yes</td><td class="colsep0 rowsep0" align="left"><LLOQ</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><LLOQ</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>72</b></td><td class="colsep0 rowsep0" align="left">no</td><td class="colsep0 rowsep0" align="left">10.5</td><td class="colsep0 rowsep0" align="left">0.029</td><td class="colsep0 rowsep0" align="left">19.4</td><td class="colsep0 rowsep0" align="left">0.270</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup><sup>a</sup></sup><p class="last">Single subcutaneous dosing of 30 mg/kg.</p></div><div class="footnote" id="t10fn2"><sup><sup>b</sup></sup><p class="last">Topical application on 20% of body surface of AD patients with 16 mg of compound <b>40</b>.</p></div></div></div><div class="NLM_p last">The efficacy of <b>40</b> in patients with atopic dermatitis was investigated in a left/right setup, treating two similar lesions with either placebo cream or <b>40</b> suspended 0.25% in a lipid cream. Efficacy was observed in AD patients, especially after the first week of treatment, but after 3 weeks of treatment the efficacy of the applied drug was only marginally better than placebo cream.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> We were concerned that the exposure of the compound in human skin was too low to result in clinical efficacy; however the dermal concentrations of <b>40</b> were determined from skin biopsies, and an average total drug concentration of 6 μM was measured, which should be sufficient for clinical efficacy. These contradictory results led to the initiation of a retrospective and in-depth investigation of the topical delivery of <b>40</b> to the skin using freshly excised human skin in dermal open flow microperfusion<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> studies and a comparison of dermal interstitial fluid concentrations to skin biopsy concentrations and the response of cAMP as a pharmacodynamic biomarker.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The conclusion of this investigation was that the unbound concentration of <b>40</b> in dermal interstitial fluid was low (6.5 nM). This could be explained partly by a higher than predicted level of skin metabolism and partly by a poor penetration of <b>40</b> through the skin even though stratum corneum was completely removed in the study to simulate barrier impaired AD skin. Furthermore, no or limited effect on the pharmacodynamic biomarker cAMP was observed.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> These results, taken together with MALDI imaging studies on other topically applied drugs,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> indicate that skin biopsy concentrations can be subject to contamination from, for example, residual formulation during sampling or drug in follicles and therefore should be used with caution. In the case of <b>40</b>, the 6 μM skin biopsy drug concentration did not reflect the drug available at the site of the target in the skin.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45163" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45163" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">PDE4 inhibition is an attractive target for topical treatment of AD, and a “dual-soft” approach was investigated: PDE4 inhibitors with high local concentration in the skin and low circulating systemic concentrations based on rapid degradation in blood <i>and</i> the liver.</div><div class="NLM_p">We employed an empirical screening approach for optimization, using metabolism in human whole blood, human liver microsomes, and human keratinocytes. This turned out to be a powerful strategy, although it did leave some unknowns related to esterase specificity of the compounds.</div><div class="NLM_p">Even though some trends were observed, design of unstable compounds turned out to be far more difficult than we initially expected. We learned that the incorporation of an ester group is absolutely no guarantee of instability in whole blood, and it became evident to us that it is indeed a very challenging task to design inhibitors that meet all of the <i>in vitro</i> PK and potency criteria of a “dual-soft” compound. The lactone moiety turned out to be desirable in the structure, though in this case we had to combine it with another ester to achieve the desired properties.</div><div class="NLM_p">The underlying hypothesis that there are differences in esterase expression in skin vs blood was eventually validated as compounds with various profiles could be prepared and the final candidate <b>40</b> fulfilled the criteria of being stable in skin and unstable in blood (and liver).</div><div class="NLM_p">Species differences in metabolism were observed, with only the cynomolgus monkey fully resembling the human metabolite profile. The dual elimination mechanism was successful in delivering a drug candidate with <i>in vivo</i> clearance exceeding LBF 5- to 10-fold in all species tested. Due to the dual elimination mechanism (blood and liver) and the significant species differences observed in metabolite pathways, the human clearance and PK were predicted based on allometric scaling of total clearance. Human clearance was predicted to be 110 mL min<sup>–1</sup> kg<sup>–1</sup>, and while clinical PK data to confirm this are not available, it was evident in healthy volunteer and AD patients that only very low levels of <b>40</b> could be detected and that significantly higher levels of themetabolites <b>53</b>, <b>54</b>, and <b>55</b> were observed after dermal administration.</div><div class="NLM_p last">The systemic PK was in line with expectations for a “dual-soft” compound, and skin PK from biopsies indicated minimal degradation of <b>40</b> in human skin. It was therefore somewhat surprising that the clinical effect was only marginally different from placebo. The reasons behind lacking clinical efficacy have been investigated in depth, and our belief is that this is related to low free drug exposure of the candidate, not predicted by the biopsy sampling technique.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> We believe translational biomarkers and more advanced methods such as dermal open flow microperfusion or MALDI imaging which can determine drug at site of the target are likely necessary to measure relevant skin concentrations.<a onclick="showRef(event, 'ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28">(26−28)</a></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46563" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46563" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Synthesis</h3><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Chemistry: General Methods and Compound Characterization</h4><div class="NLM_p">All reagents and starting materials were obtained from commercial suppliers and used without further purification unless otherwise stated. The organic solvents used were usually anhydrous, and the reactions were run under an atmosphere of nitrogen or argon unless otherwise noted. Reaction progress was monitored using a variety of LC instruments equipped with electrospray positive ionization detectors.</div><div class="NLM_p last"><sup>1</sup>H nuclear magnetic resonance (NMR) spectra were recorded at 300, 400, or 600 MHz. Chemical shift values (δ, in ppm) are quoted in the specified solvent relative to internal tetramethylsilane (δ = 0.00) or chloroform (δ = 7.25) standards. The value of a multiplet, either defined (doublet (d), triplet (t), quartet (q)) or not (m), at the approximate midpoint is given unless a range is quoted. br s indicates a broad singlet. Chromatography was performed on Merck silica gel 60 (0.040–0.063 mm). Preparative HPLC/MS was performed on a Waters APS system with the following parameters: acid prep HPLC; column, Waters Sunfire C-18, 100 mm × 19 mm, 5 μm; solvent system, A = water (0.1% formic acid) and B = acetonitrile (0.1% formic acid); basic prep HPLC; column, Waters XBridge C-18, 100 mm × 19 mm, 5 μm; solvent system, A = 50 mM ammonium hydrogen carbonate and B = acetonitrile; flow rate = 20 mL/min; method (8 min), linear gradient methods going from 5, 15, 30, or 50% B to 100% B in 6 min and staying at 100% B for another 2 min. The fractions were collected based on ion traces of relevant ions and PDA signal (240–400 nm). All compounds were analyzed by UPLC–MS. High resolution chromatography was performed using the Waters Acquity UPLC and a 2.1 mm × 50 mm C18 RP column (1.8 μm particles). The mobile phases consisted of 0.1% formic acid in an aqueous 10 mM ammonium acetate solution for buffer A and 0.1% formic acid in acetonitrile for buffer B. A standard binary gradient was used for the reverse phase chromatography. All compounds had an estimated UV purity of >95% by UPLC–MS.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Synthesis of 2-Cyclopropyl-8-methoxy-5-phenyl-[1,2,4]triazolo[1,5-<i>a</i>]pyridine (<b>5</b>)</h4><div class="NLM_p last">See the preparation of compound <b>102</b> described in WO 2010/069322. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 266.13 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.94–7.88 (m, 2H), 7.58–7.51 (m, 2H), 7.50 (tt, 1H), 7.16 (d, <i>J</i> = 8.1 Hz, 1H), 7.13 (d, <i>J</i> = 8.2 Hz, 1H), 3.98 (s, 3H), 2.15 (tt, <i>J</i> = 4.8, 8.2 Hz, 1H), 1.04–0.99 (m, 2H), 0.98–0.94 (m, 2H).</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 1-[3-(2-Cyclopropyl-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl)phenyl]ethanone (<b>6</b>)</h4><div class="NLM_p last">See the preparation of compound <b>101</b> described in WO 2010/069322. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 308.14 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.49 (t, <i>J</i> = 1.9 Hz, 1H), 8.18–8.11 (m, 1H), 8.07–8.01 (m, 1H), 7.62 (t, <i>J</i> = 7.8 Hz, 1H), 6.98 (d, <i>J</i> = 8.0 Hz, 1H), 6.84 (d, <i>J</i> = 8.0 Hz, 1H), 4.07 (s, 3H), 2.67 (s, 3H), 2.24 (tt, <i>J</i> = 5.0, 8.4 Hz, 1H), 1.25–1.17 (m, 2H), 1.08–0.99 (m, 2H).</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 1-[3-(2-Cyclopropyl-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl)phenyl]propan-1-one (<b>7</b>)</h4><div class="NLM_p last">The title compound was prepared following the same procedure as the one outlined for <b>6</b>, the only difference being that (3-acetylphenyl)boronic acid was replaced by (3-propanoylphenyl)boronic acid. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 322.16 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.49 (t, <i>J</i> = 1.8 Hz, 1H), 8.17 (ddd, <i>J</i> = 1.1, 1.9, 7.8 Hz, 1H), 8.06 (dt, <i>J</i> = 1.3, 7.7 Hz, 1H), 7.69 (t, <i>J</i> = 7.8 Hz, 1H), 7.27 (d, <i>J</i> = 8.1 Hz, 1H), 7.15 (d, <i>J</i> = 8.2 Hz, 1H), 4.00 (s, 3H), 3.13 (q, <i>J</i> = 7.2 Hz, 2H), 2.15 (tt, <i>J</i> = 4.9, 8.2 Hz, 1H), 1.13 (t, <i>J</i> = 7.2 Hz, 3H), 1.06–1.00 (m, 2H), 1.00–0.94 (m, 2H).</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 1-[3-(2-Cyclopropyl-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl)phenyl]butan-1-one (<b>8</b>)</h4><div class="NLM_p last">The title compound was prepared following the same procedure as the one outlined for <b>6</b>, the only difference being that (3-acetylphenyl)boronic acid was replaced by (3-butanoylphenyl)boronic acid. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 336.17 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.50 (t, <i>J</i> = 1.8 Hz, 1H), 8.16 (dt, <i>J</i> = 1.4, 7.8 Hz, 1H), 8.06 (dt, <i>J</i> = 1.4, 7.9 Hz, 1H), 7.69 (t, <i>J</i> = 7.8 Hz, 1H), 7.27 (d, <i>J</i> = 8.1 Hz, 1H), 7.15 (d, <i>J</i> = 8.2 Hz, 1H), 4.00 (s, 3H), 3.07 (t, <i>J</i> = 7.1 Hz, 2H), 2.15 (tt, <i>J</i> = 4.9, 8.2 Hz, 1H), 1.76–1.61 (m, 2H), 1.13–0.84 (m, 7H).</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 1-[4-(2-Cyclopropyl-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl)phenyl]ethanone (<b>9</b>)</h4><div class="NLM_p last">The title compound was prepared following the same procedure as the one outlined for <b>6</b>, the only difference being that (3-acetylphenyl)boronic acid was replaced by (4-acetylphenyl)boronic acid. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 308.14 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.10 (s, 4H), 7.29 (d, <i>J</i> = 8.1 Hz, 1H), 7.16 (d, <i>J</i> = 8.3 Hz, 1H), 4.00 (s, 3H), 2.65 (s, 3H), 2.16 (tt, <i>J</i> = 4.8, 8.2 Hz, 1H), 1.05–1.00 (m, 2H), 1.00–0.95 (m, 2H).</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 1-[4-(2-Cyclopropyl-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl)phenyl]propan-1-one (<b>10</b>)</h4><div class="NLM_p last">The title compound was prepared following the same procedure as the one outlined for <b>6</b>, the only difference being that (3-acetylphenyl)boronic acid was replaced by (4-propanoylphenyl)boronic acid. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 322.16 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.10 (s, 4H), 7.28 (d, <i>J</i> = 8.1 Hz, 1H), 7.15 (d, <i>J</i> = 8.2 Hz, 1H), 4.00 (s, 3H), 3.12 (q, <i>J</i> = 7.2 Hz, 2H), 2.16 (tt, <i>J</i> = 4.9, 8.2 Hz, 1H), 1.13 (t, <i>J</i> = 7.2 Hz, 3H), 1.07–0.92 (m, 4H).</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 1-[4-(2-Cyclopropyl-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl)phenyl]butan-1-one (<b>11</b>)</h4><div class="NLM_p last">The title compound was prepared following the same procedure as the one outlined for <b>6</b>, the only difference being that (3-acetylphenyl)boronic acid was replaced by (4-butanoylphenyl)boronic acid. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 336.17 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.10 (s, 4H), 7.29 (d, <i>J</i> = 8.1 Hz, 1H), 7.15 (d, <i>J</i> = 8.2 Hz, 1H), 4.00 (s, 3H), 3.06 (t, <i>J</i> = 7.1 Hz, 2H), 2.16 (tt, <i>J</i> = 4.9, 8.2 Hz, 1H), 1.75–1.61 (m, 2H), 1.12–0.86 (m, 7H).</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 6-(2-Cyclopropyl-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl)indan-1-one (<b>12</b>)</h4><div class="NLM_p last">The title compound was prepared following the same procedure as the one outlined for <b>6</b>, the only difference being that (3-acetylphenyl)boronic acid was replaced by (3-oxoindan-5-yl)boronic acid. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 320.14 (MH<sup>+</sup>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27–8.13 (m, 2H), 7.75 (dd, <i>J</i> = 1.0, 7.9 Hz, 1H), 7.25 (d, <i>J</i> = 8.1 Hz, 1H), 7.13 (d, <i>J</i> = 8.2 Hz, 1H), 3.99 (s, 3H), 3.23–3.14 (m, 2H), 2.78–2.69 (m, 2H), 2.15 (tt, <i>J</i> = 4.9, 8.2 Hz, 1H), 1.08–0.90 (m, 4H).</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 4-(2-Cyclopropyl-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl)indan-1-one (<b>13</b>)</h4><div class="NLM_p last">See the preparation of compound <b>162</b> described in WO 2010/069322. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 320.14 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.91 (dd, <i>J</i> = 1.1, 7.6 Hz, 1H), 7.75 (dd, <i>J</i> = 1.2, 7.3 Hz, 1H), 7.53 (t, <i>J</i> = 7.5 Hz, 1H), 6.84 (s, 2H), 4.08 (s, 3H), 3.07–2.99 (m, 2H), 2.74–2.67 (m, 2H), 2.19 (tt, <i>J</i> = 4.9, 8.3 Hz, 1H), 1.22–1.15 (m, 2H), 1.08–0.98 (m, 2H).</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 5-(2-Cyclopropyl-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl)indan-1-one (<b>14</b>)</h4><div class="NLM_p last">See the preparation of compound <b>160</b> described in WO 2010/069322. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 320.14 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.16–8.09 (m, 1H), 7.96 (dd, <i>J</i> = 1.5, 8.2 Hz, 1H), 7.77 (d, <i>J</i> = 8.0 Hz, 1H), 7.28 (d, <i>J</i> = 8.3 Hz, 1H), 7.16 (d, <i>J</i> = 8.1 Hz, 1H), 4.00 (s, 3H), 3.22–3.16 (m, 2H), 2.75–2.68 (m, 2H), 2.16 (tt, <i>J</i> = 5.0, 8.1 Hz, 1H), 1.08–0.93 (m, 4H).</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 3-(2-Cyclopropyl-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl)benzonitrile (<b>15</b>)</h4><div class="NLM_p last">See the preparation of compound <b>135</b> described in WO 2010/069322. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 291.13 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 8.40 (t, <i>J</i> = 1.7 Hz, 1H), 8.33–8.25 (m, 1H), 7.95 (dt, <i>J</i> = 1.3, 7.6 Hz, 1H), 7.75 (t, <i>J</i> = 7.9 Hz, 1H), 7.32 (d, <i>J</i> = 8.1 Hz, 1H), 7.15 (d, <i>J</i> = 8.2 Hz, 1H), 4.00 (s, 3H), 2.18 (tt, <i>J</i> = 5.0, 8.1 Hz, 1H), 1.09–0.92 (m, 4H).</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 1-[5-(3-Cyanophenyl)-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]-<i>N</i>-isobutyl-cyclopropanecarboxamide (<b>16</b>)</h4><div class="NLM_p last">See the preparation of compound <b>279</b> following the “general procedure 4” described in WO 2010/069322. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 390.19 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.51 (t, <i>J</i> = 5.7 Hz, 1H), 8.41 (t, <i>J</i> = 1.7 Hz, 1H), 8.29–8.22 (m, 1H), 8.00–7.93 (m, 1H), 7.74 (t, <i>J</i> = 7.9 Hz, 1H), 7.38 (d, <i>J</i> = 8.1 Hz, 1H), 7.24 (d, <i>J</i> = 8.3 Hz, 1H), 4.04 (s, 3H), 3.00 (dd, <i>J</i> = 5.7, 6.8 Hz, 2H), 1.77–1.66 (m, 1H), 1.55–1.49 (m, 2H), 1.44–1.37 (m, 2H), 0.81 (d, <i>J</i> = 6.8 Hz, 6H).</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Methyl 3-(2-Cyclopropyl-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl)benzoate (<b>17</b>)</h4><div class="NLM_p last">See the preparation of compound <b>117</b> described in WO 2010/069322. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 324.14 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.51 (t, <i>J</i> = 1.8 Hz, 1H), 8.19 (dt, <i>J</i> = 1.5, 7.8 Hz, 1H), 8.07 (dt, <i>J</i> = 1.4, 7.8 Hz, 1H), 7.70 (t, <i>J</i> = 7.8 Hz, 1H), 7.26 (d, <i>J</i> = 8.1 Hz, 1H), 7.14 (d, <i>J</i> = 8.1 Hz, 1H), 4.00 (s, 3H), 3.90 (s, 3H), 2.15 (tt, <i>J</i> = 4.9, 8.3 Hz, 1H), 1.05–1.00 (m, 2H), 1.00–0.94 (m, 2H).</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 3-(2-Cyclopropyl-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl)benzoic Acid (Putative Metabolite of <b>17</b>)</h4><div class="NLM_p last">See the preparation of compound <b>136</b> described in WO 2010/069322. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 310.12 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.87 (br s, 1H), 8.48 (t, <i>J</i> = 1.8 Hz, 1H), 8.15 (dt, <i>J</i> = 1.5, 7.9 Hz, 1H), 8.05 (dt, <i>J</i> = 1.4, 7.7 Hz, 1H), 7.67 (t, <i>J</i> = 7.8 Hz, 1H), 7.24 (d, <i>J</i> = 8.1 Hz, 1H), 7.14 (d, <i>J</i> = 8.2 Hz, 1H), 4.00 (s, 3H), 2.16 (tt, <i>J</i> = 5.0, 8.1 Hz, 1H), 1.08–0.91 (m, 4H).</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Methyl 3-[2-[1-(Isobutylcarbamoyl)cyclopropyl]-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl]benzoate (<b>18</b>)</h4><div class="NLM_p last">The title compound was prepared following the “general procedure 2” described in WO 2010/069322. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 423.20 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.65 (t, <i>J</i> = 5.7 Hz, 1H), 8.50 (t, <i>J</i> = 1.8 Hz, 1H), 8.18 (dt, <i>J</i> = 1.6, 7.7 Hz, 1H), 8.08 (dt, <i>J</i> = 1.7, 8.0 Hz, 1H), 7.70 (t, <i>J</i> = 7.8 Hz, 1H), 7.34 (d, <i>J</i> = 8.1 Hz, 1H), 7.23 (d, <i>J</i> = 8.1 Hz, 1H), 4.03 (s, 3H), 3.90 (s, 3H), 2.99 (dd, 2H), 1.71–1.60 (m, 1H), 1.57–1.48 (m, 2H), 1.48–1.39 (m, 2H), 0.77 (d, <i>J</i> = 6.6 Hz, 6H).</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 3-[2-[1-(Isobutylcarbamoyl)cyclopropyl]-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl]benzoic Acid (Putative Metabolite of <b>18</b>)</h4><div class="NLM_p last">A screw cap vial charged with <b>18</b> (25 mg, 0.060 mmol), water (200 μL), dioxane (400 μL), and 2 M aqueous NaOH (500 μL) was shaken at 40 °C for 10 min. Acidic prep HPLC purification afforded the title compound. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 409.19 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.19 (br s, 1H), 8.67 (t, <i>J</i> = 5.7 Hz, 1H), 8.48 (t, <i>J</i> = 1.8 Hz, 1H), 8.15 (dt, <i>J</i> = 1.6, 7.7 Hz, 1H), 8.06 (dt, <i>J</i> = 1.5, 7.7 Hz, 1H), 7.67 (t, <i>J</i> = 7.8 Hz, 1H), 7.34 (d, <i>J</i> = 8.1 Hz, 1H), 7.23 (d, <i>J</i> = 8.1 Hz, 1H), 4.03 (s, 3H), 2.99 (dd, <i>J</i> = 5.7, 6.8 Hz, 2H), 1.70–1.60 (m, 1H), 1.56–1.48 (m, 2H), 1.47–1.38 (m, 2H), 0.77 (d, <i>J</i> = 6.7 Hz, 6H).</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 4-(2-Cyclopropyl-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl)-3<i>H</i>-isobenzofuran-1-one (<b>19</b>)</h4><div class="NLM_p last">See the preparation of compound <b>170</b> described in WO 2010/069322. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 322.12 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.12 (dd, <i>J</i> = 1.0, 7.6 Hz, 1H), 8.02 (dd, <i>J</i> = 1.0, 7.6 Hz, 1H), 7.79 (t, <i>J</i> = 7.6 Hz, 1H), 7.25 (d, <i>J</i> = 8.1 Hz, 1H), 7.15 (d, <i>J</i> = 8.1 Hz, 1H), 5.47 (s, 2H), 4.01 (s, 3H), 2.15 (tt, <i>J</i> = 4.9, 8.2 Hz, 1H), 1.07–0.89 (m, 4H).</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 3-(2-Cyclopropyl-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl)-2-(hydroxymethyl)benzoic Acid (Putative Metabolite of <b>19</b>)</h4><div class="NLM_p last">A screw cap vial charged with <b>19</b> (19 mg, 0.060 mmol), water (200 μL), dioxane (400 μL), and 2 M aqueous NaOH (500 μL) was shaken at 40 °C until completion of hydrolysis. Bacic prep HPLC purification afforded the title compound. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 340.13 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.80 (dd, <i>J</i> = 2.1, 7.3 Hz, 1H), 7.36–7.25 (m, 2H), 7.13 (d, <i>J</i> = 8.0 Hz, 1H), 6.94 (d, <i>J</i> = 8.0 Hz, 1H), 6.05 (br s, 1H), 4.40 (br s, 1H), 3.99 (s, 3H), 3.86–3.65 (m, 2H), 2.14–1.99 (m, 1H), 1.04–0.78 (m, 4H).</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>N</i>-Isobutyl-1-[8-methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-4-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxamide (<b>20</b>)</h4><div class="NLM_p">4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-3<i>H</i>-isobenzofuran-1-one was synthesized as described in “preparation 14” in WO 2010/069322 using 4-bromophthalide as the starting material instead of 4-bromoindan-1-one. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.08 (dd, <i>J</i> = 1.2, 7.2 Hz, 1H), 8.00 (dd, <i>J</i> = 1.1, 7.7 Hz, 1H), 7.54 (t, <i>J</i> = 7.5 Hz, 1H), 5.45 (s, 2H), 1.36 (s, 12H).</div><div class="NLM_p">A vial charged with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3<i>H</i>-isobenzofuran-1-one (1.63 g, 6.27 mmol), 1-(5-iodo-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl)cyclopropanecarboxylic acid (<b>65</b>) (aka compound <b>306</b> described in WO 2010/069322) (1.50 g, 4.18 mmol), K<sub>3</sub>PO<sub>4</sub> (3.10 g, 14.6 mmol, Pd<sub>2</sub>(dba)<sub>3</sub> (76.5 mg, 0.0835 mmol), and PCy<sub>3</sub> (46.9 mg, 0.167 mmol) in a degassed 2:1 dioxane–water mixture (15 mL) was heated in a microwave oven at 130 °C for 10 min. The crude reaction mixture was then poured into 0.4 M aqueous NaOH (220 mL). The aqueous phase was washed with EtOAc (2 × 40 mL) before it was acidified with 4 M HCl and extracted with EtOAc (3 × 50 mL). The combined organic phases were dried over MgSO<sub>4</sub>, filtered, and evaporated to dryness. The obtained solid was suspended in hot MeOH. Filtration afforded 1-[8-methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-4-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylic acid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.55 (br s, 1H), 8.10 (dd, <i>J</i> = 1.1, 7.6 Hz, 1H), 8.02 (dd, <i>J</i> = 1.0, 7.6 Hz, 1H), 7.80 (t, <i>J</i> = 7.6 Hz, 1H), 7.32 (d, <i>J</i> = 8.0 Hz, 1H), 7.21 (d, <i>J</i> = 8.1 Hz, 1H), 5.49 (s, 2H), 4.04 (s, 3H), 2.07 (s, 1H), 1.57–1.46 (m, 2H), 1.46–1.35 (m, 2H).</div><div class="NLM_p last">A vial charged with 1-[8-methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-4-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylic acid (10 mg, 0.027 mmol), PYBROP (19 mg, 0.041 mmol), TEA (11.4 μL, 0.082 mmol), isobutyl amine (6.0 mg, 0.082 mmol), and DMF (0.5 mL) was shaken at rt overnight. Acid prep HPLC purification afforded compound <b>20</b>. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 421.19 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.40 (t, <i>J</i> = 5.8 Hz, 1H), 8.15 (dd, <i>J</i> = 1.1, 7.7 Hz, 1H), 8.03 (dd, <i>J</i> = 1.0, 7.7 Hz, 1H), 7.78 (t, <i>J</i> = 7.7 Hz, 1H), 7.34 (d, <i>J</i> = 8.1 Hz, 1H), 7.24 (d, <i>J</i> = 8.1 Hz, 1H), 5.45 (s, 2H), 4.05 (s, 3H), 2.94 (dd, <i>J</i> = 5.7, 6.8 Hz, 2H), 1.62 (dh, <i>J</i> = 6.7, 13.5 Hz, 1H), 1.51–1.46 (m, 2H), 1.40–1.34 (m, 2H), 0.73 (d, <i>J</i> = 6.6 Hz, 6H).</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Methyl 4-(2-Cyclopropyl-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl)benzoate (<b>21</b>)</h4><div class="NLM_p last">See the preparation of compound <b>119</b> described in WO 2010/069322. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 324.14 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.13–8.08 (m, 4H), 7.30 (d, <i>J</i> = 8.1 Hz, 1H), 7.16 (d, <i>J</i> = 8.1 Hz, 1H), 4.00 (s, 3H), 3.91 (s, 3H), 2.16 (tt, <i>J</i> = 4.9, 8.3 Hz, 1H), 1.05–1.00 (m, 2H), 1.00–0.95 (m, 2H).</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 4-(2-Cyclopropyl-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl)benzoic Acid (Putative Metabolite of <b>21</b>)</h4><div class="NLM_p last">See the preparation of compound <b>140</b> described in WO 2010/069322. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 310.12 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.11 (br s, 1H), 8.12–8.03 (m, 4H), 7.28 (d, <i>J</i> = 8.1 Hz, 1H), 7.15 (d, <i>J</i> = 8.1 Hz, 1H), 4.00 (s, 3H), 2.16 (tt, <i>J</i> = 5.0, 8.2 Hz, 1H), 1.09–0.91 (m, 4H).</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Methyl 4-[2-[1-(Isobutylcarbamoyl)cyclopropyl]-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl]benzoate (<b>22</b>)</h4><div class="NLM_p last">The title compound was prepared following the “general procedure 2” described in WO 2010/069322. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 423.20 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.57 (t, <i>J</i> = 5.4 Hz, 1H), 8.13–8.03 (m, 4H), 7.37 (d, <i>J</i> = 8.1 Hz, 1H), 7.24 (d, <i>J</i> = 8.3 Hz, 1H), 4.04 (s, 3H), 3.91 (s, 3H), 2.99 (dd, <i>J</i> = 5.6, 6.8 Hz, 2H), 1.81–1.62 (m, 1H), 1.55–1.47 (m, 2H), 1.46–1.37 (m, 2H), 0.81 (d, <i>J</i> = 6.8 Hz, 6H).</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 4-[2-[1-(Isobutylcarbamoyl)cyclopropyl]-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl]benzoic Acid (Putative Metabolite of <b>22</b>)</h4><div class="NLM_p last">A screw cap vial charged with compound <b>22</b> (15 mg, 0.036 mmol), water (120 μL), dioxane (240 μL), and 2 M aqueous NaOH (500 μL) was shaken at rt for 1 h. Acidic prep HPLC purification afforded the title compound. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 409.19 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.12 (br s, 1H), 8.58 (t, <i>J</i> = 5.6 Hz, 1H), 8.07 (s, 4H), 7.36 (d, <i>J</i> = 8.1 Hz, 1H), 7.24 (d, <i>J</i> = 8.3 Hz, 1H), 4.03 (s, 3H), 2.99 (dd, <i>J</i> = 5.7, 6.7 Hz, 2H), 1.69 (dh, <i>J</i> = 6.7, 13.4 Hz, 1H), 1.54–1.46 (m, 2H), 1.46–1.38 (m, 2H), 0.81 (d, <i>J</i> = 6.7 Hz, 6H).</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 5-(2-Cyclopropyl-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl)-3<i>H</i>-isobenzofuran-1-one (<b>23</b>)</h4><div class="NLM_p last">See the preparation of compound <b>167</b> described in WO 2010/069322. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 322.12 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.19–8.14 (m, 1H), 8.05 (d, <i>J</i> = 8.0 Hz, 1H), 8.02–7.96 (m, 1H), 7.02 (d, <i>J</i> = 8.0 Hz, 1H), 6.86 (d, <i>J</i> = 8.1 Hz, 1H), 5.43 (s, 2H), 4.08 (s, 3H), 2.24 (tt, <i>J</i> = 4.9, 8.4 Hz, 1H), 1.25–1.17 (m, 2H), 1.10–1.01 (m, 2H).</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 4-(2-Cyclopropyl-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl)-2-(hydroxymethyl)benzoic Acid (Putative Metabolite of <b>23</b>)</h4><div class="NLM_p last">A screw cap vial charged with compound <b>23</b> (28 mg, 0.087 mmol), MeOH (0.5 mL), and 2 M aqueous NaOH (0.5 mL) was shaken at rt for 2 h. Basic prep HPLC purification afforded the title compound. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 340.13 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.88 (d, <i>J</i> = 8.0 Hz, 1H), 7.82–7.70 (m, 2H), 7.20–7.03 (m, 2H), 6.02 (br s, 1H), 4.58 (s, 2H), 2.17 (tt, <i>J</i> = 5.0, 8.0 Hz, 1H), 1.08–0.86 (m, 4H).</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>N</i>-Isobutyl-1-[8-methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxamide (<b>24</b>)</h4><div class="NLM_p last">The title compound was prepared following the “general procedure 3” described in WO 2010/069322. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 421.19 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.52 (t, <i>J</i> = 5.6 Hz, 1H), 8.21 (s, 1H), 8.14 (dd, <i>J</i> = 1.5, 8.0 Hz, 1H), 7.98 (d, <i>J</i> = 8.1 Hz, 1H), 7.39 (d, <i>J</i> = 8.2 Hz, 1H), 7.27 (d, <i>J</i> = 8.2 Hz, 1H), 5.50 (s, 2H), 4.05 (s, 3H), 2.98 (dd, <i>J</i> = 5.7, 6.8 Hz, 2H), 1.77–1.59 (m, 1H), 1.54–1.46 (m, 2H), 1.45–1.37 (m, 2H), 0.79 (d, <i>J</i> = 6.7 Hz, 6H).</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 2-(Hydroxymethyl)-4-[2-[1-(isobutylcarbamoyl)cyclopropyl]-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl]benzoic Acid (Putative Metabolite of <b>24</b>)</h4><div class="NLM_p last">A screw cap vial charged with <b>24</b> (13 mg, 0.030 mmol), THF (0.5 mL), and 1 M aqueous LiOH (0.5 mL) was shaken at rt for 2 h. Basic prep HPLC purification afforded the title compound. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 439.20 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.77 (br s, 1H), 8.72 (t, <i>J</i> = 5.7 Hz, 1H), 8.21 (d, <i>J</i> = 1.7 Hz, 1H), 7.98 (d, <i>J</i> = 8.1 Hz, 1H), 7.93 (dd, <i>J</i> = 1.9, 8.2 Hz, 1H), 7.32 (d, <i>J</i> = 8.1 Hz, 1H), 7.25 (d, <i>J</i> = 8.1 Hz, 1H), 5.30 (br s, 1H), 4.92 (s, 2H), 4.04 (s, 3H), 3.05–2.97 (m, 2H), 1.70 (dh, <i>J</i> = 6.6, 13.4 Hz, 1H), 1.57–1.49 (m, 2H), 1.48–1.40 (m, 2H), 0.79 (d, <i>J</i> = 6.6 Hz, 6H).</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 3-[2-[1-(Hydroxymethyl)cyclopropyl]-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl]benzonitrile (<b>25</b>)</h4><div class="NLM_p last">See the preparation of compound <b>150</b> described in WO 2010/069322. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 321.14 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 8.45 (t, <i>J</i> = 1.6 Hz, 1H), 8.34 (dt, <i>J</i> = 1.4, 8.0 Hz, 1H), 7.95 (dt, <i>J</i> = 1.3, 7.7 Hz, 1H), 7.75 (t, <i>J</i> = 7.9 Hz, 1H), 7.36 (d, <i>J</i> = 8.1 Hz, 1H), 7.17 (d, <i>J</i> = 8.2 Hz, 1H), 4.60 (t, <i>J</i> = 5.8 Hz, 1H), 4.01 (s, 3H), 3.89 (d, <i>J</i> = 5.9 Hz, 2H), 1.13–1.06 (m, 2H), 1.06–0.99 (m, 2H).</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 3-[2-[1-(2-Hydroxyethyl)cyclopropyl]-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl]benzonitrile (<b>26</b>)</h4><div class="NLM_p last">A suspension of compound <b>30</b> (20 mg, 58 μmol) in THF (1.0 mL) was cooled under an argon atmosphere to −10 °C. BH<sub>3</sub>·THF (1 M in THF, 100 μL, 100 μmol) was added, and the mixture was stirred at 0 °C for 3 h before more BH<sub>3</sub>·THF (1 M in THF, 100 μL, 100 μmol) was added. The mixture was left stirring in a cool bath overnight, and the temperature reached 10 °C. More BH<sub>3</sub>·THF (1 M in THF, 300 μL, 300 μmol) was then added, and the reaction mixture was allowed to reach rt. After 6 h at rt basic prep HPLC purification afforded the title compound. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 335.15 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.40 (t, <i>J</i> = 1.5 Hz, 1H), 8.33 (dt, <i>J</i> = 1.7, 8.0 Hz, 1H), 7.95 (dt, <i>J</i> = 1.5, 7.7 Hz, 1H), 7.75 (t, <i>J</i> = 7.9 Hz, 1H), 7.34 (d, <i>J</i> = 8.1 Hz, 1H), 7.15 (d, <i>J</i> = 8.2 Hz, 1H), 4.42 (t, <i>J</i> = 5.2 Hz, 1H), 4.01 (s, 3H), 3.63 (td, <i>J</i> = 5.0, 7.2 Hz, 2H), 2.00 (t, <i>J</i> = 7.2 Hz, 2H), 1.19–1.06 (m, 2H), 1.02–0.88 (m, 2H).</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 3-[2-[1-(3-Hydroxypropyl)cyclopropyl]-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl]benzonitrile (<b>27</b>)</h4><div class="NLM_p last">The title compound was synthesized following the same procedure as the one described for compound <b>26</b> the only difference being that <b>31</b> was used as starting material instead of <b>30</b>. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 349.17 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.46 (t, <i>J</i> = 1.8 Hz, 1H), 8.34 (dt, <i>J</i> = 1.6, 8.2 Hz, 1H), 7.94 (dt, <i>J</i> = 1.6, 7.5 Hz, 1H), 7.74 (t, <i>J</i> = 7.9 Hz, 1H), 7.37 (d, <i>J</i> = 8.1 Hz, 1H), 7.15 (d, <i>J</i> = 8.3 Hz, 1H), 4.32 (t, <i>J</i> = 5.1 Hz, 1H), 4.01 (s, 3H), 3.43 (q, <i>J</i> = 6.1 Hz, 2H), 1.83 (dd, <i>J</i> = 5.2, 10.3 Hz, 2H), 1.74–1.60 (m, 2H), 1.19–1.08 (m, 2H), 0.95–0.82 (m, 2H).</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> [1-[5-(3-Cyanophenyl)-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropyl]methyl 2-methylpropanoate (<b>28</b>)</h4><div class="NLM_p last">A screw cap vial charged with compound <b>25</b> (20 mg, 0.062 mmol), DIPEA (12 mg, 0.094 mmol), 2-methylpropanoyl chloride (9.8 μL, 0.094 mmol), and DCE (0.5 mL) was shaken at rt overnight. Volatiles was removed under reduced pressure after which acidic prep HPLC purification afforded the title compound. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 391.18 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.42 (t, <i>J</i> = 1.8 Hz, 1H), 8.31 (dt, <i>J</i> = 1.6, 8.1 Hz, 1H), 7.95 (dt, <i>J</i> = 1.4, 7.7 Hz, 1H), 7.72 (t, <i>J</i> = 7.9 Hz, 1H), 7.38 (d, <i>J</i> = 8.1 Hz, 1H), 7.18 (d, <i>J</i> = 8.1 Hz, 1H), 4.45 (s, 2H), 4.01 (s, 3H), 2.51–2.37 (m, 1H), 1.32–1.26 (m, 2H), 1.19–1.14 (m, 2H), 0.97 (d, <i>J</i> = 7.0 Hz, 6H).</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 1-[5-(3-Cyanophenyl)-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylic Acid (<b>29</b>)</h4><div class="NLM_p last">See the preparation of compound <b>191</b> described in WO 2010/069322. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 335.12 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.12–8.07 (m, 2H), 7.78 (dt, <i>J</i> = 1.5, 7.9 Hz, 1H), 7.69–7.61 (m, 1H), 7.11 (d, <i>J</i> = 8.2 Hz, 1H), 7.01 (d, <i>J</i> = 8.2 Hz, 1H), 4.12 (s, 3H), 2.02–1.90 (m, 2H), 1.86–1.74 (m, 2H).</div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 2-[1-[5-(3-Cyanophenyl)-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropyl]acetic Acid (<b>30</b>)</h4><div class="NLM_p">A mixture of [1-(5-iodo-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl)cyclopropyl]methanol (<b>63</b>) (prepared as compound <b>308</b> in WO 2010/069322) (4.0 g, 12 mmol), TEA (4.7 mL, 35 mmol), and MsCl (1.0 mL, 13 mmol) in DCM (50 mL) was stirred at 0 °C for 15 min. Water was added, and the reaction mixture was extracted with DCM. The combined organic phases were dried over MgSO<sub>4</sub>, and evaporation to dryness afforded [1-(5-iodo-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl)cyclopropyl]methylmethanesulfonate (4.5 g, 91% yield) which was used in the next step without further purification.</div><div class="NLM_p">NaCN (825 mg, 16.8 mmol) was added slowly to a solution of [1-(5-iodo-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl)cyclopropyl]methylmethanesulfonate (3.7 g, 8.4 mmol) in DMF (20 mL). The mixture was heated at 80 °C for 2 h. Water was added, and the mixture was carefully extracted with EtOAc. The aqueous phase was quenched with a solution of KMnO<sub>4</sub>. The combined organic phases were dried over MgSO<sub>4</sub>, and evaporation to dryness afforded 2-[1-(5-iodo-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl)cyclopropyl]acetonitrile (2.0 g, 66% yield) which was used in the next step without further purification.</div><div class="NLM_p">A solution of 2-[1-(5-iodo-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl)cyclopropyl]acetonitrile (4.0 g, 11 mmol) and HCl in MeOH was stirred for 8 h at 70 °C. The solvent was then removed. Aqueous NaHCO<sub>3</sub> was added, and the mixture was extracted with EtOAc. Column chromatography afforded methyl 2-[1-(5-iodo-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl)cyclopropyl]acetate (3.5 g, 81% yield).</div><div class="NLM_p">Solid LiOH (1.8 g, 45 mmol) was added at rt to a solution of methyl 2-[1-(5-iodo-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl)cyclopropyl]acetate (3.5 g, 9.0 mmol) in THF (20 mL), MeOH (7 mL), and water (3.5 mL). The mixture was heated at 50 °C for 2 h before the solvents were removed under reduced pressure. Water was added, and the pH of the crude reaction mixture was adjusted to 5 with 1 M HCl before the aqueous phase was extracted with EtOAc. Column chromatography afforded 2-[1-(5-iodo-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl)cyclopropyl]acetic acid (<b>66</b>) (2.3 g, 69% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.46 (d, <i>J</i> = 8.1 Hz, 1H), 6.88 (d, <i>J</i> = 8.2 Hz, 1H), 3.93 (s, 3H), 2.82 (s, 2H), 1.28–1.21 (m, 2H), 1.06–0.98 (m, 2H).</div><div class="NLM_p last">A vial charged with compound <b>66</b> (800 mg, 2.14 mmol), (3-cyanophenyl)boronic acid (473 mg, 3.22 mmol), K<sub>3</sub>PO<sub>4</sub> (1.59 g, 7.50 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (39.3 mg, 0.0429 mmol), and PCy<sub>3</sub> (24.1 mg, 0.0858 mmol) in a degassed 2:1 dioxane–water mixture (19.2 mL) was heated in a microwave oven at 130 °C for 10 min. The crude reaction mixture was then poured into 0.05 M aqueous NaOH (210 mL). The aqueous phase was washed with EtOAc (2 × 40 mL) after which the pH was adjusted to 3 with 4 M HCl. The aqueous phase was extracted with EtOAc (3 × 50 mL). The combined organic extracts were dried over MgSO<sub>4</sub>, filtered, and evaporated to dryness. Acidic prep HPLC purification afforded compound <b>30</b>. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 349.13 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.42 (t, <i>J</i> = 1.8 Hz, 1H), 8.40–8.32 (m, 1H), 7.94 (dt, <i>J</i> = 1.5, 7.8 Hz, 1H), 7.72 (t, <i>J</i> = 7.9 Hz, 1H), 7.38 (d, <i>J</i> = 8.3 Hz, 1H), 7.16 (d, <i>J</i> = 8.3 Hz, 1H), 4.01 (s, 3H), 2.78 (s, 2H), 1.31–1.17 (m, 2H), 1.14–0.98 (m, 2H).</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 3-[1-[5-(3-Cyanophenyl)-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropyl]propanoic Acid (<b>31</b>)</h4><div class="NLM_p">Dimethyl malonate (4.54 mL, 37.9 mmol) was slowly added to a suspension of NaH (60%, 1.19 g, 37.9 mmol) in toluene (200 mL) at 0 °C. The mixture was heated at reflux for 1.5 h before a solution of [1-(5-iodo-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl)cyclopropyl]methylmethanesulfonate (see preparation of compound <b>30</b>) (5.0 g, 11.8 mmol) in toluene was slowly added at rt. The reaction mixture was heated at reflux for an additional 3 h. Volatiles were removed under reduced pressure, water was added, and the aqueous phase was extracted with EtOAc. The organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. Column chromatography (eluent: 5% EtOAc in DCM) afforded dimethyl 2-[[1-(5-iodo-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl)cyclopropyl]methyl]propanedioate (3.7 g, 68% yield).</div><div class="NLM_p">A mixture of dimethyl 2-[[1-(5-iodo-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl)cyclopropyl]methyl]propanedioate (3.78 g, 8.06 mmol) in 6 N HCl (40 mL, 240 mmol) was heated at 100 °C for 16 h before it was cooled to 0 °C. Water was added, and the aqueous phase was extracted with EtOAc. The organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. Column chromatography (eluent: 3% MeOH in CHCl<sub>3</sub>) afforded 3-[1-(5-iodo-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl)cyclopropyl]propanoic acid (<b>67</b>) (2.1 g, 68% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.04 (s, 1H), 7.47 (d, <i>J</i> = 8.1 Hz, 1H), 6.89 (d, <i>J</i> = 8.3 Hz, 1H), 3.93 (s, 3H), 2.58–2.52 (m, 2H), 2.14–1.98 (m, 2H), 1.22–1.11 (m, 2H), 1.02–0.90 (m, 2H).</div><div class="NLM_p last">A vial charged with compound <b>67</b> (800 mg, 2.01 mmol), (3-cyanophenyl)boronic acid (455 mg, 3.10 mmol), K<sub>3</sub>PO<sub>4</sub> (1.54 g, 7.23 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (37.8 mg, 0.0413 mmol), and PCy<sub>3</sub> (23.2 mg, 0.0827 mmol) in a degassed 2:1 dioxane–water mixture (19.2 mL) was heated in a microwave oven at 130 °C for 10 min. The crude reaction mixture was then poured into 0.05 M aqueous NaOH (210 mL). The aqueous phase was washed with EtOAc (2 × 40 mL) after which the pH was adjusted to 3 with 4 M HCl. The aqueous phase was extracted with EtOAc (3 × 50 mL). The combined organic extracts were dried over MgSO<sub>4</sub>, filtered, and evaporated to dryness. Acidic prep HPLC purification afforded compound <b>31</b>. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 363.15 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.41 (t, <i>J</i> = 1.7 Hz, 1H), 8.34 (dt, <i>J</i> = 1.5, 8.0 Hz, 1H), 7.94 (dt, <i>J</i> = 1.2, 7.7 Hz, 1H), 7.73 (t, <i>J</i> = 7.9 Hz, 1H), 7.36 (d, <i>J</i> = 8.3 Hz, 1H), 7.16 (d, <i>J</i> = 8.3 Hz, 1H), 4.01 (s, 3H), 2.54–2.45 (m, 2H), 2.07–2.00 (m, 2H), 1.19–1.09 (m, 2H), 1.02–0.91 (m, 2H).</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Isobutyl 1-[5-(3-Cyanophenyl)-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylate (<b>32</b>)</h4><div class="NLM_p last">A mixture of compound <b>29</b> (17 mg, 0.050 mmol), EDAC·HCl (19 mg, 0.10 mmol), DMAP (12 mg, 0.10 mmol), <sup>i</sup>BuOH (45 μL, 0.49 mmol) in DCM (1.0 mL) was stirred at rt overnight. Volatiles were removed under reduced pressure. Acidic prep HPLC purification afforded the title compound. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 391.18 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.40 (t, <i>J</i> = 1.9 Hz, 1H), 8.29 (dt, <i>J</i> = 1.4, 8.0 Hz, 1H), 7.96 (dt, <i>J</i> = 1.3, 7.7 Hz, 1H), 7.75 (t, <i>J</i> = 7.9 Hz, 1H), 7.41 (d, <i>J</i> = 8.1 Hz, 1H), 7.21 (d, <i>J</i> = 8.1 Hz, 1H), 4.03 (s, 3H), 3.85 (d, <i>J</i> = 6.5 Hz, 2H), 1.95–1.67 (m, 1H), 1.62–1.54 (m, 2H), 1.54–1.46 (m, 2H), 0.79 (d, <i>J</i> = 6.8 Hz, 6H).</div></div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Methyl 1-[8-Methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylate (<b>33</b>)</h4><div class="NLM_p last">Compound <b>33</b> was synthesized following the same procedure as the one outlined for compound <b>32</b>, the only difference being that <b>54</b> was used as starting material instead of <b>29</b>. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 380.13 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.23 (br s, 1H), 8.14 (dd, <i>J</i> = 1.5, 8.1 Hz, 1H), 8.01 (d, <i>J</i> = 8.1 Hz, 1H), 7.41 (d, <i>J</i> = 8.1 Hz, 1H), 7.24 (d, <i>J</i> = 8.3 Hz, 1H), 5.52 (s, 2H), 4.04 (s, 3H), 3.62 (s, 3H), 1.59–1.53 (m, 2H), 1.53–1.47 (m, 2H).</div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> Ethyl 1-[8-Methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylate (<b>34</b>)</h4><div class="NLM_p last">Compound <b>34</b> was synthesized following the same procedure as the one outlined for compound <b>33</b>, the only difference being that EtOH was used as coupling partner instead of MeOH. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 394.14 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.23 (br s, 1H), 8.14 (dd, <i>J</i> = 1.4, 8.1 Hz, 1H), 8.00 (d, <i>J</i> = 8.1 Hz, 1H), 7.41 (d, <i>J</i> = 8.1 Hz, 1H), 7.24 (d, <i>J</i> = 8.3 Hz, 1H), 5.52 (s, 2H), 4.11 (q, <i>J</i> = 7.1 Hz, 2H), 4.04 (s, 3H), 1.60–1.53 (m, 2H), 1.53–1.44 (m, 2H), 1.14 (t, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec5_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Propyl 1-[8-Methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylate (<b>35</b>)</h4><div class="NLM_p last">Compound <b>35</b> was synthesized following the same procedure as the one outlined for compound <b>33</b>, the only difference being that <sup><i>n</i></sup>PrOH was used as coupling partner instead of MeOH. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 408.16 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.25–8.21 (br s, 1H), 8.14 (dd, <i>J</i> = 1.5, 8.1 Hz, 1H), 8.00 (d, <i>J</i> = 8.0 Hz, 1H), 7.40 (d, <i>J</i> = 8.1 Hz, 1H), 7.23 (d, <i>J</i> = 8.2 Hz, 1H), 5.51 (s, 2H), 4.04 (s, 3H), 4.01 (t, <i>J</i> = 6.6 Hz, 2H), 1.59–1.55 (m, 2H), 1.55–1.47 (m, 4H), 0.79 (t, <i>J</i> = 7.5 Hz, 3H).</div></div><div id="sec5_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> Isopropyl 1-[8-Methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylate (<b>36</b>)</h4><div class="NLM_p last">Compound <b>36</b> was synthesized following the same procedure as the one outlined for compound <b>33</b>, the only difference being that <sup><i>i</i></sup>PrOH was used as coupling partner instead of MeOH. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 408.16 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.23 (br s, 1H), 8.15 (dd, <i>J</i> = 1.5, 8.1 Hz, 1H), 7.99 (d, <i>J</i> = 7.9 Hz, 1H), 7.41 (d, <i>J</i> = 8.1 Hz, 1H), 7.23 (d, <i>J</i> = 8.3 Hz, 1H), 5.51 (s, 2H), 4.98–4.90 (m, 1H), 4.04 (s, 3H), 1.58–1.51 (m, 2H), 1.51–1.45 (m, 2H), 1.16 (d, <i>J</i> = 6.2 Hz, 6H).</div></div><div id="sec5_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> <i>tert</i>-Butyl 1-[8-Methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylate (<b>37</b>)</h4><div class="NLM_p last">See the preparation of compound <b>4</b> described in WO 2013/092739. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 422.17 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.25 (br s, 1H), 8.16 (dd, <i>J</i> = 1.5, 8.0 Hz, 1H), 8.00 (d, <i>J</i> = 8.0 Hz, 1H), 7.40 (d, <i>J</i> = 8.3 Hz, 1H), 7.22 (d, <i>J</i> = 8.3 Hz, 1H), 5.51 (s, 2H), 4.04 (s, 3H), 1.54–1.47 (m, 2H), 1.45–1.40 (m, 2H), 1.38 (s, 9H).</div></div><div id="sec5_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> [(1<i>R</i>)-1-Methylpropyl] 1-[8-Methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylate (<b>38</b>)</h4><div class="NLM_p last">See the preparation of compound <b>2</b> described in WO 2013/092739. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 422.17 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.24–8.20 (br s, 1H), 8.14 (dd, <i>J</i> = 1.4, 8.0 Hz, 1H), 7.99 (d, <i>J</i> = 8.0 Hz, 1H), 7.40 (d, <i>J</i> = 8.1 Hz, 1H), 7.23 (d, <i>J</i> = 8.2 Hz, 1H), 5.51 (s, 2H), 4.85–4.71 (m, 1H), 4.04 (s, 3H), 1.60–1.56 (m, 1H), 1.56–1.50 (m, 2H), 1.50–1.41 (m, 3H), 1.13 (d, <i>J</i> = 6.3 Hz, 3H), 0.78 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec5_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> [(1<i>S</i>)-1-Methylpropyl] 1-[8-methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylate (<b>39</b>)</h4><div class="NLM_p last">See the preparation of compound <b>1</b> described in WO 2013/092739. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 422.17 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.22 (br s, 1H), 8.14 (dd, <i>J</i> = 1.5, 8.0 Hz, 1H), 7.99 (d, <i>J</i> = 8.0 Hz, 1H), 7.41 (d, <i>J</i> = 8.3 Hz, 1H), 7.23 (d, <i>J</i> = 8.3 Hz, 1H), 5.51 (s, 2H), 4.82–4.74 (m, 1H), 4.04 (s, 3H), 1.60–1.56 (m, 1H), 1.56–1.50 (m, 2H), 1.50–1.40 (m, 3H), 1.13 (d, <i>J</i> = 6.2 Hz, 3H), 0.78 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec5_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> Isobutyl 1-[8-Methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylate (<b>40</b>)</h4><div class="NLM_p last">See the preparation of compound <b>3</b> described in WO 2013/092739. The synthesis of compound <b>40</b> on kilogram scale is provided in WO 2014/206903. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 422.17 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.22 (br s, 1H), 8.13 (dd, <i>J</i> = 1.5, 8.1 Hz, 1H), 8.00 (d, <i>J</i> = 8.0 Hz, 1H), 7.40 (d, <i>J</i> = 8.2 Hz, 1H), 7.24 (d, <i>J</i> = 8.2 Hz, 1H), 5.51 (s, 2H), 4.04 (s, 3H), 3.84 (d, <i>J</i> = 6.5 Hz, 2H), 1.85–1.74 (m, 1H), 1.61–1.54 (m, 2H), 1.54–1.46 (m, 2H), 0.78 (d, <i>J</i> = 6.7 Hz, 6H).</div></div><div id="sec5_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> Butyl 1-[8-Methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylate (<b>41</b>)</h4><div class="NLM_p last">Compound <b>41</b> was synthesized following the same procedure as the one outlined for compound <b>33</b>, the only difference being that <sup><i>n</i></sup>BuOH was used as coupling partner instead of MeOH. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 422.17 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.22 (br s, 1H), 8.14 (dd, <i>J</i> = 1.6, 8.1 Hz, 1H), 8.00 (d, <i>J</i> = 8.1 Hz, 1H), 7.40 (d, <i>J</i> = 8.1 Hz, 1H), 7.24 (d, <i>J</i> = 8.2 Hz, 1H), 5.52 (s, 2H), 4.05 (t, <i>J</i> = 6.6 Hz, 2H), 4.04 (s, 3H), 1.60–1.53 (m, 2H), 1.53–1.45 (m, 4H), 1.27–1.19 (m, 2H), 0.78 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec5_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> Cyclobutyl 1-[8-Methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylate (<b>42</b>)</h4><div class="NLM_p last">Compound <b>42</b> was synthesized following the same procedure as the one outlined for compound <b>33</b>, the only difference being that cyclobutanol was used as coupling partner instead of MeOH. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 420.16 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.23 (br s, 1H), 8.15 (dd, <i>J</i> = 1.5, 8.0 Hz, 1H), 8.00 (d, <i>J</i> = 8.1 Hz, 1H), 7.41 (d, <i>J</i> = 8.3 Hz, 1H), 7.24 (d, <i>J</i> = 8.3 Hz, 1H), 5.52 (s, 2H), 4.98–4.89 (m, 1H), 4.04 (s, 3H), 2.28–2.20 (m, 2H), 1.98–1.89 (m, 2H), 1.74–1.66 (m, 1H), 1.61–1.52 (m, 3H), 1.52–1.47 (m, 2H).</div></div><div id="sec5_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> Cyclopentyl 1-[8-Methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylate (<b>43</b>)</h4><div class="NLM_p last">Compound <b>43</b> was synthesized following the same procedure as the one outlined for compound <b>33</b>, the only difference being that cyclopentanol was used as coupling partner instead of MeOH. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 434.17 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.22 (br s, 1H), 8.13 (dd, <i>J</i> = 1.5, 8.0 Hz, 1H), 7.99 (d, <i>J</i> = 8.0 Hz, 1H), 7.40 (d, <i>J</i> = 8.1 Hz, 1H), 7.23 (d, <i>J</i> = 8.3 Hz, 1H), 5.51 (s, 2H), 5.10 (tt, <i>J</i> = 2.7, 5.9 Hz, 1H), 4.04 (s, 3H), 1.83–1.72 (m, 2H), 1.59–1.52 (m, 4H), 1.52–1.43 (m, 6H).</div></div><div id="sec5_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> Cyclohexyl 1-[8-Methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylate (<b>44</b>)</h4><div class="NLM_p last">Compound <b>44</b> was synthesized following the same procedure as the one outlined for compound <b>33</b>, the only difference being that cyclohexanol was used as coupling partner instead of MeOH. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 448.19 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.23 (br s, 1H), 8.14 (dd, <i>J</i> = 1.4, 8.1 Hz, 1H), 7.99 (d, <i>J</i> = 8.0 Hz, 1H), 7.41 (d, <i>J</i> = 8.1 Hz, 1H), 7.23 (d, <i>J</i> = 8.1 Hz, 1H), 5.51 (s, 2H), 4.73 (tt, <i>J</i> = 3.7, 8.1 Hz, 1H), 4.04 (s, 3H), 1.75–1.66 (m, 2H), 1.60–1.51 (m, 4H), 1.51–1.46 (m, 2H), 1.43–1.32 (m, 3H), 1.31–1.24 (m, 2H), 1.21–1.12 (m, 1H).</div></div><div id="sec5_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> Cycloheptyl 1-[8-Methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylate (<b>45</b>)</h4><div class="NLM_p last">Compound <b>45</b> was synthesized following the same procedure as the one outlined for compound <b>33</b>, the only difference being that cycloheptanol was used as coupling partner instead of MeOH. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 462.20 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.22 (br s, 1H), 8.14 (dd, <i>J</i> = 1.5, 8.1 Hz, 1H), 7.99 (d, <i>J</i> = 7.8 Hz, 1H), 7.40 (d, <i>J</i> = 8.1 Hz, 1H), 7.23 (d, <i>J</i> = 8.1 Hz, 1H), 5.51 (s, 2H), 4.89 (tt, <i>J</i> = 4.1, 8.0 Hz, 1H), 4.04 (s, 3H), 1.81–1.72 (m, 2H), 1.62–1.52 (m, 4H), 1.52–1.30 (m, 10H).</div></div><div id="sec5_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> Oxetan-3-yl 1-[8-Methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylate (<b>46</b>)</h4><div class="NLM_p last">Compound <b>46</b> was synthesized following the same procedure as the one outlined for compound <b>33</b>, the only difference being that 3-oxetanol was used as coupling partner instead of MeOH. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 422.14 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.25 (br s, 1H), 8.16 (dd, <i>J</i> = 1.3, 8.1 Hz, 1H), 8.01 (d, <i>J</i> = 8.1 Hz, 1H), 7.42 (d, <i>J</i> = 8.1 Hz, 1H), 7.25 (d, <i>J</i> = 8.1 Hz, 1H), 5.51 (s, 2H), 5.42 (t, <i>J</i> = 5.8 Hz, 1H), 4.81–4.76 (m, 2H), 4.44 (dd, <i>J</i> = 4.9, 7.9 Hz, 2H), 4.04 (s, 3H), 1.69–1.61 (m, 2H), 1.61–1.51 (m, 2H).</div></div><div id="sec5_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> [(3<i>R</i>)-Tetrahydrofuran-3-yl] 1-[8-methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylate (<b>47</b>)</h4><div class="NLM_p last">Compound <b>47</b> was synthesized following the same procedure as the one outlined for compound <b>33</b>, the only difference being that (3<i>R</i>)-tetrahydrofuran-3-ol was used as coupling partner instead of MeOH. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 436.15 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.23 (br s, 1H), 8.14 (dd, <i>J</i> = 1.4, 8.1 Hz, 1H), 8.00 (d, <i>J</i> = 8.0 Hz, 1H), 7.41 (d, <i>J</i> = 8.1 Hz, 1H), 7.24 (d, <i>J</i> = 8.3 Hz, 1H), 5.52 (s, 2H), 5.31–5.27 (m, 1H), 4.04 (s, 3H), 3.77 (dd, <i>J</i> = 4.6, 10.4 Hz, 1H), 3.68–3.60 (m, 3H), 2.11 (dtd, <i>J</i> = 6.3, 8.2, 13.6 Hz, 1H), 1.87–1.79 (m, 1H), 1.62–1.55 (m, 2H), 1.54–1.47 (m, 2H).</div></div><div id="sec5_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> [(3<i>S</i>)-Tetrahydrofuran-3-yl] 1-[8-methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-5-yl)-[1,2,4]triazolo-[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylate (<b>48</b>)</h4><div class="NLM_p last">Compound <b>48</b> was synthesized following the same procedure as the one outlined for compound <b>33</b>, the only difference being that (3<i>S</i>)-tetrahydrofuran-3-ol was used as coupling partner instead of MeOH. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 436.15 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.23 (br s, 1H), 8.14 (dd, <i>J</i> = 1.5, 8.0 Hz, 1H), 8.00 (d, <i>J</i> = 8.1 Hz, 1H), 7.41 (d, <i>J</i> = 8.2 Hz, 1H), 7.24 (d, <i>J</i> = 8.3 Hz, 1H), 5.51 (s, 2H), 5.32–5.26 (m, 1H), 4.04 (s, 3H), 3.78 (dd, <i>J</i> = 4.6, 10.4 Hz, 1H), 3.69–3.60 (m, 3H), 2.11 (dtd, <i>J</i> = 6.3, 8.2, 13.5 Hz, 1H), 1.87–1.79 (m, 1H), 1.62–1.55 (m, 2H), 1.55–1.47 (m, 2H).</div></div><div id="sec5_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> Tetrahydropyran-4-yl 1-[8-methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylate (<b>49</b>)</h4><div class="NLM_p last">Compound <b>49</b> was synthesized following the same procedure as the one outlined for compound <b>33</b>, the only difference being that tetrahydropyran-4-ol was used as coupling partner instead of MeOH. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 450.17 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.23 (br s, 1H), 8.13 (dd, <i>J</i> = 1.4, 8.1 Hz, 1H), 8.00 (d, <i>J</i> = 8.1 Hz, 1H), 7.40 (d, <i>J</i> = 8.1 Hz, 1H), 7.24 (d, <i>J</i> = 8.2 Hz, 1H), 5.51 (s, 2H), 4.93 (tt, <i>J</i> = 3.8, 7.8 Hz, 1H), 4.04 (s, 3H), 3.64 (ddd, <i>J</i> = 3.8, 6.1, 10.7 Hz, 2H), 3.41 (ddd, <i>J</i> = 3.3, 8.0, 11.4 Hz, 2H), 1.81 (ddd, <i>J</i> = 3.4, 6.4, 13.5 Hz, 2H), 1.62–1.56 (m, 2H), 1.56–1.44 (m, 4H).</div></div><div id="sec5_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> (2-Hydroxy-2-methylpropyl) 1-[8-methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylate (<b>50</b>)</h4><div class="NLM_p last">Compound <b>50</b> was synthesized following a procedure similar to the one outlined for compound <b>33</b>, the major difference being that 2-methylpropane-1,2-diol was used as coupling partner instead of MeOH. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 438.17 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.24 (br s, 1H), 8.13 (dd, <i>J</i> = 1.4, 8.1 Hz, 1H), 8.00 (d, <i>J</i> = 8.1 Hz, 1H), 7.40 (d, <i>J</i> = 8.1 Hz, 1H), 7.24 (d, <i>J</i> = 8.2 Hz, 1H), 5.51 (s, 2H), 4.54 (s, 1H), 4.04 (s, 3H), 3.83 (s, 2H), 1.66–1.56 (m, 2H), 1.56–1.47 (m, 2H), 0.98 (s, 6H).</div></div><div id="sec5_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> [(2<i>R</i>)-3-Hydroxy-2-methylpropyl] 1-[8-Methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylate (<b>51</b>)</h4><div class="NLM_p last">A mixture of compound <b>54</b> (100 mg, 0.274 mmol), (2<i>R</i>)-3-bromo-2-methylpropan-1-ol (200 mg, 1.31 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (44,6 mg, 0.137 mmol) in DMSO (4.0 mL) was stirred over the weekend. Acidic prep HPLC purification afforded the title compound. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 438.17 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.11 (br s, 1H), 8.05 (d, <i>J</i> = 8.0 Hz, 1H), 7.98 (dd, <i>J</i> = 1.4, 8.1 Hz, 1H), 7.10 (d, <i>J</i> = 8.0 Hz, 1H), 6.91 (d, <i>J</i> = 8.2 Hz, 1H), 5.43 (s, 2H), 4.23 (dd, <i>J</i> = 4.6, 11.0 Hz, 1H), 4.10 (s, 3H), 4.01 (dd, <i>J</i> = 7.5, 11.0 Hz, 1H), 3.53–3.34 (m, 2H), 2.00–1.90 (m, 1H), 1.76–1.68 (m, 2H), 1.67–1.59 (m, 2H), 0.85 (d, <i>J</i> = 6.9 Hz, 3H).</div></div><div id="sec5_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> [(2<i>S</i>)-3-Hydroxy-2-methylpropyl] 1-[8-Methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylate (<b>52</b>)</h4><div class="NLM_p last">Compound <b>52</b> was synthesized following the same procedure as the one outlined for compound <b>51</b>, the only difference being that (2<i>S</i>)-3-bromo-2-methylpropan-1-ol was used as alkylation reagent instead of (2<i>R</i>)-3-bromo-2-methylpropan-1-ol. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 438.17 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.22 (br s, 1H), 8.13 (dd, <i>J</i> = 1.5, 8.1 Hz, 1H), 8.00 (d, <i>J</i> = 8.0 Hz, 1H), 7.40 (d, <i>J</i> = 8.1 Hz, 1H), 7.23 (d, <i>J</i> = 8.3 Hz, 1H), 5.51 (s, 2H), 4.51 (t, <i>J</i> = 5.3 Hz, 1H), 4.10–3.97 (m, 4H), 3.92 (dd, <i>J</i> = 6.2, 10.7 Hz, 1H), 3.20 (t, <i>J</i> = 5.5 Hz, 2H), 1.87–1.68 (m, <i>J</i> = 6.6 Hz, 1H), 1.62–1.54 (m, 2H), 1.54–1.46 (m, 2H), 0.75 (d, <i>J</i> = 6.9 Hz, 3H).</div></div><div id="sec5_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 2-(Hydroxymethyl)-4-[2-(1-isobutoxycarbonylcyclopropyl)-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl]benzoic Acid (<b>53</b>)</h4><div class="NLM_p last">Aqueous NaOH (0.10 M, 1.2 mL, 0.12 mmol) was added to a suspension of compound <b>40</b> (50 mg, 0.12 mmol) in dioxane (5.0 mL), and the reaction mixture was stirred at rt overnight. More NaOH (0.10 M, 0.24 mL, 0.024 mmol) was then added, and after an additional 1.5 h of stirring at rt, basic prep HPLC purification afforded the title compound. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 440.18 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.19 (br s, 1H), 7.98 (d, <i>J</i> = 8.2 Hz, 1H), 7.93 (dd, <i>J</i> = 1.9, 8.1 Hz, 1H), 7.32 (d, <i>J</i> = 8.1 Hz, 1H), 7.21 (d, <i>J</i> = 8.2 Hz, 1H), 4.90 (s, 2H), 4.03 (s, 3H), 3.84 (d, <i>J</i> = 6.5 Hz, 2H), 1.87–1.72 (m, 1H), 1.59–1.53 (m, 2H), 1.53–1.47 (m, 2H), 0.78 (d, <i>J</i> = 6.7 Hz, 6H).</div></div><div id="sec5_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> 1-[8-Methoxy-5-(1-oxo-3<i>H</i>-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-yl]cyclopropanecarboxylic Acid (<b>54</b>)</h4><div class="NLM_p last">See the “Preparation 1 to 11” described in WO 2013/092739. The synthesis of compound <b>54</b> on kilogram scale is provided in WO 2014/206903. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 366.11 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.23 (br s, 1H), 8.13 (dd, <i>J</i> = 1.5, 8.1 Hz, 1H), 8.00 (d, <i>J</i> = 8.1 Hz, 1H), 7.39 (d, <i>J</i> = 8.1 Hz, 1H), 7.23 (d, <i>J</i> = 8.2 Hz, 1H), 5.51 (s, 2H), 4.04 (s, 3H), 1.56–1.46 (m, 2H), 1.45–1.35 (m, 2H).</div></div><div id="sec5_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> 4-[2-(1-Carboxycyclopropyl)-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl]-2-(hydroxymethyl)benzoic Acid (<b>55</b>)</h4><div class="NLM_p last">The preparation is described in WO 2014/206903. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 384.12 (MH<sup>+</sup>). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.21 (br s, 1H), 7.99 (d, <i>J</i> = 8.2 Hz, 1H), 7.93 (dd, <i>J</i> = 1.8, 8.1 Hz, 1H), 7.31 (d, <i>J</i> = 8.1 Hz, 1H), 7.21 (d, <i>J</i> = 8.3 Hz, 1H), 4.91 (s, 2H), 4.03 (s, 3H), 1.58–1.47 (m, 2H), 1.47–1.38 (m, 2H).</div></div><div id="sec5_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> 2-(Hydroxymethyl)-4-[2-[1-(2-hydroxy-2-methylpropoxy)carbonylcyclopropyl]-8-methoxy-[1,2,4]triazolo[1,5-<i>a</i>]pyridin-5-yl]benzoic Acid (<b>72</b>)</h4><div class="NLM_p last">A suspension of compound <b>50</b> (60 mg, 0.14 mmol) and solid K<sub>3</sub>PO<sub>4</sub> (44 mg, 0.21 mmol) in MeCN (10 mL) and water (4.0 mL) was stirred at rt for 3 days. Acidic prep HPLC purification afforded the title compound. UPLC–MS (ESI+) <i>m</i>/<i>z</i> 456.18 (MH<sup>+</sup>). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.13 (br s, 1H), 7.97 (d, <i>J</i> = 8.1 Hz, 1H), 7.92 (dd, <i>J</i> = 2.0, 8.3 Hz, 1H), 7.30 (d, <i>J</i> = 8.1 Hz, 1H), 7.21 (d, <i>J</i> = 8.1 Hz, 1H), 4.86 (s, 2H), 4.55 (s, 1H), 4.03 (s, 3H), 3.82 (s, 2H), 1.65–1.56 (m, 2H), 1.52–1.47 (m, 2H).</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> PDE4 Assay</h3><div class="NLM_p last">Inhibition of PDE4 activity was measured using the IMAP (immobilized metal ion affinity particles) TR-FRET progressive binding assay (Molecular Devices). In brief, the human PDE4D catalytic domain was incubated with titrated test compound and a mixture of nonlabeled cAMP and fluorescein amidite (FAM) conjugated cAMP. Following a brief incubation, the enzymatic reaction was stopped by the addition of nanoparticles containing a Tb labeled TR-FRET donor and capable of binding AMP phospho groups. Time-resolved FRET was measured on an Envision detection system and was inversely proportional to PDE4 inhibition.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> TNF-α Release</h3><div class="NLM_p last">Human peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats using Lymphoprep tubes (Medinor AB). The PBMCs were resuspended in RPMI1640 and preincubated for 30 min with titrated test compounds in 384-well assay plates at 5000 cells/well. Following 18 h stimulation with 10 ng/mL lipopolysaccharide (Sigma), secreted TNF-α was quantified by AlphaLISA (PerkinElmer).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> Modeling</h3><div class="NLM_p">Docking of <b>3</b> in the enol tautomeric form to PDE4 was performed using the crystal structure of PDE4 complexed roflumilast PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XOQ">1XOQ</a>). <b>3</b> was docked flexibly with Glide XP with 0.8 scaling of the protein atoms and default settings for ligand scaling. The highest scoring docking pose is shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>.</div><div class="NLM_p">A five-point pharmacophore model based on the docked conformation of <b>3</b> was generated with Phase. Low-energy conformations of <b>13</b> were generated with Macromodel (OPLS3e, water, TNCG minimization) and fitted to the pharmacophore hypothesis. The best fit (shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) is obtained with a conformation with a relative energy of 0.142 kJ/mol.</div><div class="NLM_p last">MacroModel, Phase, Glide, and Maestro were used as implemented in the Schrödinger software suite; Schrödinger, LLC, New York, NY.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> Crystallography</h3><div class="NLM_p last">The crystal structure of <b>40</b> complexed with PDE4D was solved to a resolution of 1.6 Å at SARomics Biostructures AB, Lund, Sweden. Hydrogens were added, H-bonds were optimized, and the complex was minimized using the Protein Preparation Wizard implemented in Maestro.</div></div><div id="sec5_5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> HLM Clearance</h3><div class="NLM_p last">Metabolic stability in human liver microsomes was measured as compound clearance following a 40 min incubation with human liver microsomes (0.5 mg/mL) and NADPH (1 mM) at a test compound concentration of 0.5 μM. Samples are taken out before addition of NADPH and at 5, 10, 20, and 40 min thereafter, and protein precipitation using cold acetonitrile with added internal standard is performed prior to centrifugation and sample analysis using compound specific LC–MS/MS methods. Control incubations in buffer and without NADPH are performed in the same manner. Compound depletion is determined and apparent clearance calculated.</div></div><div id="sec5_5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> Hepatocyte Clearance</h3><div class="NLM_p last">Metabolic stability in cryopreserved human, rat, and minipig hepatocytes is determined with 1 million cells/mL suspended in buffer at a test compound concentration of 0.5 μM in duplicate. After a preheating period of 10 min the test compound is added and the incubation continues with stirring for 0, 5, 10, 30, and 60 min. This is followed by protein precipitation using cold acetonitrile with added internal standard, centrifugation, and sample analysis using compound specific LC–MS/MS methods. Control incubations in buffer are performed in the same manner. The compound depletion over time was used to estimate the elimination rate constant, from which the apparent intrinsic clearance (CL<sub>app</sub>) and half-life (<i>t</i><sub>1/2</sub>) were calculated. The hepatic clearance is calculated using the well-stirred model.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div></div><div id="sec5_5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> Human Keratinocyte Stability</h3><div class="NLM_p last">The half-life of test compounds is determined in a human keratinocyte stability assay as surrogate for stability in the human skin. Plated human epidermal keratinocytes (1 × 10<sup>4</sup> cells/well) are incubated for up to 24 h with a test compound concentration of 1 μM in duplicate. Samples are taken at 0, 1, 2, 4, and 24 h and followed by protein precipitation using cold acetonitrile with added internal standard, centrifugation, and sample analysis using compound specific LC–MS/MS methods. Control incubations in growing medium are performed in the same manner. Compound half-life is reported.</div></div><div id="sec5_5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> Whole Blood Stability</h3><div class="NLM_p last">Compounds were incubated in diluted fresh rat, dog, cynomolgus monkey, or human whole blood (heparin stabilized, 50% blood and 50% phosphate buffer with 1% bovine serum albumin) for 120 min at 0.1 μM at 37 °C, and the half-lives were determined. Samples were taken at 0, 15, 30, 60, and 120 min, and reactions were terminated by addition of acetonitrile containing analytical internal standard (IS). All compounds were tested in duplicate. Testing for compound depletion used compound specific LC–MS/MS methods. The elimination rate constants (<i>k</i>) were calculated from peak areas, and the half-lives were determined (<i>t</i><sub>1/2</sub> = ln 2/<i>k</i>).</div></div><div id="ssecz" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> Metabolite Identification</h3><div class="NLM_p last">A cross-species comparison of metabolite profiles for both <b>40</b> and <b>53</b> was performed in hepatocytes (2 h, 10 μM incubation) and whole blood (2 h, 10 μM incubation) from human, rat, minipig, and monkey. The metabolite profiles were from using UPLC/TOF-MS analysis of the samples and with both targeted and untargeted search for metabolites using Metabolynx software (Waters) followed by confirmation with analytical standards of metabolites of <b>53</b>, <b>54</b>, <b>55</b>, <b>50</b> and <b>72</b>.</div></div><div id="sec5_5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> <i>In Vivo</i> Pharmacokinetics</h3><div class="NLM_p">The pharmacokinetic profile of <b>40</b> was determined in rat (<i>n</i> = 3, male, Sprague Dawley) after an intravenous (iv) injection in 20% cyclodextrin once at 0.075 mg/kg (50 μg/mL, 1.5 mL/kg). Blood is collected after 1, 3, 6, 9, 12, 15, and 30 min from the tongue vein in lithium-heparin vacutainers and immediately hereafter, transferred to Micronic vials containing heparin water, ratio blood–water (1:1). Protein precipitation with ice-cold acetonitrile (containing internal standard for bioanalysis) is performed, and samples were kept on ice until centrifugation and stored at −20 °C until analysis of <b>40</b>, <b>53</b>, <b>54</b>, and <b>55</b> by compound specific LC–MS/MS methods using an API 5500 QTRAP mass spectrometer.</div><div class="NLM_p last">The pharmacokinetic profile of <b>40</b> in minipig (2 female, 2 male, Göttingen) and monkey (2 female, 2 male cynomolgus) was determined in a 24 h infusion study dosed at 0.5 and 2.0 mg/kg (0.1 and 0.4 mg/mL at 5 mL/kg) in 100% tetraethylene glycol, and blood samples were taken at 0.25, 0.5, 1, 3, 7, and 24 h after the start of infusion and 6, 12, and 24 h after the end of the 24 h infusion period. Blood was sampled in tubes EDTA-K<sub>3</sub> as anticoagulant, centrifuged to prepare plasma, and stabilized with 50 mg of ascorbic acid prior to storage at −80 °C until analysis of <b>40</b>, <b>53</b>, <b>54</b>, <b>55, 50</b>, <b>71</b> by compound specific LC–MS/MS methods using an API 5500 QTRAP mass spectrometer. Pharmacokinetic parameters were derived from a noncompartment model in Phoenix64 (Pharsight, Certara).</div></div><div id="sec5_5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> Dermal Pharmacokinetics</h3><div class="NLM_p last">The dermal concentration of <b>40</b>, <b>53</b>, <b>54</b>, and <b>55</b> was investigated in female Göttingen minipigs after single topical application of <b>40</b> in 2.5 and 1 mg/g monoglyceride formulations (10 μL/cm<sup>2</sup> on a 4 cm<sup>2</sup> area on the belly/flank area). After dosing, excess formulation was removed, and after 24 h the test sites were tape stripped 2 times in order to remove surplus test item from stratum corneum followed by 10 times to remove stratum corneum. Punch biopsies of 8 mm were taken from each of the tape-stripped application sites and the biopsies were snap frozen in liquid nitrogen until analysis. The skin biopsies were homogenized, and protein precipitation was performed with acetonitrile containing internal standard and centrifugation prior to analysis until analysis of the samples by compound specific LC–MS/MS methods using an API 5500 QTRAP mass spectrometer.</div></div><div id="sec5_5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> <i>In Vivo</i> Study Procedures</h3><div class="NLM_p last">Animal experimental procedures as well as animal housing and husbandry were in compliance with Danish legislation, EU Directive, as well as the project license approved by the Danish authorities for animal experimentation.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i103"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00797" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61705" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61705" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00797?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00797</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">HPLC traces of key compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00797/suppl_file/jm0c00797_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00797/suppl_file/jm0c00797_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00797/suppl_file/jm0c00797_si_001.pdf">jm0c00797_si_001.pdf (949.62 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00797/suppl_file/jm0c00797_si_002.csv">jm0c00797_si_002.csv (4.0 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The atomic coordinates of <b>40</b> (LEO 39652) bound to PDE4D has been deposited with the Protein Data Bank under the accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ZBA">6ZBA</a>.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c00797" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45150" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45150" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon F. Nielsen</span> - <span class="hlFld-Affiliation affiliation">Drug
Design, , , , , and , LEO Pharma Global Research &
Development, 2750 Ballerup, Denmark</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8263-4469" title="Orcid link">http://orcid.org/0000-0001-8263-4469</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#27544149434c674b42480a574f46554a460944484a"><span class="__cf_email__" data-cfemail="c1b2a7afa5aa81ada4aeecb1a9a0b3aca0efa2aeac">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jens Larsen</span> - <span class="hlFld-Affiliation affiliation">Drug
Design, , , , , and , LEO Pharma Global Research &
Development, 2750 Ballerup, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maja Lambert</span> - <span class="hlFld-Affiliation affiliation">Drug
Design, , , , , and , LEO Pharma Global Research &
Development, 2750 Ballerup, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Henrik Pettersson</span> - <span class="hlFld-Affiliation affiliation">Drug
Design, , , , , and , LEO Pharma Global Research &
Development, 2750 Ballerup, Denmark</span>; 
    <span>Present Address:
                        H.P.: Altran Scandinavia. Email: <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="09616c677b606227796c7d7d6c7b7a7a66674968657d7b6867276a6664">[email protected]</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas Vifian</span> - <span class="hlFld-Affiliation affiliation">Drug
Design, , , , , and , LEO Pharma Global Research &
Development, 2750 Ballerup, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mogens Larsen</span> - <span class="hlFld-Affiliation affiliation">Drug
Design, , , , , and , LEO Pharma Global Research &
Development, 2750 Ballerup, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna Ollerstam</span> - <span class="hlFld-Affiliation affiliation">Skin Research, , , , , and , LEO Pharma Global Research &
Development, 2750 Ballerup, Denmark</span>; 
    <span>Present Address:
                        A.O.: AstraZeneca, Mölndal</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pontus Hegardt</span> - <span class="hlFld-Affiliation affiliation">Global Clinical Operations Projects, , , , , and , LEO Pharma Global Research &
Development, 2750 Ballerup, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cecilia Eskilsson</span> - <span class="hlFld-Affiliation affiliation">Preclinical Development, , , , , and , LEO Pharma Global Research &
Development, 2750 Ballerup, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steen Laursen</span> - <span class="hlFld-Affiliation affiliation">Preclinical Development, , , , , and , LEO Pharma Global Research &
Development, 2750 Ballerup, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anders Soehoel</span> - <span class="hlFld-Affiliation affiliation">Clinical Pharmacology, , , , , and , LEO Pharma Global Research &
Development, 2750 Ballerup, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tine Skak-Nielsen</span> - <span class="hlFld-Affiliation affiliation">Skin Research, , , , , and , LEO Pharma Global Research &
Development, 2750 Ballerup, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lene M. Hansen</span> - <span class="hlFld-Affiliation affiliation">Early Formulation and
Analytics, , , , , and , LEO Pharma Global Research &
Development, 2750 Ballerup, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nina Ø. Knudsen</span> - <span class="hlFld-Affiliation affiliation">Early Formulation and
Analytics, , , , , and , LEO Pharma Global Research &
Development, 2750 Ballerup, Denmark</span>; 
    <span>Present Address:
                        N.Ø.K.: R&D and Regulatory Affairs, Riemann A/S</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan Eirefelt</span> - <span class="hlFld-Affiliation affiliation">Drug
Design, , , , , and , LEO Pharma Global Research &
Development, 2750 Ballerup, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Morten D. Sørensen</span> - <span class="hlFld-Affiliation affiliation">Drug
Design, , , , , and , LEO Pharma Global Research &
Development, 2750 Ballerup, Denmark</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tatiana G. Stilou</span> - <span class="hlFld-Affiliation affiliation">Skin Research, , , , , and , LEO Pharma Global Research &
Development, 2750 Ballerup, Denmark</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i108">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66354" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66354" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Saromics Biostructures AB is gratefully acknowledge for expert assistance in determination of the structure of the PDE4-<b>40</b> complex.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">atopic dermatitis</p></td></tr><tr><td class="NLM_term">CES</td><td class="NLM_def"><p class="first last">carboxylesterase</p></td></tr><tr><td class="NLM_term">Hep</td><td class="NLM_def"><p class="first last">hepatotocytes</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">KC</td><td class="NLM_def"><p class="first last">keratinocyte</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">human peripheral blood mononuclear cell</p></td></tr><tr><td class="NLM_term">PON</td><td class="NLM_def"><p class="first last">paraoxonase</p></td></tr><tr><td class="NLM_term">Th1</td><td class="NLM_def"><p class="first last">T helper cell type 1</p></td></tr><tr><td class="NLM_term">Th2</td><td class="NLM_def"><p class="first last">T helper cell type 2</p></td></tr><tr><td class="NLM_term">Th17</td><td class="NLM_def"><p class="first last">T helper cell type 17</p></td></tr><tr><td class="NLM_term">TCI</td><td class="NLM_def"><p class="first last">topical calcineurin inhibitor</p></td></tr><tr><td class="NLM_term">TCS</td><td class="NLM_def"><p class="first last">topical corticosteroid</p></td></tr><tr><td class="NLM_term">WB</td><td class="NLM_def"><p class="first last">whole blood</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i110">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26521" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26521" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 30 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deluran, M.</span>; <span class="NLM_string-name">Olesen, A. B.</span>; <span class="NLM_string-name">Thestrup-Pedersen, K.</span></span> <span> </span><span class="NLM_article-title">Clinical Symptoms of Atopic Eczema</span>. In  <i>Handbook of Atopic Eczema</i>, <span class="NLM_edition">2</span>nd ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Ring, J.</span>, <span class="NLM_string-name">Przybilla, B.</span>, <span class="NLM_string-name">Ruzicka, T.</span></span>, Eds.; <span class="NLM_publisher-name">Springer-Verlag</span>: <span class="NLM_publisher-loc">Berlin</span>, <span class="NLM_year">2006</span>; pp  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">44</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1007%2F3-540-29856-8_5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=37-44&author=M.+Deluran&author=A.+B.+Olesen&author=K.+Thestrup-Pedersenauthor=J.+Ring&author=B.+Przybilla&author=T.+Ruzicka&title=Handbook+of+Atopic+Eczema"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2F3-540-29856-8_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F3-540-29856-8_5%26sid%3Dliteratum%253Aachs%26aulast%3DDeluran%26aufirst%3DM.%26atitle%3DClinical%2520Symptoms%2520of%2520Atopic%2520Eczema%26btitle%3DHandbook%2520of%2520Atopic%2520Eczema%26aulast%3DRing%26aufirst%3DJ.%26pub%3DSpringer-Verlag%26date%3D2006%26spage%3D37%26epage%3D44" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guttman-Yassky, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanifin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boguniewicz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollenberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bissonnette, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilty, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zielinski, A. M.</span></span> <span> </span><span class="NLM_article-title">The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition</span>. <i>Exp. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1111/exd.13808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1111%2Fexd.13808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=30332502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A280%3ADC%252BB3cvgsVOisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2019&pages=3-10&issue=1&author=E.+Guttman-Yasskyauthor=J.+M.+Hanifinauthor=M.+Boguniewiczauthor=A.+Wollenbergauthor=R.+Bissonnetteauthor=V.+Purohitauthor=I.+Kiltyauthor=A.+M.+Tallmanauthor=A.+M.+Zielinski&title=The+role+of+phosphodiesterase+4+in+the+pathophysiology+of+atopic+dermatitis+and+the+perspective+for+its+inhibition&doi=10.1111%2Fexd.13808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition</span></div><div class="casAuthors">Guttman-Yassky Emma; Hanifin Jon M; Boguniewicz Mark; Wollenberg Andreas; Bissonnette Robert; Purohit Vivek; Kilty Iain; Tallman Anna M; Zielinski Michael A</div><div class="citationInfo"><span class="NLM_cas:title">Experimental dermatology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Atopic dermatitis (AD) is a highly prevalent, chronic inflammatory skin disease that affects children and adults.  The pathophysiology of AD is complex and involves skin barrier and immune dysfunction.  Many immune cytokine pathways are amplified in AD, including T helper (Th) 2, Th22, Th17 and Th1.  Current treatment guidelines recommend topical medications as initial therapy; however, until recently, only two drug classes were available: topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs).  Several limitations are associated with these agents.  TCSs can cause a wide range of adverse effects, including skin atrophy, telangiectasia, rosacea and acne.  TCIs can cause burning and stinging, and the prescribing information lists a boxed warning for a theoretical risk of malignancy.  Novel medications with new mechanisms of action are necessary to provide better long-term control of AD.  Phosphodiesterase 4 (PDE4) regulates cyclic adenosine monophosphate in cells and has been shown to be involved in the pathophysiology of AD, making it an attractive therapeutic target.  Several PDE4 inhibitors are in clinical development for use in the treatment of AD, including crisaborole, which recently became the first topical PDE4 inhibitor approved for treatment of mild to moderate AD.  This review will further describe the pathophysiology of AD, explain the possible role of PDE4 in AD and review PDE4 inhibitors currently approved or being investigated for use in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQHPKrjoHI3K0ewzGPswiWOfW6udTcc2eadR35mK0TITrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvgsVOisA%253D%253D&md5=b52d04bd70a35a6d23b2dcc3c05aa959</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fexd.13808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fexd.13808%26sid%3Dliteratum%253Aachs%26aulast%3DGuttman-Yassky%26aufirst%3DE.%26aulast%3DHanifin%26aufirst%3DJ.%2BM.%26aulast%3DBoguniewicz%26aufirst%3DM.%26aulast%3DWollenberg%26aufirst%3DA.%26aulast%3DBissonnette%26aufirst%3DR.%26aulast%3DPurohit%26aufirst%3DV.%26aulast%3DKilty%26aufirst%3DI.%26aulast%3DTallman%26aufirst%3DA.%2BM.%26aulast%3DZielinski%26aufirst%3DA.%2BM.%26atitle%3DThe%2520role%2520of%2520phosphodiesterase%25204%2520in%2520the%2520pathophysiology%2520of%2520atopic%2520dermatitis%2520and%2520the%2520perspective%2520for%2520its%2520inhibition%26jtitle%3DExp.%2520Dermatol.%26date%3D2019%26volume%3D28%26issue%3D1%26spage%3D3%26epage%3D10%26doi%3D10.1111%2Fexd.13808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paton, D. M.</span></span> <span> </span><span class="NLM_article-title">Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1358/dot.2017.53.4.2604174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1358%2Fdot.2017.53.4.2604174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A280%3ADC%252BC1crmtVykug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2017&pages=239-245&issue=4&author=D.+M.+Paton&title=Crisaborole%3A+Phosphodiesterase+inhibitor+for+treatment+of+atopic+dermatitis&doi=10.1358%2Fdot.2017.53.4.2604174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis</span></div><div class="casAuthors">Paton D M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">239-245</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Atopic dermatitis (AD) is an extremely common condition affecting as many as 10-20% of children and 2-10% of adults.  A particularly distressing symptom of AD is pruritus.  One of the important aspects of AD is inflammation associated with increased activity of phosphodiesterase 4 (PDE4), resulting in decreased intracellular levels of cyclic adenosine monophosphate, which in turn causes increased production of inflammatory cytokines.  Crisaborole was developed as a small-molecule, boron-based, selective PDE4 inhibitor that can be used topically.  Clinical trials have demonstrated its efficacy in treating patients with mild to moderate AD, resulting in significant relief of pruritus.  Unlike PDE4 inhibitors that act systemically, crisaborole does not cause significant gastrointestinal adverse effects.  The most common adverse effect has been temporary stinging and burning in about 4% of patients upon application of the 2% ointment.  To date there is no evidence of atrophy, telangiectasia or hypopigmentation resulting from its use.  Crisaborole is the first topically applied PDE4 inhibitor to be approved by the FDA for use in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTC3c4rt0Hyh4qdXsLcGTEUfW6udTcc2eadR35mK0TITrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crmtVykug%253D%253D&md5=a854efec1d46127283db4e443c22221f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1358%2Fdot.2017.53.4.2604174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2017.53.4.2604174%26sid%3Dliteratum%253Aachs%26aulast%3DPaton%26aufirst%3DD.%2BM.%26atitle%3DCrisaborole%253A%2520Phosphodiesterase%2520inhibitor%2520for%2520treatment%2520of%2520atopic%2520dermatitis%26jtitle%3DDrugs%2520Today%26date%3D2017%26volume%3D53%26issue%3D4%26spage%3D239%26epage%3D245%26doi%3D10.1358%2Fdot.2017.53.4.2604174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freund, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maples, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plattner, J. J.</span></span> <span> </span><span class="NLM_article-title">Discovery and structure–activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2129</span>– <span class="NLM_lpage">2132</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.03.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1016%2Fj.bmcl.2009.03.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=19303290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkt1Sjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2129-2132&issue=8&author=T.+Akamaauthor=S.+J.+Bakerauthor=Y.+K.+Zhangauthor=V.+Hernandezauthor=H.+Zhouauthor=V.+Sandersauthor=Y.+Freundauthor=R.+Kimuraauthor=K.+R.+Maplesauthor=J.+J.+Plattner&title=Discovery+and+structure%E2%80%93activity+study+of+a+novel+benzoxaborole+anti-inflammatory+agent+%28AN2728%29+for+the+potential+topical+treatment+of+psoriasis+and+atopic+dermatitis&doi=10.1016%2Fj.bmcl.2009.03.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis</span></div><div class="casAuthors">Akama, Tsutomu; Baker, Stephen J.; Zhang, Yong-Kang; Hernandez, Vincent; Zhou, Huchen; Sanders, Virginia; Freund, Yvonne; Kimura, Richard; Maples, Kirk R.; Plattner, Jacob J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2129-2132</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of phenoxy benzoxaboroles were synthesized and screened for their inhibitory activity against PDE4 and cytokine release.  5-(4-Cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2728) showed potent activity both in vitro and in vivo.  This compd. is now in clin. development for the topical treatment of psoriasis and being pursued for the topical treatment of atopic dermatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYdD-T7O2W57Vg90H21EOLACvtfcHk0lj1hAQF6Ekoag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkt1Sjsb4%253D&md5=a526278d0506fc5916432cf20c6ff5e5</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.03.007%26sid%3Dliteratum%253Aachs%26aulast%3DAkama%26aufirst%3DT.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%2BK.%26aulast%3DHernandez%26aufirst%3DV.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DSanders%26aufirst%3DV.%26aulast%3DFreund%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DR.%26aulast%3DMaples%26aufirst%3DK.%2BR.%26aulast%3DPlattner%26aufirst%3DJ.%2BJ.%26atitle%3DDiscovery%2520and%2520structure%25E2%2580%2593activity%2520study%2520of%2520a%2520novel%2520benzoxaborole%2520anti-inflammatory%2520agent%2520%2528AN2728%2529%2520for%2520the%2520potential%2520topical%2520treatment%2520of%2520psoriasis%2520and%2520atopic%2520dermatitis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26issue%3D8%26spage%3D2129%26epage%3D2132%26doi%3D10.1016%2Fj.bmcl.2009.03.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grewe, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanifin, J. M.</span></span> <span> </span><span class="NLM_article-title">Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">452</span>– <span class="NLM_lpage">457</span>, <span class="refDoi"> DOI: 10.1016/0091-6749(82)90008-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1016%2F0091-6749%2882%2990008-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=6128357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A280%3ADyaL3s%252FlslOktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1982&pages=452-457&author=S.+R.+Greweauthor=S.+C.+Chanauthor=J.+M.+Hanifin&title=Elevated+leukocyte+cyclic+AMP-phosphodiesterase+in+atopic+disease%3A+a+possible+mechanism+for+cyclic+AMP-agonist+hyporesponsiveness&doi=10.1016%2F0091-6749%2882%2990008-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness</span></div><div class="casAuthors">Grewe S R; Chan S C; Hanifin J M</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of allergy and clinical immunology</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">452-7</span>
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    </div><div class="casAbstract">Previous studies have documented that leukocytes from atopic individuals show reduced cyclic AMP (cAMP) responsiveness to isoproterenol, histamine, and prostaglandin E1.  We questioned whether this blunted response was due to rapid enzymic breakdown of cAMP.  We measured cAMP-phosphodiesterase activity in mononuclear leukocytes of patients with atopic dermatitis and allergic rhinitis and noted consistent, significantly elevated levels.  Kinetic studies showed differences in two of three leukocyte enzyme forms between normals and patients.  Isolated lymphocytes from atopic dermatitis patients lacked a low Km phosphodiesterase form and showed an increase in the high Km, high-activity form seen in normal monocytes.  The increased phosphodiesterase activity provides an explanation for the blunted cAMP responsiveness in atopic leukocytes and may reflect a basic biochemical characteristic relevant to abnormal immunocellular regulation in atopic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcROnDD72nitREodMGTatQ7LfW6udTcc2ebBDg_Kh3A5Urntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3s%252FlslOktA%253D%253D&md5=8f924e4bf94ef45f71b4a685a6f78844</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2F0091-6749%2882%2990008-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0091-6749%252882%252990008-2%26sid%3Dliteratum%253Aachs%26aulast%3DGrewe%26aufirst%3DS.%2BR.%26aulast%3DChan%26aufirst%3DS.%2BC.%26aulast%3DHanifin%26aufirst%3DJ.%2BM.%26atitle%3DElevated%2520leukocyte%2520cyclic%2520AMP-phosphodiesterase%2520in%2520atopic%2520disease%253A%2520a%2520possible%2520mechanism%2520for%2520cyclic%2520AMP-agonist%2520hyporesponsiveness%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D1982%26volume%3D70%26spage%3D452%26epage%3D457%26doi%3D10.1016%2F0091-6749%2882%2990008-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halling-Overgaard, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kezic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakasa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engebretsen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maibach, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thyssen, J. P.</span></span> <span> </span><span class="NLM_article-title">Skin absorption through atopic dermatitis skin: a systematic review</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1111/bjd.15065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1111%2Fbjd.15065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=27639188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A280%3ADC%252BC2svhsVajsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2017&pages=84-103&author=A.+S.+Halling-Overgaardauthor=S.+Kezicauthor=I.+Jakasaauthor=K.+A.+Engebretsenauthor=H.+Maibachauthor=J.+P.+Thyssen&title=Skin+absorption+through+atopic+dermatitis+skin%3A+a+systematic+review&doi=10.1111%2Fbjd.15065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Skin absorption through atopic dermatitis skin: a systematic review</span></div><div class="casAuthors">Halling-Overgaard A-S; Engebretsen K A; Thyssen J P; Halling-Overgaard A-S; Engebretsen K A; Thyssen J P; Kezic S; Jakasa I; Maibach H</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of dermatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-106</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Patients with atopic dermatitis (AD) have skin barrier impairment in both lesional and nonlesional skin.  They are typically exposed daily to emollients and intermittently to topical anti-inflammatory medicaments, thereby increasing the risk of developing contact allergy and systemic exposure to chemical ingredients found in these topical preparations.  We systematically searched for studies that investigated skin absorption of various penetrants, including medicaments, in patients with AD, but also in animals with experimentally-induced dermatitis.  We identified 40 articles: 11 human studies examining model penetrants, 26 human studies examining AD drugs, and three animal studies.  We conclude that patients with AD have almost twofold increased skin absorption compared with healthy controls.  There is a need for well-designed epidemiological and dermatopharmacokinetic studies that examine to what extent AD causes patients to be systemically exposed to chemicals compared with nonatopic dermatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS3QV_bk8ER-a2q3xNe7a7QfW6udTcc2ebBDg_Kh3A5Urntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svhsVajsA%253D%253D&md5=e0a84bc578c51cdedfff9e4f2c25e8ff</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1111%2Fbjd.15065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.15065%26sid%3Dliteratum%253Aachs%26aulast%3DHalling-Overgaard%26aufirst%3DA.%2BS.%26aulast%3DKezic%26aufirst%3DS.%26aulast%3DJakasa%26aufirst%3DI.%26aulast%3DEngebretsen%26aufirst%3DK.%2BA.%26aulast%3DMaibach%26aufirst%3DH.%26aulast%3DThyssen%26aufirst%3DJ.%2BP.%26atitle%3DSkin%2520absorption%2520through%2520atopic%2520dermatitis%2520skin%253A%2520a%2520systematic%2520review%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2017%26volume%3D177%26spage%3D84%26epage%3D103%26doi%3D10.1111%2Fbjd.15065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moustafa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, S. R.</span></span> <span> </span><span class="NLM_article-title">A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology</span>. <i>Dermatol. Online J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">22608</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=24852768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A280%3ADC%252BC2cjlsVegsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=22608&author=F.+Moustafaauthor=S.+R.+Feldman&title=A+review+of+phosphodiesterase-inhibition+and+the+potential+role+for+phosphodiesterase+4-inhibitors+in+clinical+dermatology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology</span></div><div class="casAuthors">Moustafa Farah; Feldman Steven R</div><div class="citationInfo"><span class="NLM_cas:title">Dermatology online journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">22608</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Phosphodiesterase inhibitors are commonly used drugs.  Specific phosphodiesterase inhibitors with anti-inflammatory properties are being assessed as dermatological treatments.  PURPOSE:  To describe important aspects of phosphodiesterase inhibition and the safety and efficacy of 2 phosphodiesterase- 4 inhibitors being studied for the treatment of dermatologic diseases  METHODS:  We did a non-systematic analysis of literature on phosphodiesterase inhibition followed by a review of published information on apremilast and topical AN2728 and their use for psoriasis and atopic dermatitis.  FINDINGS:  Apremilast and topical AN2728 have modest efficacy in treatment of psoriasis.  Apremilast achieved PASI-75 scores ranging from 24-33%.  In phase 2 studies, AN2728 had modest efficacy for psoriasis (40% of patients achieved a ≥ 2 grade improvement as assessed by the Overall target Plaque Severity Score).  In phase 2 studies of AN2728 use in atopic dermatitis, subjects achieved a 71% improvement from baseline Atopic Dermatitis Severity Index.  In all studies, most adverse effects were minimal.  The limitations of this paper are the limited number of published studies, the lack of long-term data, and the lack of head -to - head trials directly comparing phosphodiesterase inhibitors with other treatments.  CONCLUSION:  Phosphodiesterase inhibitors constitute a widely used class of drugs that may see growing use for inflammatory dermatologic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRwzFx2xHbtDHWEEzDrymxmfW6udTcc2ebBDg_Kh3A5Urntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjlsVegsQ%253D%253D&md5=66adc0384bc37c232512711c3743a2c4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoustafa%26aufirst%3DF.%26aulast%3DFeldman%26aufirst%3DS.%2BR.%26atitle%3DA%2520review%2520of%2520phosphodiesterase-inhibition%2520and%2520the%2520potential%2520role%2520for%2520phosphodiesterase%25204-inhibitors%2520in%2520clinical%2520dermatology%26jtitle%3DDermatol.%2520Online%2520J.%26date%3D2014%26volume%3D20%26spage%3D22608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bodor, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, P.</span></span> <span> </span><span class="NLM_article-title">Soft drug design: general principles and recent applications</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1098-1128(200001)20:1<58::AID-MED3>3.0.CO;2-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1002%2F%28SICI%291098-1128%28200001%2920%3A1%3C58%3A%3AAID-MED3%3E3.0.CO%3B2-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10608921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltFWqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=58-101&issue=1&author=N.+Bodorauthor=P.+Buchwald&title=Soft+drug+design%3A+general+principles+and+recent+applications&doi=10.1002%2F%28SICI%291098-1128%28200001%2920%3A1%3C58%3A%3AAID-MED3%3E3.0.CO%3B2-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Soft drug design: general principles and recent applications</span></div><div class="casAuthors">Bodor, Nicholas; Buchwald, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-101</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review with 208 refs.  Soft drug design represents a new approach aimed to design safer drugs with an increased therapeutic index by integrating metab. considerations into the drug design process.  Soft drugs are new therapeutic agents that undergo predictable metab. to inactive metabolites after exerting their therapeutic effect.  Hence, they are obtained by building into the mol., in addn. to the activity, the most desired way in which the mol. is to be deactivated and detoxified.  In an attempt to systematize and summarize the related work done in a no. of labs., including ours, the present review presents an overview of the general soft drug design principles and provides a variety of specific examples to illustrate the concepts.  A no. of already marketed drugs, such as esmolol, remifentanil, or loteprednol etabonate, resulted from the successful application of such design principles.  Many other promising drug candidates are currently under investigation in a variety of fields including possible soft antimicrobials, anticholinergics, corticosteroids, β-blockers, analgetics, ACE inhibitors, antiarrhythmics, and others.  Whenever possible, pharmacokinetic and pharmacodynamic properties are briefly summarized and compared to those of other compds. used in the same field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphV1vhXwTl8LVg90H21EOLACvtfcHk0lhm0CIc7wD_yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltFWqsg%253D%253D&md5=e0ca493ba31d001e62a759be0fc4bcc8</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291098-1128%28200001%2920%3A1%3C58%3A%3AAID-MED3%3E3.0.CO%3B2-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291098-1128%2528200001%252920%253A1%253C58%253A%253AAID-MED3%253E3.0.CO%253B2-X%26sid%3Dliteratum%253Aachs%26aulast%3DBodor%26aufirst%3DN.%26aulast%3DBuchwald%26aufirst%3DP.%26atitle%3DSoft%2520drug%2520design%253A%2520general%2520principles%2520and%2520recent%2520applications%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2000%26volume%3D20%26issue%3D1%26spage%3D58%26epage%3D101%26doi%3D10.1002%2F%28SICI%291098-1128%28200001%2920%3A1%3C58%3A%3AAID-MED3%3E3.0.CO%3B2-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Felding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sørensen, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Refer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladefoged, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thormann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinggaard, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegardt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Søhoel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, S. F.</span></span> <span> </span><span class="NLM_article-title">Discovery and early clinical development of 2-{6-[2-(3,5-dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy}-<i>N</i>-propylacetamide (LEO 29102), a soft-drug inhibitor of phosphodiesterase 4 for topical treatment of atopic dermatitis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5893</span>– <span class="NLM_lpage">5903</span>, <span class="refDoi"> DOI: 10.1021/jm500378a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500378a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtV2jsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5893-5903&issue=14&author=J.+Feldingauthor=M.+D.+S%C3%B8rensenauthor=T.+D.+Poulsenauthor=J.+Larsenauthor=C.+Anderssonauthor=P.+Referauthor=K.+Engellauthor=L.+G.+Ladefogedauthor=T.+Thormannauthor=A.+M.+Vinggaardauthor=P.+Hegardtauthor=A.+S%C3%B8hoelauthor=S.+F.+Nielsen&title=Discovery+and+early+clinical+development+of+2-%7B6-%5B2-%283%2C5-dichloro-4-pyridyl%29acetyl%5D-2%2C3-dimethoxyphenoxy%7D-N-propylacetamide+%28LEO+29102%29%2C+a+soft-drug+inhibitor+of+phosphodiesterase+4+for+topical+treatment+of+atopic+dermatitis&doi=10.1021%2Fjm500378a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Early Clinical Development of 2-{6-[2-(3,5-Dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy}-N-propylacetamide (LEO 29102), a Soft-Drug Inhibitor of Phosphodiesterase 4 for Topical Treatment of Atopic Dermatitis</span></div><div class="casAuthors">Felding, Jakob; Soerensen, Morten D.; Poulsen, Tina D.; Larsen, Jens; Andersson, Christina; Refer, Pia; Engell, Karen; Ladefoged, Lotte G.; Thormann, Thorsten; Vinggaard, Anne Marie; Hegardt, Pontus; Soehoel, Anders; Nielsen, Simon Feldbaek</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5893-5903</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Development of orally available phosphodiesterase 4 (PDE4) inhibitors as anti-inflammatory drugs has been going on for decades.  However, only roflumilast has received FDA approval.  One key challenge has been the low therapeutic window obsd. in the clinic for PDE4 inhibitors, primarily due to PDE4 mediated side effects.  Here we describe our approach to circumvent this issue by applying a soft-drug concept in the design of a topically acting PDE4 inhibitor for treatment of dermatol. diseases.  We used a fast follower approach, starting from piclamilast.  In particular, simultaneous introduction of 2'-alkoxy substituents and changing an amide to a keto linker proved to be beneficial when designing potential soft-drug candidates.  This effort culminated in identification of LEO 29102 (20), a potent, selective, and soft-drug PDE4 inhibitor with properties suitable for patient-friendly formulations giving efficient drug delivery to the skin.  Compd. 20 has reached phase 2 and demonstrated clin. relevant efficacy in the treatment of atopic dermatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6hRC8lktjRrVg90H21EOLACvtfcHk0lhm0CIc7wD_yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtV2jsrfF&md5=9d236da8f314edec69f5b442e1a41141</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm500378a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500378a%26sid%3Dliteratum%253Aachs%26aulast%3DFelding%26aufirst%3DJ.%26aulast%3DS%25C3%25B8rensen%26aufirst%3DM.%2BD.%26aulast%3DPoulsen%26aufirst%3DT.%2BD.%26aulast%3DLarsen%26aufirst%3DJ.%26aulast%3DAndersson%26aufirst%3DC.%26aulast%3DRefer%26aufirst%3DP.%26aulast%3DEngell%26aufirst%3DK.%26aulast%3DLadefoged%26aufirst%3DL.%2BG.%26aulast%3DThormann%26aufirst%3DT.%26aulast%3DVinggaard%26aufirst%3DA.%2BM.%26aulast%3DHegardt%26aufirst%3DP.%26aulast%3DS%25C3%25B8hoel%26aufirst%3DA.%26aulast%3DNielsen%26aufirst%3DS.%2BF.%26atitle%3DDiscovery%2520and%2520early%2520clinical%2520development%2520of%25202-%257B6-%255B2-%25283%252C5-dichloro-4-pyridyl%2529acetyl%255D-2%252C3-dimethoxyphenoxy%257D-N-propylacetamide%2520%2528LEO%252029102%2529%252C%2520a%2520soft-drug%2520inhibitor%2520of%2520phosphodiesterase%25204%2520for%2520topical%2520treatment%2520of%2520atopic%2520dermatitis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D14%26spage%3D5893%26epage%3D5903%26doi%3D10.1021%2Fjm500378a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aprile, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirali, T.</span></span> <span> </span><span class="NLM_article-title">Soft drugs for dermatological applications: recent trends</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2234</span>– <span class="NLM_lpage">2246</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2019.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1016%2Fj.drudis.2019.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=31494188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslKntbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=2234-2246&issue=12&author=S.+Aprileauthor=M.+Serafiniauthor=T.+Pirali&title=Soft+drugs+for+dermatological+applications%3A+recent+trends&doi=10.1016%2Fj.drudis.2019.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Soft drugs for dermatological applications: recent trends</span></div><div class="casAuthors">Aprile, Silvio; Serafini, Marta; Pirali, Tracey</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2234-2246</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  A soft drug (SD) displays a metabolically labile spot and, after having exerted its activity in the site of action, undergoes a fast metab., leading to inactive metabolites.  The SD approach has recently found widespread application in the dermatol. field because it provides a means of localising the therapeutic effect in skin, while minimising systemic exposure.  The literature is rapidly growing of successful examples of compds. targeting sphingosine-1-phosphate receptor 1 (S1PR1), transient receptor potential vanilloid 1 (TRPV1), Janus kinase (JAK), caspase 1, and histone deacetylase (HDAC), for the treatment of skin inflammatory, autoimmune, and oncol. diseases.  As a demonstration of the potential of this strategy, the SD approach recently led to the approval of crisaborole, a soft phosphodiesterase 4 (PDE4) inhibitor, for atopic dermatitis, while other agents are in clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTJdakAL6BWLVg90H21EOLACvtfcHk0lgSW3PW3GyK2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslKntbvE&md5=995df11d311bb50cde6bcc0395a8624f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2019.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2019.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DAprile%26aufirst%3DS.%26aulast%3DSerafini%26aufirst%3DM.%26aulast%3DPirali%26aufirst%3DT.%26atitle%3DSoft%2520drugs%2520for%2520dermatological%2520applications%253A%2520recent%2520trends%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2019%26volume%3D24%26issue%3D12%26spage%3D2234%26epage%3D2246%26doi%3D10.1016%2Fj.drudis.2019.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span>LEO 29102
Cream in the Treatment of Atopic Dermatitis. <a href="https://clinicaltrials.gov/ct2/show/NCT01037881" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01037881</a> (accessed May 1, <span class="NLM_year">2020</span>); <a href="https://www.clinicaltrialsregister.eu/ctr-search/rest/download/result/attachment/2009-013792-22/1/17100" class="extLink">https://www.clinicaltrialsregister.eu/ctr-search/rest/download/result/attachment/2009-013792-22/1/17100</a> (accessed May 1, 2020)</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=LEO+29102%0ACream+in+the+Treatment+of+Atopic+Dermatitis.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01037881+%28accessed+May+1%2C+2020%29%3B+https%3A%2F%2Fwww.clinicaltrialsregister.eu%2Fctr-search%2Frest%2Fdownload%2Fresult%2Fattachment%2F2009-013792-22%2F1%2F17100+%28accessed+May+1%2C+2020%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, T.</span></span> <span> </span><span class="NLM_article-title">The emerging role of human esterases</span>. <i>Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">466</span>– <span class="NLM_lpage">477</span>, <span class="refDoi"> DOI: 10.2133/dmpk.DMPK-12-RV-042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.2133%2Fdmpk.DMPK-12-RV-042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=22813719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVykurzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2012&pages=466-477&issue=5&author=T.+Fukamiauthor=T.+Yokoi&title=The+emerging+role+of+human+esterases&doi=10.2133%2Fdmpk.DMPK-12-RV-042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The emerging role of human esterases</span></div><div class="casAuthors">Fukami, Tatsuki; Yokoi, Tsuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">466-477</span>CODEN:
                <span class="NLM_cas:coden">DMPRB8</span>;
        ISSN:<span class="NLM_cas:issn">1347-4367</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society for the Study of Xenobiotics</span>)
        </div><div class="casAbstract">In this review, novel aspects of the role of esterases, which contribute to the metab. of 10% of therapeutic drugs, are described.  Esterases hydrolyze the compds. that contain ester, amide, and thioester bonds, which cause prodrug activation or detoxification.  Among esterases, carboxylesterases are well known to be involved in the hydrolysis of a variety of drugs.  Addnl., other esterases have recently received attention for their pharmacol. and toxicol. roles.  Arylacetamide deacetylase (AADAC) is involved in the hydrolysis of flutamide, phenacetin, and rifamycins.  AADAC is assocd. with adverse drug reactions because the hydrolytic metabolites of flutamide and phenacetin appear to be assocd. with hepatotoxicity and nephrotoxicity/hematotoxicity, resp.  Paraoxonase and butyrylcholinesterase hydrolyze pirocarpine/simvastatin and succinylcholine/bambuterol, resp.  Although the esterases that hydrolyze the acyl-glucuronides of drugs have largely been unknown, we recently found that α/β hydrolase domain contg. 10 (ABHD10) is responsible for the hydrolysis of mycophenolic acid acyl-glucuronide in human liver.  Because acyl-glucuronides are assocd. with toxicity, ABHD10 might function as a detoxification enzyme.  Thus, various esterases, which include enzymes that have not been known to hydrolyze drugs, are involved in drug metab. with different substrate specificity.  Further esterase studies should be conducted to promote our understanding in clin. pharmacotherapy and drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDhsUJ4NrYQbVg90H21EOLACvtfcHk0lgSW3PW3GyK2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVykurzE&md5=d760b8a6a3217a4ab9716190800012b0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2133%2Fdmpk.DMPK-12-RV-042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2133%252Fdmpk.DMPK-12-RV-042%26sid%3Dliteratum%253Aachs%26aulast%3DFukami%26aufirst%3DT.%26aulast%3DYokoi%26aufirst%3DT.%26atitle%3DThe%2520emerging%2520role%2520of%2520human%2520esterases%26jtitle%3DDrug%2520Metab.%2520Pharmacokinet.%26date%3D2012%26volume%3D27%26issue%3D5%26spage%3D466%26epage%3D477%26doi%3D10.2133%2Fdmpk.DMPK-12-RV-042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berry, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollenberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span> <span> </span><span class="NLM_article-title">Esterase activities in the blood, liver and intestine of several preclinical species and humans</span>. <i>Drug Metab. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">70</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.2174/187231209788654081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.2174%2F187231209788654081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=19601867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsVGju70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2009&pages=70-77&issue=2&author=L.+M.+Berryauthor=L.+Wollenbergauthor=Z.+Zhao&title=Esterase+activities+in+the+blood%2C+liver+and+intestine+of+several+preclinical+species+and+humans&doi=10.2174%2F187231209788654081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Esterase activities in the blood, liver and intestine of several preclinical species and humans</span></div><div class="casAuthors">Berry, Loren M.; Wollenberg, Lance; Zhao, Zhiyang</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">70-77</span>CODEN:
                <span class="NLM_cas:coden">DMLRBM</span>;
        ISSN:<span class="NLM_cas:issn">1872-3128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Species and tissue differences in the activity of three major classes of esterases, carboxylesterase (CE), butyrylcholinesterase (BChE) and paraoxonase (PON), were studied.  Substantial species differences in activity of these esterases were obsd. between the mouse, rat, dog monkey and human.  Such species differences must be considered when using these preclin. species to optimize the pharmacokinetic properties of ester compds. intended for human use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDFldzEQtQKLVg90H21EOLACvtfcHk0lgSW3PW3GyK2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsVGju70%253D&md5=f480d5a0b9f54e7a34eadac588521caa</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F187231209788654081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187231209788654081%26sid%3Dliteratum%253Aachs%26aulast%3DBerry%26aufirst%3DL.%2BM.%26aulast%3DWollenberg%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DZ.%26atitle%3DEsterase%2520activities%2520in%2520the%2520blood%252C%2520liver%2520and%2520intestine%2520of%2520several%2520preclinical%2520species%2520and%2520humans%26jtitle%3DDrug%2520Metab.%2520Lett.%26date%3D2009%26volume%3D3%26issue%3D2%26spage%3D70%26epage%3D77%26doi%3D10.2174%2F187231209788654081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oesch, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oesch-Bartlomowicz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landsiedel, R.</span></span> <span> </span><span class="NLM_article-title">Drug-metabolizing enzymes in the skin of man, rat, and pig</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">659</span>– <span class="NLM_lpage">698</span>, <span class="refDoi"> DOI: 10.1080/03602530701690366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1080%2F03602530701690366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=18058329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlyitbnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2007&pages=659-698&issue=4&author=F.+Oeschauthor=E.+Fabianauthor=B.+Oesch-Bartlomowiczauthor=C.+Wernerauthor=R.+Landsiedel&title=Drug-metabolizing+enzymes+in+the+skin+of+man%2C+rat%2C+and+pig&doi=10.1080%2F03602530701690366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Metabolizing Enzymes in the Skin of Man, Rat, and Pig</span></div><div class="casAuthors">Oesch, Franz; Fabian, Eric; Oesch-Bartlomowicz, Barbara; Werner, Christoph; Landsiedel, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">659-698</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The mammalian skin has long been considered to be poor in drug metab.  However, many reports clearly show that most drug metabolizing enzymes also occur in the mammalian skin albeit at relatively low specific activities.  This review summarizes the current state of knowledge on drug metabolizing enzymes in the skin of human, rat, and pig, the latter, because it is often taken as a model for human skin on grounds of anatomical similarities.  However only little is known about drug metabolizing enzymes in pig skin.  Interestingly, some cytochromes P 450 (CYP) have been obsd. in the rat skin which are not expressed in the rat liver, such as CYP 2B12 and CYP2D4.  As far as investigated most drug metabolizing enzymes occur in the suprabasal (i.e. differentiating) layers of the epidermis, but the rat CYP1A1 rather in the basal layer and human UDP-glucuronosyltransferase rather in the stratum corneum.  The pattern of drug metabolizing enzymes and their localization will impact not only the beneficial as well as detrimental properties of drugs for the skin but also dictate whether a drug reaches the blood flow unchanged or as activated or inactivated metabolite(s).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofhs_tmoLY7bVg90H21EOLACvtfcHk0lgSW3PW3GyK2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlyitbnO&md5=43dcf77be2bd31c8a5629321f959bc10</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1080%2F03602530701690366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F03602530701690366%26sid%3Dliteratum%253Aachs%26aulast%3DOesch%26aufirst%3DF.%26aulast%3DFabian%26aufirst%3DE.%26aulast%3DOesch-Bartlomowicz%26aufirst%3DB.%26aulast%3DWerner%26aufirst%3DC.%26aulast%3DLandsiedel%26aufirst%3DR.%26atitle%3DDrug-metabolizing%2520enzymes%2520in%2520the%2520skin%2520of%2520man%252C%2520rat%252C%2520and%2520pig%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2007%26volume%3D39%26issue%3D4%26spage%3D659%26epage%3D698%26doi%3D10.1080%2F03602530701690366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Felding, J.</span>; <span class="NLM_string-name">Sørensen, M. D.</span></span> <span> </span><span class="NLM_article-title">Triazolopyridines as Phosphodiesterase Inhibitors for treatment of Dermal Diseases</span>. PTC Int. Appl. <span class="NLM_patent">WO2008/125111 A1</span>, Oct 23, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=J.+Felding&author=M.+D.+S%C3%B8rensen&title=Triazolopyridines+as+Phosphodiesterase+Inhibitors+for+treatment+of+Dermal+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFelding%26aufirst%3DJ.%26atitle%3DTriazolopyridines%2520as%2520Phosphodiesterase%2520Inhibitors%2520for%2520treatment%2520of%2520Dermal%2520Diseases%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatzelmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schudt, C.</span></span> <span> </span><span class="NLM_article-title">Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast <i>in vitro</i></span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>297</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">279</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=11259554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BD3MXisVSrsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=297&publication_year=2001&pages=267-279&issue=1&author=A.+Hatzelmannauthor=C.+Schudt&title=Anti-inflammatory+and+immunomodulatory+potential+of+the+novel+PDE4+inhibitor+roflumilast+in+vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro</span></div><div class="casAuthors">Hatzelmann, Armin; Schudt, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">297</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">267-279</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">From a series of benzamide derivs., roflumilast (3-cyclopropylmethoxy-4-difluoromethoxy-N-[3,5-di-chloropyrid-4-yl]b enzamide) was identified as a potent and selective PDE4 inhibitor.  It inhibits PDE4 activity from human neutrophils with an IC50 of 0.8 nM without affecting PDE1 (bovine brain), PDE2 (rat heart), and PDE3 and PDE5 (human platelets) even at 10,000-fold higher concns.  Roflumilast is almost equipotent to its major metabolite formed in vivo (roflumilast N-oxide) and piclamilast (RP 73401), however, more than 100-fold more potent than rolipram and Ariflo (cilomilast; SB 207499).  The anti-inflammatory and immunomodulatory potential of roflumilast and the ref. compds. was investigated in various human leukocytes using cell-specific responses: neutrophils [N-formyl-methyl-leucyl-phenylalanine (fMLP)-induced formation of LTB4 and reactive oxygen species (ROS)], eosinophils (fMLP- and C5a-induced ROS formation), monocytes, monocyte-derived macrophages, and dendritic cells (lipopolysaccharide-induced tumor necrosis factor-α synthesis), and CD4+ T cells (anti-CD3/anti-CD28 monoclonal antibody-stimulated proliferation, IL-2, IL-4, IL-5, and interferon-γ release).  Independent of the cell type and the response investigated, the corresponding IC values (for half-max. inhibition) of roflumilast were within a narrow range (2-21 nM), very similar to roflumilast N-oxide (3-40 nM) and piclamilast (2-13 nM).  In contrast, cilomilast (40-3000 nM) and rolipram (10-600 nM) showed greater differences with the highest potency for neutrophils.  Compared with neutrophils and eosinophils, representing the terminal inflammatory effector cells, the relative potency of roflumilast and its N-oxide for monocytes, CD4+ T cells, and dendritic cells is substantially higher compared with cilomilast and rolipram, probably reflecting an improved immunomodulatory potential.  The efficacy or roflumilast in vitro and in vivo (see accompanying article in this issue) suggests that roflumilast will be useful in the treatment of chronic inflammatory disorders such as asthma and chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpANJYEeXGhmLVg90H21EOLACvtfcHk0lgHb_rvguBD3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXisVSrsbc%253D&md5=07296ba5ffb2bc94fc154627c8877bdb</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHatzelmann%26aufirst%3DA.%26aulast%3DSchudt%26aufirst%3DC.%26atitle%3DAnti-inflammatory%2520and%2520immunomodulatory%2520potential%2520of%2520the%2520novel%2520PDE4%2520inhibitor%2520roflumilast%2520in%2520vitro%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2001%26volume%3D297%26issue%3D1%26spage%3D267%26epage%3D279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, J. A.</span>; <span class="NLM_string-name">Eady, R. A. J.</span>; <span class="NLM_string-name">Pope, F. M.</span></span> <span> </span><span class="NLM_article-title">Anatomy and Organization of Human Skin</span>. In  <i>Rook’s Textbook of Dermatology</i>, <span class="NLM_edition">7</span>th ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, T.</span>, <span class="NLM_string-name">Breathnach, S.</span>, <span class="NLM_string-name">Cox, N.</span>, <span class="NLM_string-name">Griffiths, C.</span></span>, Eds.; <span class="NLM_publisher-name">Blackwell Publishing</span>: <span class="NLM_publisher-loc">Oxford, U.K.</span>, <span class="NLM_year">2004</span>; pp  <span class="NLM_fpage">4190</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1002%2F9780470750520.ch3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&pages=4190&author=J.+A.+McGrath&author=R.+A.+J.+Eady&author=F.+M.+Popeauthor=T.+Burns&author=S.+Breathnach&author=N.+Cox&author=C.+Griffiths&title=Rook%E2%80%99s+Textbook+of+Dermatology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2F9780470750520.ch3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9780470750520.ch3%26sid%3Dliteratum%253Aachs%26aulast%3DMcGrath%26aufirst%3DJ.%2BA.%26atitle%3DAnatomy%2520and%2520Organization%2520of%2520Human%2520Skin%26btitle%3DRook%25E2%2580%2599s%2520Textbook%2520of%2520Dermatology%26aulast%3DBurns%26aufirst%3DT.%26pub%3DBlackwell%2520Publishing%26date%3D2004%26spage%3D4190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Man, M. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feingold, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holleran, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elias, P. M.</span></span> <span> </span><span class="NLM_article-title">Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunological, and biochemical changes following single versus multiple oxazolone challenges</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1038/sj.jid.5701011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1038%2Fsj.jid.5701011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=17671515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVSksbvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2008&pages=79-86&author=M.+Q.+Manauthor=Y.+Hatanoauthor=S.+H.+Leeauthor=M.+Manauthor=S.+Changauthor=K.+R.+Feingoldauthor=D.+Y.+Leungauthor=W.+Holleranauthor=Y.+Uchidaauthor=P.+M.+Elias&title=Characterization+of+a+hapten-induced%2C+murine+model+with+multiple+features+of+atopic+dermatitis%3A+structural%2C+immunological%2C+and+biochemical+changes+following+single+versus+multiple+oxazolone+challenges&doi=10.1038%2Fsj.jid.5701011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a Hapten-Induced, Murine Model with Multiple Features of Atopic Dermatitis: Structural, Immunologic, and Biochemical Changes following Single Versus Multiple Oxazolone Challenges</span></div><div class="casAuthors">Man, Mao-Qiang; Hatano, Yutaka; Lee, Seung H.; Man, Mona; Chang, Sandra; Feingold, Kenneth R.; Leung, Donald Y. M.; Holleran, Walter; Uchida, Yoshikazu; Elias, Peter M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-86</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Atopic dermatitis (AD) is a chronic dermatosis bearing clin., histol., and immunol. similarities to chronic allergic contact dermatitis (ACD).  AD shows a Th2 cell-dominant inflammatory infiltrate, elevated serum IgE levels, a permeability barrier abnormality, and Staphylococcus aureas colonization.  Repeated hapten challenges reportedly produce a Th2-like hypersensitivity reaction (Th2-like HR).  Here, 9-10 challenges with oxazolone (Ox) to hairless mice also produced a chronic Th2-like HR.  Permeability barrier function and expression of differentiation proteins, filaggrin, loricrin, and involucrin, became abnormal.  CRTH-pos. Th2-dominant inflammatory infiltrate, with increased IL-4 expression, and a large increase in serum IgE levels were obsd.  The barrier abnormality was assocd. with decreased stratum corneum (SC) ceramide content and impaired lamellar body secretion, resulting in abnormal lamellar membranes, as in human AD.  Furthermore, as in human AD, epidermal serine protease activity in SC increased and expression of two lamellar body-derived antimicrobial peptides, CRAMP and mBD3, declined after Ox challenges, paralleling the decrease of their human homologs in AD.  Thus, multiple Ox challenges to normal murine skin produce a chronic Th2-like HR, with multiple features of human AD.  Because of its reproducibility, predictability, and low cost, this model could prove useful for evaluating both pathogenic mechanisms and potential therapies for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3yt_71_rf17Vg90H21EOLACvtfcHk0lgHb_rvguBD3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVSksbvN&md5=105e48a210092f15687bcc60e966fdc1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fsj.jid.5701011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.jid.5701011%26sid%3Dliteratum%253Aachs%26aulast%3DMan%26aufirst%3DM.%2BQ.%26aulast%3DHatano%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DMan%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DFeingold%26aufirst%3DK.%2BR.%26aulast%3DLeung%26aufirst%3DD.%2BY.%26aulast%3DHolleran%26aufirst%3DW.%26aulast%3DUchida%26aufirst%3DY.%26aulast%3DElias%26aufirst%3DP.%2BM.%26atitle%3DCharacterization%2520of%2520a%2520hapten-induced%252C%2520murine%2520model%2520with%2520multiple%2520features%2520of%2520atopic%2520dermatitis%253A%2520structural%252C%2520immunological%252C%2520and%2520biochemical%2520changes%2520following%2520single%2520versus%2520multiple%2520oxazolone%2520challenges%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2008%26volume%3D128%26spage%3D79%26epage%3D86%26doi%3D10.1038%2Fsj.jid.5701011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walmsley, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tate, M.</span></span> <span> </span><span class="NLM_article-title">The GADD45a-GFP Green Screen HC assay</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>817</i></span>,  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1007/978-1-61779-421-6_12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1007%2F978-1-61779-421-6_12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=22147576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1OnsrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=817&publication_year=2012&pages=231-50&author=R.+M.+Walmsleyauthor=M.+Tate&title=The+GADD45a-GFP+Green+Screen+HC+assay&doi=10.1007%2F978-1-61779-421-6_12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The GADD45a-GFP GreenScreen HC assay</span></div><div class="casAuthors">Walmsley, Richard M.; Tate, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">817</span>
        (<span class="NLM_cas:issue">Genetic Toxicology</span>),
    <span class="NLM_cas:pages">231-250</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Mutagens, clastogens, and aneugens cause increased expression of the human GADD45a gene.  This has been exploited in the GreenScreen HC genotoxicity assay in which the gene's expression is linked to the expression of green fluorescent protein (GFP).  The host for the reporter construct is the human lymphoblastoid cell line TK6.  It was chosen for its growth as a cell suspension, which allows simple pipet transfers, and for its wild-type p53 competent status.  P53 is required for proper GADD45a expression, and more generally for genome stability.  TK6 is a karyotypically stable cell line.  The GreenScreen assays were designed to facilitate screening, and this is reflected in its microplate format and low compd. requirement.  Protocols are available for testing with and without S9 as a source of exogenous metabolic activation.  Data is collected either spectrophotometrically or by flow cytometry, and a simple spreadsheet converts raw data into dose-response curves, and provides a statistically significant pos. or neg. result.  Extensive validation has demonstrated that in contrast to other in vitro mammalian genotoxicity assays, the GADD45a assays have both high sensitivity and specificity - they very rarely produce misleading pos. results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD0EqM59A-NbVg90H21EOLACvtfcHk0lgIoilWYyhMJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1OnsrrO&md5=5d7e9eea24272b838150333970e51ef8</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2F978-1-61779-421-6_12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-61779-421-6_12%26sid%3Dliteratum%253Aachs%26aulast%3DWalmsley%26aufirst%3DR.%2BM.%26aulast%3DTate%26aufirst%3DM.%26atitle%3DThe%2520GADD45a-GFP%2520Green%2520Screen%2520HC%2520assay%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2012%26volume%3D817%26spage%3D231%26epage%3D50%26doi%3D10.1007%2F978-1-61779-421-6_12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, S. F.</span>; <span class="NLM_string-name">Vifian, T.</span>; <span class="NLM_string-name">Horneman, A. M.</span>; <span class="NLM_string-name">Lau, J. F.</span></span> <span> </span><span class="NLM_article-title">Triazolopyridines as Phosphodiesterase Inhibitors for Treatment of Dermal Diseases</span>. PTC Int. Appl. <span class="NLM_patent">WO2010/069322 A1</span>, Jun 24, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+F.+Nielsen&author=T.+Vifian&author=A.+M.+Horneman&author=J.+F.+Lau&title=Triazolopyridines+as+Phosphodiesterase+Inhibitors+for+Treatment+of+Dermal+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNielsen%26aufirst%3DS.%2BF.%26atitle%3DTriazolopyridines%2520as%2520Phosphodiesterase%2520Inhibitors%2520for%2520Treatment%2520of%2520Dermal%2520Diseases%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, S. F.</span>; <span class="NLM_string-name">Larsen, J. C. H.</span></span> <span> </span><span class="NLM_article-title">[1,2,4]Triazolopyridines and Their Use as Phosphodiesterase Inhibitors</span>. PTC Int. Appl. <span class="NLM_patent">WO2013/092739 A1</span>, Jun 27, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=S.+F.+Nielsen&author=J.+C.+H.+Larsen&title=%5B1%2C2%2C4%5DTriazolopyridines+and+Their+Use+as+Phosphodiesterase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNielsen%26aufirst%3DS.%2BF.%26atitle%3D%255B1%252C2%252C4%255DTriazolopyridines%2520and%2520Their%2520Use%2520as%2520Phosphodiesterase%2520Inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, M.</span>; <span class="NLM_string-name">Dahl, A. C.</span>; <span class="NLM_string-name">McParland, J.</span></span> <span> </span><span class="NLM_article-title">Methods for the Preparations of Substituted [1,2,4]triazolo[1,5-a]pyridines</span>. PTC Int. Appl. <span class="NLM_patent">WO2014/206903 A1</span>, Dec 31, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=M.+Larsen&author=A.+C.+Dahl&author=J.+McParland&title=Methods+for+the+Preparations+of+Substituted+%5B1%2C2%2C4%5Dtriazolo%5B1%2C5-a%5Dpyridines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLarsen%26aufirst%3DM.%26atitle%3DMethods%2520for%2520the%2520Preparations%2520of%2520Substituted%2520%255B1%252C2%252C4%255Dtriazolo%255B1%252C5-a%255Dpyridines%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taketani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shii, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ninomiya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, T.</span></span> <span> </span><span class="NLM_article-title">Carboxylesterase in the liver and small intestine of experimental animals and human</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>81</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">924</span>– <span class="NLM_lpage">932</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2007.07.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1016%2Fj.lfs.2007.07.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=17764701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVCmur%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2007&pages=924-932&issue=11&author=M.+Taketaniauthor=M.+Shiiauthor=K.+Ohuraauthor=S.+Ninomiyaauthor=T.+Imai&title=Carboxylesterase+in+the+liver+and+small+intestine+of+experimental+animals+and+human&doi=10.1016%2Fj.lfs.2007.07.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Carboxylesterase in the liver and small intestine of experimental animals and human</span></div><div class="casAuthors">Taketani, Megumi; Shii, Mayumi; Ohura, Kayoko; Ninomiya, Shinichi; Imai, Teruko</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">924-932</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Native PAGE showed carboxylesterase (CES) to be the most abundant hydrolase in the liver and small intestine of humans, monkeys, dogs, rabbits and rats.  The liver contains both CES1 and CES2 enzymes in all these species.  The small intestine contains only enzymes from the CES2 family in humans and rats, while in rabbits and monkeys, enzymes from both CES1 and CES2 families are present.  Interestingly, no hydrolase activity at all was found in dog small intestine.  Flurbiprofen derivs. were R-preferentially hydrolyzed in the liver microsomes of all species, but hardly hydrolyzed in the small intestine microsomes of any species except rabbit.  Propranolol derivs. were hydrolyzed in the small intestine and liver microsomes of all species except dog small intestine.  Monkeys and rabbits showed R-preferential and non-enantio-selective hydrolysis, resp., for propranolol derivs. in both organs.  Human and rat liver showed R- and S-preferential hydrolysis, resp., in spite of non-enantio-selective hydrolysis in their small intestines.  The proximal-to-distal gradient of CES activity in human small intestine (1.1-1.5) was less steep than that of CYP 3A4 and 2C9 activity (three-fold difference).  These findings indicate that human small intestine and liver show extensive hydrolase activity attributed to CES, which is different from that in species commonly used as exptl. animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXCn7QUZQMsLVg90H21EOLACvtfcHk0lgIoilWYyhMJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVCmur%252FN&md5=6f3bdd3ea26d3a8d48c25d558264832d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2007.07.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2007.07.026%26sid%3Dliteratum%253Aachs%26aulast%3DTaketani%26aufirst%3DM.%26aulast%3DShii%26aufirst%3DM.%26aulast%3DOhura%26aufirst%3DK.%26aulast%3DNinomiya%26aufirst%3DS.%26aulast%3DImai%26aufirst%3DT.%26atitle%3DCarboxylesterase%2520in%2520the%2520liver%2520and%2520small%2520intestine%2520of%2520experimental%2520animals%2520and%2520human%26jtitle%3DLife%2520Sci.%26date%3D2007%26volume%3D81%26issue%3D11%26spage%3D924%26epage%3D932%26doi%3D10.1016%2Fj.lfs.2007.07.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taketani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shii, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosokawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, K.</span></span> <span> </span><span class="NLM_article-title">Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1734</span>– <span class="NLM_lpage">1741</span>, <span class="refDoi"> DOI: 10.1124/dmd.106.009381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1124%2Fdmd.106.009381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=16837570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVCltbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=1734-1741&issue=10&author=T.+Imaiauthor=M.+Taketaniauthor=M.+Shiiauthor=M.+Hosokawaauthor=K.+Chiba&title=Substrate+specificity+of+carboxylesterase+isozymes+and+their+contribution+to+hydrolase+activity+in+human+liver+and+small+intestine&doi=10.1124%2Fdmd.106.009381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine</span></div><div class="casAuthors">Imai, Teruko; Taketani, Megumi; Shii, Mayumi; Hosokawa, Masakiyo; Chiba, Kan</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1734-1741</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Hydrolase activity from human liver and small intestine microsomes was compared with that of recombinant human carboxylesterases, hCE-1 and hCE-2.  Although both hCE-1 and hCE-2 are present in human liver, the dominant component was found to be hCE-1, whereas the hydrolase activity of the human small intestine was found to be predominantly hCE-2.  HCE-2 has a limited ability to hydrolyze large acyl compd. substrates.  Interestingly, propranolol derivs., good substrates for hCE-2, were easily hydrolyzed by substitution of the Me group on the 2-position of the acyl moiety, but were barely hydrolyzed when the Me group was substituted on the 3-position.  These findings suggest that hCE-2 does not easily form acylated intermediates because of conformational interference in its active site.  In contrast, hCE-1 could hydrolyze a variety of substrates.  The hydrolytic activity of hCE-2 increased with increasing alc. chain length in benzoic acid deriv. substrates, whereas hCE-1 preferentially catalyzed the hydrolysis of substrates with short alc. chains.  Kinetic data showed that the detg. factor for the rate of hydrolysis of p-aminobenzoic acid esters was Vmax for hCE-1 and Km for hCE-2.  Furthermore, the addn. of hydrophobic alcs. to the reaction mixt. with p-aminobenzoic acid Pr ester induced high and low levels of transesterification by hCE-1 and hCE-2, resp.  When considering the substrate specificities of hCE-1, it is necessary to consider the transesterification ability of hCE-1, in addn. to the binding structure of the substrate in the active site of the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_5Qby7_S88LVg90H21EOLACvtfcHk0ljEU6enbJ7LoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVCltbvI&md5=b2d3c1d2aee89b647e1c8030daee8c3a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1124%2Fdmd.106.009381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.106.009381%26sid%3Dliteratum%253Aachs%26aulast%3DImai%26aufirst%3DT.%26aulast%3DTaketani%26aufirst%3DM.%26aulast%3DShii%26aufirst%3DM.%26aulast%3DHosokawa%26aufirst%3DM.%26aulast%3DChiba%26aufirst%3DK.%26atitle%3DSubstrate%2520specificity%2520of%2520carboxylesterase%2520isozymes%2520and%2520their%2520contribution%2520to%2520hydrolase%2520activity%2520in%2520human%2520liver%2520and%2520small%2520intestine%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26issue%3D10%26spage%3D1734%26epage%3D1741%26doi%3D10.1124%2Fdmd.106.009381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span>An Explorative
Trial Evaluating the Effect of LEO 39652 Cream 2.5 mg/g in Adults
with Mild to Moderate Atopic Dermatitis (AD). <a href="https://clinicaltrials.gov/ct2/show/NCT02496546" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02496546</a> (accessed May 1, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=An+Explorative%0ATrial+Evaluating+the+Effect+of+LEO+39652+Cream+2.5+mg%2Fg+in+Adults%0Awith+Mild+to+Moderate+Atopic+Dermatitis+%28AD%29.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02496546+%28accessed+May+1%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eirefelt, S.</span>; <span class="NLM_string-name">Hummer, J.</span>; <span class="NLM_string-name">Basse, L. H.</span>; <span class="NLM_string-name">Bertelsen, M.</span>; <span class="NLM_string-name">Johansson, F.</span>; <span class="NLM_string-name">Birngruber, T.</span>; <span class="NLM_string-name">Sinner, F.</span>; <span class="NLM_string-name">Larsen, J.</span>; <span class="NLM_string-name">Nielsen, S. F.</span>; <span class="NLM_string-name">Lambert, M.</span></span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Eirefelt%2C+S.%3B+Hummer%2C+J.%3B+Basse%2C+L.+H.%3B+Bertelsen%2C+M.%3B+Johansson%2C+F.%3B+Birngruber%2C+T.%3B+Sinner%2C+F.%3B+Larsen%2C+J.%3B+Nielsen%2C+S.+F.%3B+Lambert%2C+M.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DEirefelt%26aufirst%3DS." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonnel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legouffe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortensen, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pamelard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, K. T.</span></span> <span> </span><span class="NLM_article-title">MALDI imaging facilitates new topical drug development process by determining quantitative skin distribution profiles</span>. <i>Anal. Bioanal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>410</i></span>,  <span class="NLM_fpage">2815</span>– <span class="NLM_lpage">2828</span>, <span class="refDoi"> DOI: 10.1007/s00216-018-0964-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1007%2Fs00216-018-0964-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=29546543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFOltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=410&publication_year=2018&pages=2815-2828&author=D.+Bonnelauthor=R.+Legouffeauthor=A.+H.+Erikssonauthor=R.+W.+Mortensenauthor=F.+Pamelardauthor=J.+Stauberauthor=K.+T.+Nielsen&title=MALDI+imaging+facilitates+new+topical+drug+development+process+by+determining+quantitative+skin+distribution+profiles&doi=10.1007%2Fs00216-018-0964-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">MALDI imaging facilitates new topical drug development process by determining quantitative skin distribution profiles</span></div><div class="casAuthors">Bonnel, David; Legouffe, Raphael; Eriksson, Andre H.; Mortensen, Rasmus W.; Pamelard, Fabien; Stauber, Jonathan; Nielsen, Kim T.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical and Bioanalytical Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">410</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2815-2828</span>CODEN:
                <span class="NLM_cas:coden">ABCNBP</span>;
        ISSN:<span class="NLM_cas:issn">1618-2642</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Generation of skin distribution profiles and reliable detn. of drug mol. concn. in the target region are crucial during the development process of topical products for treatment of skin diseases like psoriasis and atopic dermatitis.  Imaging techniques like mass spectrometric imaging (MSI) offer sufficient spatial resoln. to generate meaningful distribution profiles of a drug mol. across a skin section.  In this study, the authors use matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) to generate quant. skin distribution profiles based on tissue extinction coeff. (TEC) detns. of four different mols. in cross sections of human skin explants after topical administration.  The four drug mols.: roflumilast, tofacitinib, ruxolitinib, and LEO 29102 have different physicochem. properties.  In addn., tofacitinib was administered in two different formulations.  The study reveals that with MALDI-MSI, the authors were able to observe differences in penetration profiles for both the four drug mols. and the two formulations and thereby demonstrate its applicability as a screening tool when developing a topical drug product.  Furthermore, the study reveals that the sensitivity of the MALDI-MSI techniques appears to be inversely correlated to the drug mols.' ability to bind to the surrounding tissues, which can be estd. by their Log D values.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocPcMlQ4QHu7Vg90H21EOLACvtfcHk0ljEU6enbJ7LoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFOltb8%253D&md5=b9c42c78f372eddbd9413ac3bbc5cbeb</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2Fs00216-018-0964-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00216-018-0964-3%26sid%3Dliteratum%253Aachs%26aulast%3DBonnel%26aufirst%3DD.%26aulast%3DLegouffe%26aufirst%3DR.%26aulast%3DEriksson%26aufirst%3DA.%2BH.%26aulast%3DMortensen%26aufirst%3DR.%2BW.%26aulast%3DPamelard%26aufirst%3DF.%26aulast%3DStauber%26aufirst%3DJ.%26aulast%3DNielsen%26aufirst%3DK.%2BT.%26atitle%3DMALDI%2520imaging%2520facilitates%2520new%2520topical%2520drug%2520development%2520process%2520by%2520determining%2520quantitative%2520skin%2520distribution%2520profiles%26jtitle%3DAnal.%2520Bioanal.%2520Chem.%26date%3D2018%26volume%3D410%26spage%3D2815%26epage%3D2828%26doi%3D10.1007%2Fs00216-018-0964-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bodenlenz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragatin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liebenberger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschapeller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulgaropoulos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raml, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatschelhofer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benkali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rony, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinner, F.</span></span> <span> </span><span class="NLM_article-title">Kinetics of clobetasol-17-propionate in psoriatic lesional and non-lesional skin assessed by dermal open flow microperfusion with time and space resolution</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">2229</span>– <span class="NLM_lpage">2238</span>, <span class="refDoi"> DOI: 10.1007/s11095-016-1960-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1007%2Fs11095-016-1960-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=27271272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVOnur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2016&pages=2229-2238&author=M.+Bodenlenzauthor=C.+Dragatinauthor=L.+Liebenbergerauthor=B.+Tschapellerauthor=B.+Boulgaropoulosauthor=T.+Augustinauthor=R.+Ramlauthor=C.+Gatschelhoferauthor=N.+Wagnerauthor=K.+Benkaliauthor=F.+Ronyauthor=T.+Pieberauthor=F.+Sinner&title=Kinetics+of+clobetasol-17-propionate+in+psoriatic+lesional+and+non-lesional+skin+assessed+by+dermal+open+flow+microperfusion+with+time+and+space+resolution&doi=10.1007%2Fs11095-016-1960-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetics of Clobetasol-17-Propionate in Psoriatic Lesional and Non-Lesional Skin Assessed by Dermal Open Flow Microperfusion with Time and Space Resolution</span></div><div class="casAuthors">Bodenlenz, Manfred; Dragatin, Christian; Liebenberger, Lisa; Tschapeller, Bernd; Boulgaropoulos, Beate; Augustin, Thomas; Raml, Reingard; Gatschelhofer, Christina; Wagner, Nathalie; Benkali, Khaled; Rony, Francois; Pieber, Thomas; Sinner, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2229-2238</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: To evaluate the kinetics of topically applied clobetasol-17-propionate (CP-17) in lesional and nonlesional psoriatic skin when released from a com. available low-strength cream using in vivo dermal open-flow microperfusion (dOFM).  Methods: Twelve patients received Dermovate cream (CP-17, 0.05%) on small lesional and nonlesional skin test sites for 14 days, once daily.  On day 1 and 14, dOFM samples were continuously taken in the dermis for 24 h postdose and analyzed by LC-MS/MS.  Probe depths were assessed by 50 MHz ultrasound scanning.  Results: Mixed-effects modeling identified skin condition, treatment duration and probe-depth as kinetics detg. variables.  The time- and depth-resolved intradermal data revealed (i) slower penetration of CP-17 into lesional than into nonlesional skin, (ii) normalized (faster) skin penetration after repeated dosing, and no CP-17 accumulation within the dermis independently of the skin condition.  Conclusions: Intradermal investigation of a highly lipophilic drug released from low-strength cream was successfully performed by using dOFM and timely and spatially, i.e., probe-depth dependent, resolved kinetic data were delivered.  These data support the assumption that the thickened psoriatic stratum corneum might act as trap compartment which lowers the skin penetration rate for lipophilic topical drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowrTpeyI8lrLVg90H21EOLACvtfcHk0ljEU6enbJ7LoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVOnur0%253D&md5=4a3b0f91493967632ddfa3a5cd22d992</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1007%2Fs11095-016-1960-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-016-1960-y%26sid%3Dliteratum%253Aachs%26aulast%3DBodenlenz%26aufirst%3DM.%26aulast%3DDragatin%26aufirst%3DC.%26aulast%3DLiebenberger%26aufirst%3DL.%26aulast%3DTschapeller%26aufirst%3DB.%26aulast%3DBoulgaropoulos%26aufirst%3DB.%26aulast%3DAugustin%26aufirst%3DT.%26aulast%3DRaml%26aufirst%3DR.%26aulast%3DGatschelhofer%26aufirst%3DC.%26aulast%3DWagner%26aufirst%3DN.%26aulast%3DBenkali%26aufirst%3DK.%26aulast%3DRony%26aufirst%3DF.%26aulast%3DPieber%26aufirst%3DT.%26aulast%3DSinner%26aufirst%3DF.%26atitle%3DKinetics%2520of%2520clobetasol-17-propionate%2520in%2520psoriatic%2520lesional%2520and%2520non-lesional%2520skin%2520assessed%2520by%2520dermal%2520open%2520flow%2520microperfusion%2520with%2520time%2520and%2520space%2520resolution%26jtitle%3DPharm.%2520Res.%26date%3D2016%26volume%3D33%26spage%3D2229%26epage%3D2238%26doi%3D10.1007%2Fs11095-016-1960-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, G.</span></span> <span> </span><span class="NLM_article-title">Clearance concepts in pharmacokinetics</span>. <i>J. Pharmacokinet. Biopharm.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1007/BF01059626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1007%2FBF01059626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=4764426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A280%3ADyaE2c%252FmtVKisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1973&pages=123-136&author=M.+Rowlandauthor=L.+Benetauthor=G.+Graham&title=Clearance+concepts+in+pharmacokinetics&doi=10.1007%2FBF01059626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Clearance concepts in pharmacokinetics</span></div><div class="casAuthors">Rowland M; Benet L Z; Graham G G</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmacokinetics and biopharmaceutics</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-36</span>
        ISSN:<span class="NLM_cas:issn">0090-466X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSz4Zcsmz7GkKe0F5ixvZgXfW6udTcc2eZ9QN-G1lzGSLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE2c%252FmtVKisw%253D%253D&md5=bf6ffefba3dd092a61fb55bca443973a</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2FBF01059626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01059626%26sid%3Dliteratum%253Aachs%26aulast%3DRowland%26aufirst%3DM.%26aulast%3DBenet%26aufirst%3DL.%26aulast%3DGraham%26aufirst%3DG.%26atitle%3DClearance%2520concepts%2520in%2520pharmacokinetics%26jtitle%3DJ.%2520Pharmacokinet.%2520Biopharm.%26date%3D1973%26volume%3D1%26spage%3D123%26epage%3D136%26doi%3D10.1007%2FBF01059626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Card, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">England, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabrizizad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y. J.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the activity of drugs that inhibit phosphodiesterases</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2233</span>– <span class="NLM_lpage">2247</span>, <span class="refDoi"> DOI: 10.1016/j.str.2004.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1016%2Fj.str.2004.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=15576036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVClur3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=2233-2247&author=G.+L.+Cardauthor=B.+P.+Englandauthor=Y.+Suzukiauthor=D.+Fongauthor=B.+Powellauthor=B.+Leeauthor=C.+Luuauthor=M.+Tabrizizadauthor=S.+Gilletteauthor=P.+N.+Ibrahimauthor=D.+R.+Artisauthor=G.+Bollagauthor=M.+V.+Milburnauthor=S.-H.+Kimauthor=J.+Schlessingerauthor=K.+Y.+J.+Zhang&title=Structural+basis+for+the+activity+of+drugs+that+inhibit+phosphodiesterases&doi=10.1016%2Fj.str.2004.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases</span></div><div class="casAuthors">Card, Graeme L.; England, Bruce P.; Suzuki, Yoshihisa; Fong, Daniel; Powell, Ben; Lee, Byunghun; Luu, Catherine; Tabrizizad, Maryam; Gillette, Sam; Ibrahim, Prabha N.; Artis, Dean R.; Bollag, Gideon; Milburn, Michael V.; Kim, Sung-Hou; Schlessinger, Joseph; Zhang, Kam Y. J.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2233-2247</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) comprise a large family of enzymes that catalyze the hydrolysis of cAMP or cGMP and are implicated in various diseases.  The authors describe the high-resoln. crystal structures of the catalytic domains of PDE4B, PDE4D, and PDE5A with ten different inhibitors, including the drug candidates cilomilast and roflumilast, for respiratory diseases.  These cocrystal structures reveal a common scheme of inhibitor binding to the PDEs: (i) a hydrophobic clamp formed by highly conserved hydrophobic residues that sandwich the inhibitor in the active site; (ii) hydrogen bonding to an invariant glutamine that controls the orientation of inhibitor binding.  A scaffold can be readily identified for any given inhibitor based on the formation of these two types of conserved interactions.  These structural insights will enable the design of isoform-selective inhibitors with improved binding affinity and should facilitate the discovery of more potent and selective PDE inhibitors for the treatment of a variety of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8l4KWCohSy7Vg90H21EOLACvtfcHk0lgTBOr4itqC9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVClur3K&md5=0fa91e4b9047e3df3946c526592be396</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2004.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2004.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DCard%26aufirst%3DG.%2BL.%26aulast%3DEngland%26aufirst%3DB.%2BP.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DLuu%26aufirst%3DC.%26aulast%3DTabrizizad%26aufirst%3DM.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26atitle%3DStructural%2520basis%2520for%2520the%2520activity%2520of%2520drugs%2520that%2520inhibit%2520phosphodiesterases%26jtitle%3DStructure%26date%3D2004%26volume%3D12%26spage%3D2233%26epage%3D2247%26doi%3D10.1016%2Fj.str.2004.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 2 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dean  Paes</span>, <span class="hlFld-ContribAuthor ">Melissa  Schepers</span>, <span class="hlFld-ContribAuthor ">Ben  Rombaut</span>, <span class="hlFld-ContribAuthor ">Daniel  van den Hove</span>, <span class="hlFld-ContribAuthor ">Tim  Vanmierlo</span>, <span class="hlFld-ContribAuthor ">Jos  Prickaerts</span>, . </span><span class="cited-content_cbyCitation_article-title">The Molecular Biology of Phosphodiesterase 4 Enzymes as Pharmacological Targets: An Interplay of Isoforms, Conformational States, and Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Reviews</span><span> <strong>2021,</strong> <em>73 </em>
                                    (3)
                                     , 1016-1049. <a href="https://doi.org/10.1124/pharmrev.120.000273" title="DOI URL">https://doi.org/10.1124/pharmrev.120.000273</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/pharmrev.120.000273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fpharmrev.120.000273%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Reviews%26atitle%3DThe%252BMolecular%252BBiology%252Bof%252BPhosphodiesterase%252B4%252BEnzymes%252Bas%252BPharmacological%252BTargets%25253A%252BAn%252BInterplay%252Bof%252BIsoforms%25252C%252BConformational%252BStates%25252C%252Band%252BInhibitors%26aulast%3DPaes%26aufirst%3DDean%26date%3D2021%26date%3D2021%26volume%3D73%26issue%3D3%26spage%3D1016%26epage%3D1049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefan  Eirefelt</span>, <span class="hlFld-ContribAuthor ">Joanna  Hummer</span>, <span class="hlFld-ContribAuthor ">Line Hollesen  Basse</span>, <span class="hlFld-ContribAuthor ">Malene  Bertelsen</span>, <span class="hlFld-ContribAuthor ">Fredrik  Johansson</span>, <span class="hlFld-ContribAuthor ">Thomas  Birngruber</span>, <span class="hlFld-ContribAuthor ">Frank  Sinner</span>, <span class="hlFld-ContribAuthor ">Jens  Larsen</span>, <span class="hlFld-ContribAuthor ">Simon Feldbæk  Nielsen</span>, <span class="hlFld-ContribAuthor ">Maja  Lambert</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluating Dermal Pharmacokinetics and Pharmacodymanic Effect of Soft Topical PDE4 Inhibitors: Open Flow Microperfusion and Skin Biopsies. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutical Research</span><span> <strong>2020,</strong> <em>37 </em>
                                    (12)
                                     <a href="https://doi.org/10.1007/s11095-020-02962-1" title="DOI URL">https://doi.org/10.1007/s11095-020-02962-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11095-020-02962-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11095-020-02962-1%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutical%2520Research%26atitle%3DEvaluating%252BDermal%252BPharmacokinetics%252Band%252BPharmacodymanic%252BEffect%252Bof%252BSoft%252BTopical%252BPDE4%252BInhibitors%25253A%252BOpen%252BFlow%252BMicroperfusion%252Band%252BSkin%252BBiopsies%26aulast%3DEirefelt%26aufirst%3DStefan%26date%3D2020%26date%3D2020%26volume%3D37%26issue%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00797&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Examples of PDE4 inhibitors known prior to the discovery of the new triazolopyridine scaffold described in this paper.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00797&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Overlay of roflumilast and compound <b>3</b> docked in the roflumilast structure <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XOQ">1XOQ</a>.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Compound <b>3</b> was docked in the enol form previously described for compound <b>1</b>.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The figure was made using Maestro, Schrödinger, LLC, New York, NY, 2019.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00797&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Binding mode of roflumilast taken from <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XOQ">1XOQ</a>.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Shown are the water molecules coordinating the Mg<sup>2+</sup> metal ion and the water mediated interactions with the pyridine nitrogen of Roflumilast. The figure was made using Maestro, Schrödinger, LLC, New York, NY, 2019.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00797&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Fit of <b>13</b> (shown in green) to five-point pharmacophore model based on the docked binding model of <b>3</b> (shown in orange). The pharmacophore model and fit were done with Phase, Schrödinger Inc. The figure was made using Maestro, Schrödinger, LLC, New York, NY, 2019.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00797&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Crystal structure of <b>40</b> (shown in magenta) complexed with PDE4D solved to 1.6 Å. Key residues are shown in ball-and-stick representation. Residue numbering is as in ref <a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a>. (B) Overlay of <b>40</b> with the previously determined binding mode of an analogue (shown in green) of LEO 29102 (<b>1</b>).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The figure was made using Maestro, Schrödinger, LLC, New York, NY, 2019.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00797&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Preparation of the Triazolopyridine Scaffold Series<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00797&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 10% Pd/C, 3 atm of H<sub>2</sub>, EtOH, rt, 91%; (b) <i>O</i>-(4-nitrobenzoyl)hydroxylamine or <i>O</i>-mesitylensulfonylhydroxylamine, DCM, rt, 88–91%; (c) aldehyde, dioxane, 90 °C, 76% (R = H), 88% (R = COOEt), 47% (R = CH<sub>2</sub>O-TBDPS); (d) TBAF, THF, rt, 79%; (e) NIS, BF<sub>3</sub>·2H<sub>2</sub>O, 84% (R = H), 77% (R = COOEt); 52% (R = CH<sub>2</sub>OH); (f) aq LiOH, dioxane, rt, 98%; (g) MsCl, Et<sub>3</sub>N, DCM, 0 °C, 91%; (h) NaCN, DMF, 80 °C, 66%; (i) HCl, MeOH, 70 °C, 81%; (j) LiOH, THF–MeOH–water, 50 °C, 69%; (k) dimethyl malonate, NaH, toluene, 110 °C, 68%; (l) 6 N HCl, 100 °C, 68%; (m) Sn<sub>2</sub>Me<sub>6</sub>, (PPh<sub>3</sub>)<sub>2</sub>Pd(OAc)<sub>2</sub>, toluene, 100 °C, 100%; (n) Ar–Br, Pd(PPh<sub>3</sub>)<sub>4</sub>, toluene, 100 °C; (o) Ar-B(OR)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, aq K<sub>2</sub>CO<sub>3</sub>, DME, 80 °C or Ar-B(OR)<sub>2</sub>, Pd<sub>2</sub> dba<sub>3</sub>, PCy<sub>3</sub>, K<sub>3</sub>PO<sub>4</sub>, dioxane–water, 110–145 °C; (p) BH<sub>3</sub>·THF, THF, 0 °C to rt; (q) R′OH, EDAC·HCl, DMAP, DCM, rt or R′NH<sub>2</sub>, HATU or PYBROP, Et<sub>3</sub>N, DMF, rt; (r) R″COCl, DIPEA, DCE, rt.</p></p></figure><figure data-id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of the Clinical PDE4 Inhibitor <b>40</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00797&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 5% Pd/C, 3 atm of H<sub>2</sub>, EtOAc–MeOH, rt, 97%; (b) HOSA, DBU, MeOH, 40 °C; (c) dimethyl cyclopropane-1,1-dicarboxylate, DBU, MeOH, 65 °C; (d) aq NaOH, rt; (e) aq H<sub>2</sub>SO<sub>4</sub>, rt, 49%; (f) NBS, DMF–MeCN, 60 °C, 66%; (g) bis(pinacolato)diborane, Pd(dppf)Cl<sub>2</sub>, KOAc, dioxane, 90 °C, 76%; (h) Pd(dppf)Cl<sub>2</sub>, Et<sub>3</sub>N, dioxane–water, 80 °C; (i) aq citric acid, rt, 69%; (j) iso-BuI, K<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C, 81%.</p></p></figure><figure data-id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Metabolites Formed <i>in Vitro</i> in Human, Minipig, Monkey, and Rat Whole Blood</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00797&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/medium/jm0c00797_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Proposed Metabolic Pathway in Human, Monkey, Minipig, and Rat Hepatocytes</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c00797/20201203/images/large/jm0c00797_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00797&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i110">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26376" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26376" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 30 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deluran, M.</span>; <span class="NLM_string-name">Olesen, A. B.</span>; <span class="NLM_string-name">Thestrup-Pedersen, K.</span></span> <span> </span><span class="NLM_article-title">Clinical Symptoms of Atopic Eczema</span>. In  <i>Handbook of Atopic Eczema</i>, <span class="NLM_edition">2</span>nd ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Ring, J.</span>, <span class="NLM_string-name">Przybilla, B.</span>, <span class="NLM_string-name">Ruzicka, T.</span></span>, Eds.; <span class="NLM_publisher-name">Springer-Verlag</span>: <span class="NLM_publisher-loc">Berlin</span>, <span class="NLM_year">2006</span>; pp  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">44</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1007%2F3-540-29856-8_5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=37-44&author=M.+Deluran&author=A.+B.+Olesen&author=K.+Thestrup-Pedersenauthor=J.+Ring&author=B.+Przybilla&author=T.+Ruzicka&title=Handbook+of+Atopic+Eczema"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2F3-540-29856-8_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F3-540-29856-8_5%26sid%3Dliteratum%253Aachs%26aulast%3DDeluran%26aufirst%3DM.%26atitle%3DClinical%2520Symptoms%2520of%2520Atopic%2520Eczema%26btitle%3DHandbook%2520of%2520Atopic%2520Eczema%26aulast%3DRing%26aufirst%3DJ.%26pub%3DSpringer-Verlag%26date%3D2006%26spage%3D37%26epage%3D44" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guttman-Yassky, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanifin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boguniewicz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollenberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bissonnette, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilty, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zielinski, A. M.</span></span> <span> </span><span class="NLM_article-title">The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition</span>. <i>Exp. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1111/exd.13808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1111%2Fexd.13808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=30332502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A280%3ADC%252BB3cvgsVOisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2019&pages=3-10&issue=1&author=E.+Guttman-Yasskyauthor=J.+M.+Hanifinauthor=M.+Boguniewiczauthor=A.+Wollenbergauthor=R.+Bissonnetteauthor=V.+Purohitauthor=I.+Kiltyauthor=A.+M.+Tallmanauthor=A.+M.+Zielinski&title=The+role+of+phosphodiesterase+4+in+the+pathophysiology+of+atopic+dermatitis+and+the+perspective+for+its+inhibition&doi=10.1111%2Fexd.13808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition</span></div><div class="casAuthors">Guttman-Yassky Emma; Hanifin Jon M; Boguniewicz Mark; Wollenberg Andreas; Bissonnette Robert; Purohit Vivek; Kilty Iain; Tallman Anna M; Zielinski Michael A</div><div class="citationInfo"><span class="NLM_cas:title">Experimental dermatology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Atopic dermatitis (AD) is a highly prevalent, chronic inflammatory skin disease that affects children and adults.  The pathophysiology of AD is complex and involves skin barrier and immune dysfunction.  Many immune cytokine pathways are amplified in AD, including T helper (Th) 2, Th22, Th17 and Th1.  Current treatment guidelines recommend topical medications as initial therapy; however, until recently, only two drug classes were available: topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs).  Several limitations are associated with these agents.  TCSs can cause a wide range of adverse effects, including skin atrophy, telangiectasia, rosacea and acne.  TCIs can cause burning and stinging, and the prescribing information lists a boxed warning for a theoretical risk of malignancy.  Novel medications with new mechanisms of action are necessary to provide better long-term control of AD.  Phosphodiesterase 4 (PDE4) regulates cyclic adenosine monophosphate in cells and has been shown to be involved in the pathophysiology of AD, making it an attractive therapeutic target.  Several PDE4 inhibitors are in clinical development for use in the treatment of AD, including crisaborole, which recently became the first topical PDE4 inhibitor approved for treatment of mild to moderate AD.  This review will further describe the pathophysiology of AD, explain the possible role of PDE4 in AD and review PDE4 inhibitors currently approved or being investigated for use in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQHPKrjoHI3K0ewzGPswiWOfW6udTcc2eYeQTesjt0POrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvgsVOisA%253D%253D&md5=b52d04bd70a35a6d23b2dcc3c05aa959</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fexd.13808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fexd.13808%26sid%3Dliteratum%253Aachs%26aulast%3DGuttman-Yassky%26aufirst%3DE.%26aulast%3DHanifin%26aufirst%3DJ.%2BM.%26aulast%3DBoguniewicz%26aufirst%3DM.%26aulast%3DWollenberg%26aufirst%3DA.%26aulast%3DBissonnette%26aufirst%3DR.%26aulast%3DPurohit%26aufirst%3DV.%26aulast%3DKilty%26aufirst%3DI.%26aulast%3DTallman%26aufirst%3DA.%2BM.%26aulast%3DZielinski%26aufirst%3DA.%2BM.%26atitle%3DThe%2520role%2520of%2520phosphodiesterase%25204%2520in%2520the%2520pathophysiology%2520of%2520atopic%2520dermatitis%2520and%2520the%2520perspective%2520for%2520its%2520inhibition%26jtitle%3DExp.%2520Dermatol.%26date%3D2019%26volume%3D28%26issue%3D1%26spage%3D3%26epage%3D10%26doi%3D10.1111%2Fexd.13808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paton, D. M.</span></span> <span> </span><span class="NLM_article-title">Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1358/dot.2017.53.4.2604174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1358%2Fdot.2017.53.4.2604174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A280%3ADC%252BC1crmtVykug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2017&pages=239-245&issue=4&author=D.+M.+Paton&title=Crisaborole%3A+Phosphodiesterase+inhibitor+for+treatment+of+atopic+dermatitis&doi=10.1358%2Fdot.2017.53.4.2604174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis</span></div><div class="casAuthors">Paton D M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">239-245</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Atopic dermatitis (AD) is an extremely common condition affecting as many as 10-20% of children and 2-10% of adults.  A particularly distressing symptom of AD is pruritus.  One of the important aspects of AD is inflammation associated with increased activity of phosphodiesterase 4 (PDE4), resulting in decreased intracellular levels of cyclic adenosine monophosphate, which in turn causes increased production of inflammatory cytokines.  Crisaborole was developed as a small-molecule, boron-based, selective PDE4 inhibitor that can be used topically.  Clinical trials have demonstrated its efficacy in treating patients with mild to moderate AD, resulting in significant relief of pruritus.  Unlike PDE4 inhibitors that act systemically, crisaborole does not cause significant gastrointestinal adverse effects.  The most common adverse effect has been temporary stinging and burning in about 4% of patients upon application of the 2% ointment.  To date there is no evidence of atrophy, telangiectasia or hypopigmentation resulting from its use.  Crisaborole is the first topically applied PDE4 inhibitor to be approved by the FDA for use in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTC3c4rt0Hyh4qdXsLcGTEUfW6udTcc2eYeQTesjt0POrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crmtVykug%253D%253D&md5=a854efec1d46127283db4e443c22221f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1358%2Fdot.2017.53.4.2604174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2017.53.4.2604174%26sid%3Dliteratum%253Aachs%26aulast%3DPaton%26aufirst%3DD.%2BM.%26atitle%3DCrisaborole%253A%2520Phosphodiesterase%2520inhibitor%2520for%2520treatment%2520of%2520atopic%2520dermatitis%26jtitle%3DDrugs%2520Today%26date%3D2017%26volume%3D53%26issue%3D4%26spage%3D239%26epage%3D245%26doi%3D10.1358%2Fdot.2017.53.4.2604174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freund, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maples, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plattner, J. J.</span></span> <span> </span><span class="NLM_article-title">Discovery and structure–activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2129</span>– <span class="NLM_lpage">2132</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.03.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1016%2Fj.bmcl.2009.03.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=19303290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkt1Sjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2129-2132&issue=8&author=T.+Akamaauthor=S.+J.+Bakerauthor=Y.+K.+Zhangauthor=V.+Hernandezauthor=H.+Zhouauthor=V.+Sandersauthor=Y.+Freundauthor=R.+Kimuraauthor=K.+R.+Maplesauthor=J.+J.+Plattner&title=Discovery+and+structure%E2%80%93activity+study+of+a+novel+benzoxaborole+anti-inflammatory+agent+%28AN2728%29+for+the+potential+topical+treatment+of+psoriasis+and+atopic+dermatitis&doi=10.1016%2Fj.bmcl.2009.03.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis</span></div><div class="casAuthors">Akama, Tsutomu; Baker, Stephen J.; Zhang, Yong-Kang; Hernandez, Vincent; Zhou, Huchen; Sanders, Virginia; Freund, Yvonne; Kimura, Richard; Maples, Kirk R.; Plattner, Jacob J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2129-2132</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of phenoxy benzoxaboroles were synthesized and screened for their inhibitory activity against PDE4 and cytokine release.  5-(4-Cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2728) showed potent activity both in vitro and in vivo.  This compd. is now in clin. development for the topical treatment of psoriasis and being pursued for the topical treatment of atopic dermatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYdD-T7O2W57Vg90H21EOLACvtfcHk0lj76hO-AS5b0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkt1Sjsb4%253D&md5=a526278d0506fc5916432cf20c6ff5e5</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.03.007%26sid%3Dliteratum%253Aachs%26aulast%3DAkama%26aufirst%3DT.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%2BK.%26aulast%3DHernandez%26aufirst%3DV.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DSanders%26aufirst%3DV.%26aulast%3DFreund%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DR.%26aulast%3DMaples%26aufirst%3DK.%2BR.%26aulast%3DPlattner%26aufirst%3DJ.%2BJ.%26atitle%3DDiscovery%2520and%2520structure%25E2%2580%2593activity%2520study%2520of%2520a%2520novel%2520benzoxaborole%2520anti-inflammatory%2520agent%2520%2528AN2728%2529%2520for%2520the%2520potential%2520topical%2520treatment%2520of%2520psoriasis%2520and%2520atopic%2520dermatitis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26issue%3D8%26spage%3D2129%26epage%3D2132%26doi%3D10.1016%2Fj.bmcl.2009.03.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grewe, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanifin, J. M.</span></span> <span> </span><span class="NLM_article-title">Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">452</span>– <span class="NLM_lpage">457</span>, <span class="refDoi"> DOI: 10.1016/0091-6749(82)90008-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1016%2F0091-6749%2882%2990008-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=6128357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A280%3ADyaL3s%252FlslOktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1982&pages=452-457&author=S.+R.+Greweauthor=S.+C.+Chanauthor=J.+M.+Hanifin&title=Elevated+leukocyte+cyclic+AMP-phosphodiesterase+in+atopic+disease%3A+a+possible+mechanism+for+cyclic+AMP-agonist+hyporesponsiveness&doi=10.1016%2F0091-6749%2882%2990008-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness</span></div><div class="casAuthors">Grewe S R; Chan S C; Hanifin J M</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of allergy and clinical immunology</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">452-7</span>
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    </div><div class="casAbstract">Previous studies have documented that leukocytes from atopic individuals show reduced cyclic AMP (cAMP) responsiveness to isoproterenol, histamine, and prostaglandin E1.  We questioned whether this blunted response was due to rapid enzymic breakdown of cAMP.  We measured cAMP-phosphodiesterase activity in mononuclear leukocytes of patients with atopic dermatitis and allergic rhinitis and noted consistent, significantly elevated levels.  Kinetic studies showed differences in two of three leukocyte enzyme forms between normals and patients.  Isolated lymphocytes from atopic dermatitis patients lacked a low Km phosphodiesterase form and showed an increase in the high Km, high-activity form seen in normal monocytes.  The increased phosphodiesterase activity provides an explanation for the blunted cAMP responsiveness in atopic leukocytes and may reflect a basic biochemical characteristic relevant to abnormal immunocellular regulation in atopic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcROnDD72nitREodMGTatQ7LfW6udTcc2ebgXlAK7wlCcrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3s%252FlslOktA%253D%253D&md5=8f924e4bf94ef45f71b4a685a6f78844</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2F0091-6749%2882%2990008-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0091-6749%252882%252990008-2%26sid%3Dliteratum%253Aachs%26aulast%3DGrewe%26aufirst%3DS.%2BR.%26aulast%3DChan%26aufirst%3DS.%2BC.%26aulast%3DHanifin%26aufirst%3DJ.%2BM.%26atitle%3DElevated%2520leukocyte%2520cyclic%2520AMP-phosphodiesterase%2520in%2520atopic%2520disease%253A%2520a%2520possible%2520mechanism%2520for%2520cyclic%2520AMP-agonist%2520hyporesponsiveness%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D1982%26volume%3D70%26spage%3D452%26epage%3D457%26doi%3D10.1016%2F0091-6749%2882%2990008-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halling-Overgaard, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kezic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakasa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engebretsen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maibach, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thyssen, J. P.</span></span> <span> </span><span class="NLM_article-title">Skin absorption through atopic dermatitis skin: a systematic review</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1111/bjd.15065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1111%2Fbjd.15065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=27639188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A280%3ADC%252BC2svhsVajsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2017&pages=84-103&author=A.+S.+Halling-Overgaardauthor=S.+Kezicauthor=I.+Jakasaauthor=K.+A.+Engebretsenauthor=H.+Maibachauthor=J.+P.+Thyssen&title=Skin+absorption+through+atopic+dermatitis+skin%3A+a+systematic+review&doi=10.1111%2Fbjd.15065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Skin absorption through atopic dermatitis skin: a systematic review</span></div><div class="casAuthors">Halling-Overgaard A-S; Engebretsen K A; Thyssen J P; Halling-Overgaard A-S; Engebretsen K A; Thyssen J P; Kezic S; Jakasa I; Maibach H</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of dermatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-106</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Patients with atopic dermatitis (AD) have skin barrier impairment in both lesional and nonlesional skin.  They are typically exposed daily to emollients and intermittently to topical anti-inflammatory medicaments, thereby increasing the risk of developing contact allergy and systemic exposure to chemical ingredients found in these topical preparations.  We systematically searched for studies that investigated skin absorption of various penetrants, including medicaments, in patients with AD, but also in animals with experimentally-induced dermatitis.  We identified 40 articles: 11 human studies examining model penetrants, 26 human studies examining AD drugs, and three animal studies.  We conclude that patients with AD have almost twofold increased skin absorption compared with healthy controls.  There is a need for well-designed epidemiological and dermatopharmacokinetic studies that examine to what extent AD causes patients to be systemically exposed to chemicals compared with nonatopic dermatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS3QV_bk8ER-a2q3xNe7a7QfW6udTcc2ea3yqtqcdckwLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svhsVajsA%253D%253D&md5=e0a84bc578c51cdedfff9e4f2c25e8ff</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1111%2Fbjd.15065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.15065%26sid%3Dliteratum%253Aachs%26aulast%3DHalling-Overgaard%26aufirst%3DA.%2BS.%26aulast%3DKezic%26aufirst%3DS.%26aulast%3DJakasa%26aufirst%3DI.%26aulast%3DEngebretsen%26aufirst%3DK.%2BA.%26aulast%3DMaibach%26aufirst%3DH.%26aulast%3DThyssen%26aufirst%3DJ.%2BP.%26atitle%3DSkin%2520absorption%2520through%2520atopic%2520dermatitis%2520skin%253A%2520a%2520systematic%2520review%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2017%26volume%3D177%26spage%3D84%26epage%3D103%26doi%3D10.1111%2Fbjd.15065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moustafa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, S. R.</span></span> <span> </span><span class="NLM_article-title">A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology</span>. <i>Dermatol. Online J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">22608</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=24852768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A280%3ADC%252BC2cjlsVegsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=22608&author=F.+Moustafaauthor=S.+R.+Feldman&title=A+review+of+phosphodiesterase-inhibition+and+the+potential+role+for+phosphodiesterase+4-inhibitors+in+clinical+dermatology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology</span></div><div class="casAuthors">Moustafa Farah; Feldman Steven R</div><div class="citationInfo"><span class="NLM_cas:title">Dermatology online journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">22608</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Phosphodiesterase inhibitors are commonly used drugs.  Specific phosphodiesterase inhibitors with anti-inflammatory properties are being assessed as dermatological treatments.  PURPOSE:  To describe important aspects of phosphodiesterase inhibition and the safety and efficacy of 2 phosphodiesterase- 4 inhibitors being studied for the treatment of dermatologic diseases  METHODS:  We did a non-systematic analysis of literature on phosphodiesterase inhibition followed by a review of published information on apremilast and topical AN2728 and their use for psoriasis and atopic dermatitis.  FINDINGS:  Apremilast and topical AN2728 have modest efficacy in treatment of psoriasis.  Apremilast achieved PASI-75 scores ranging from 24-33%.  In phase 2 studies, AN2728 had modest efficacy for psoriasis (40% of patients achieved a ≥ 2 grade improvement as assessed by the Overall target Plaque Severity Score).  In phase 2 studies of AN2728 use in atopic dermatitis, subjects achieved a 71% improvement from baseline Atopic Dermatitis Severity Index.  In all studies, most adverse effects were minimal.  The limitations of this paper are the limited number of published studies, the lack of long-term data, and the lack of head -to - head trials directly comparing phosphodiesterase inhibitors with other treatments.  CONCLUSION:  Phosphodiesterase inhibitors constitute a widely used class of drugs that may see growing use for inflammatory dermatologic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRwzFx2xHbtDHWEEzDrymxmfW6udTcc2ea3yqtqcdckwLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjlsVegsQ%253D%253D&md5=66adc0384bc37c232512711c3743a2c4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoustafa%26aufirst%3DF.%26aulast%3DFeldman%26aufirst%3DS.%2BR.%26atitle%3DA%2520review%2520of%2520phosphodiesterase-inhibition%2520and%2520the%2520potential%2520role%2520for%2520phosphodiesterase%25204-inhibitors%2520in%2520clinical%2520dermatology%26jtitle%3DDermatol.%2520Online%2520J.%26date%3D2014%26volume%3D20%26spage%3D22608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bodor, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, P.</span></span> <span> </span><span class="NLM_article-title">Soft drug design: general principles and recent applications</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1098-1128(200001)20:1<58::AID-MED3>3.0.CO;2-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1002%2F%28SICI%291098-1128%28200001%2920%3A1%3C58%3A%3AAID-MED3%3E3.0.CO%3B2-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10608921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltFWqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=58-101&issue=1&author=N.+Bodorauthor=P.+Buchwald&title=Soft+drug+design%3A+general+principles+and+recent+applications&doi=10.1002%2F%28SICI%291098-1128%28200001%2920%3A1%3C58%3A%3AAID-MED3%3E3.0.CO%3B2-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Soft drug design: general principles and recent applications</span></div><div class="casAuthors">Bodor, Nicholas; Buchwald, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-101</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review with 208 refs.  Soft drug design represents a new approach aimed to design safer drugs with an increased therapeutic index by integrating metab. considerations into the drug design process.  Soft drugs are new therapeutic agents that undergo predictable metab. to inactive metabolites after exerting their therapeutic effect.  Hence, they are obtained by building into the mol., in addn. to the activity, the most desired way in which the mol. is to be deactivated and detoxified.  In an attempt to systematize and summarize the related work done in a no. of labs., including ours, the present review presents an overview of the general soft drug design principles and provides a variety of specific examples to illustrate the concepts.  A no. of already marketed drugs, such as esmolol, remifentanil, or loteprednol etabonate, resulted from the successful application of such design principles.  Many other promising drug candidates are currently under investigation in a variety of fields including possible soft antimicrobials, anticholinergics, corticosteroids, β-blockers, analgetics, ACE inhibitors, antiarrhythmics, and others.  Whenever possible, pharmacokinetic and pharmacodynamic properties are briefly summarized and compared to those of other compds. used in the same field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphV1vhXwTl8LVg90H21EOLACvtfcHk0lhUYleg7de3qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltFWqsg%253D%253D&md5=e0ca493ba31d001e62a759be0fc4bcc8</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291098-1128%28200001%2920%3A1%3C58%3A%3AAID-MED3%3E3.0.CO%3B2-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291098-1128%2528200001%252920%253A1%253C58%253A%253AAID-MED3%253E3.0.CO%253B2-X%26sid%3Dliteratum%253Aachs%26aulast%3DBodor%26aufirst%3DN.%26aulast%3DBuchwald%26aufirst%3DP.%26atitle%3DSoft%2520drug%2520design%253A%2520general%2520principles%2520and%2520recent%2520applications%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2000%26volume%3D20%26issue%3D1%26spage%3D58%26epage%3D101%26doi%3D10.1002%2F%28SICI%291098-1128%28200001%2920%3A1%3C58%3A%3AAID-MED3%3E3.0.CO%3B2-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Felding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sørensen, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Refer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladefoged, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thormann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinggaard, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegardt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Søhoel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, S. F.</span></span> <span> </span><span class="NLM_article-title">Discovery and early clinical development of 2-{6-[2-(3,5-dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy}-<i>N</i>-propylacetamide (LEO 29102), a soft-drug inhibitor of phosphodiesterase 4 for topical treatment of atopic dermatitis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5893</span>– <span class="NLM_lpage">5903</span>, <span class="refDoi"> DOI: 10.1021/jm500378a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500378a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtV2jsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5893-5903&issue=14&author=J.+Feldingauthor=M.+D.+S%C3%B8rensenauthor=T.+D.+Poulsenauthor=J.+Larsenauthor=C.+Anderssonauthor=P.+Referauthor=K.+Engellauthor=L.+G.+Ladefogedauthor=T.+Thormannauthor=A.+M.+Vinggaardauthor=P.+Hegardtauthor=A.+S%C3%B8hoelauthor=S.+F.+Nielsen&title=Discovery+and+early+clinical+development+of+2-%7B6-%5B2-%283%2C5-dichloro-4-pyridyl%29acetyl%5D-2%2C3-dimethoxyphenoxy%7D-N-propylacetamide+%28LEO+29102%29%2C+a+soft-drug+inhibitor+of+phosphodiesterase+4+for+topical+treatment+of+atopic+dermatitis&doi=10.1021%2Fjm500378a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Early Clinical Development of 2-{6-[2-(3,5-Dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy}-N-propylacetamide (LEO 29102), a Soft-Drug Inhibitor of Phosphodiesterase 4 for Topical Treatment of Atopic Dermatitis</span></div><div class="casAuthors">Felding, Jakob; Soerensen, Morten D.; Poulsen, Tina D.; Larsen, Jens; Andersson, Christina; Refer, Pia; Engell, Karen; Ladefoged, Lotte G.; Thormann, Thorsten; Vinggaard, Anne Marie; Hegardt, Pontus; Soehoel, Anders; Nielsen, Simon Feldbaek</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5893-5903</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Development of orally available phosphodiesterase 4 (PDE4) inhibitors as anti-inflammatory drugs has been going on for decades.  However, only roflumilast has received FDA approval.  One key challenge has been the low therapeutic window obsd. in the clinic for PDE4 inhibitors, primarily due to PDE4 mediated side effects.  Here we describe our approach to circumvent this issue by applying a soft-drug concept in the design of a topically acting PDE4 inhibitor for treatment of dermatol. diseases.  We used a fast follower approach, starting from piclamilast.  In particular, simultaneous introduction of 2'-alkoxy substituents and changing an amide to a keto linker proved to be beneficial when designing potential soft-drug candidates.  This effort culminated in identification of LEO 29102 (20), a potent, selective, and soft-drug PDE4 inhibitor with properties suitable for patient-friendly formulations giving efficient drug delivery to the skin.  Compd. 20 has reached phase 2 and demonstrated clin. relevant efficacy in the treatment of atopic dermatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6hRC8lktjRrVg90H21EOLACvtfcHk0lhUYleg7de3qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtV2jsrfF&md5=9d236da8f314edec69f5b442e1a41141</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm500378a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500378a%26sid%3Dliteratum%253Aachs%26aulast%3DFelding%26aufirst%3DJ.%26aulast%3DS%25C3%25B8rensen%26aufirst%3DM.%2BD.%26aulast%3DPoulsen%26aufirst%3DT.%2BD.%26aulast%3DLarsen%26aufirst%3DJ.%26aulast%3DAndersson%26aufirst%3DC.%26aulast%3DRefer%26aufirst%3DP.%26aulast%3DEngell%26aufirst%3DK.%26aulast%3DLadefoged%26aufirst%3DL.%2BG.%26aulast%3DThormann%26aufirst%3DT.%26aulast%3DVinggaard%26aufirst%3DA.%2BM.%26aulast%3DHegardt%26aufirst%3DP.%26aulast%3DS%25C3%25B8hoel%26aufirst%3DA.%26aulast%3DNielsen%26aufirst%3DS.%2BF.%26atitle%3DDiscovery%2520and%2520early%2520clinical%2520development%2520of%25202-%257B6-%255B2-%25283%252C5-dichloro-4-pyridyl%2529acetyl%255D-2%252C3-dimethoxyphenoxy%257D-N-propylacetamide%2520%2528LEO%252029102%2529%252C%2520a%2520soft-drug%2520inhibitor%2520of%2520phosphodiesterase%25204%2520for%2520topical%2520treatment%2520of%2520atopic%2520dermatitis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D14%26spage%3D5893%26epage%3D5903%26doi%3D10.1021%2Fjm500378a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aprile, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirali, T.</span></span> <span> </span><span class="NLM_article-title">Soft drugs for dermatological applications: recent trends</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2234</span>– <span class="NLM_lpage">2246</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2019.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1016%2Fj.drudis.2019.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=31494188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslKntbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=2234-2246&issue=12&author=S.+Aprileauthor=M.+Serafiniauthor=T.+Pirali&title=Soft+drugs+for+dermatological+applications%3A+recent+trends&doi=10.1016%2Fj.drudis.2019.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Soft drugs for dermatological applications: recent trends</span></div><div class="casAuthors">Aprile, Silvio; Serafini, Marta; Pirali, Tracey</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2234-2246</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  A soft drug (SD) displays a metabolically labile spot and, after having exerted its activity in the site of action, undergoes a fast metab., leading to inactive metabolites.  The SD approach has recently found widespread application in the dermatol. field because it provides a means of localising the therapeutic effect in skin, while minimising systemic exposure.  The literature is rapidly growing of successful examples of compds. targeting sphingosine-1-phosphate receptor 1 (S1PR1), transient receptor potential vanilloid 1 (TRPV1), Janus kinase (JAK), caspase 1, and histone deacetylase (HDAC), for the treatment of skin inflammatory, autoimmune, and oncol. diseases.  As a demonstration of the potential of this strategy, the SD approach recently led to the approval of crisaborole, a soft phosphodiesterase 4 (PDE4) inhibitor, for atopic dermatitis, while other agents are in clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTJdakAL6BWLVg90H21EOLACvtfcHk0ljNmPJZVpS-KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslKntbvE&md5=995df11d311bb50cde6bcc0395a8624f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2019.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2019.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DAprile%26aufirst%3DS.%26aulast%3DSerafini%26aufirst%3DM.%26aulast%3DPirali%26aufirst%3DT.%26atitle%3DSoft%2520drugs%2520for%2520dermatological%2520applications%253A%2520recent%2520trends%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2019%26volume%3D24%26issue%3D12%26spage%3D2234%26epage%3D2246%26doi%3D10.1016%2Fj.drudis.2019.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span>LEO 29102
Cream in the Treatment of Atopic Dermatitis. <a href="https://clinicaltrials.gov/ct2/show/NCT01037881" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01037881</a> (accessed May 1, <span class="NLM_year">2020</span>); <a href="https://www.clinicaltrialsregister.eu/ctr-search/rest/download/result/attachment/2009-013792-22/1/17100" class="extLink">https://www.clinicaltrialsregister.eu/ctr-search/rest/download/result/attachment/2009-013792-22/1/17100</a> (accessed May 1, 2020)</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=LEO+29102%0ACream+in+the+Treatment+of+Atopic+Dermatitis.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01037881+%28accessed+May+1%2C+2020%29%3B+https%3A%2F%2Fwww.clinicaltrialsregister.eu%2Fctr-search%2Frest%2Fdownload%2Fresult%2Fattachment%2F2009-013792-22%2F1%2F17100+%28accessed+May+1%2C+2020%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, T.</span></span> <span> </span><span class="NLM_article-title">The emerging role of human esterases</span>. <i>Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">466</span>– <span class="NLM_lpage">477</span>, <span class="refDoi"> DOI: 10.2133/dmpk.DMPK-12-RV-042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.2133%2Fdmpk.DMPK-12-RV-042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=22813719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVykurzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2012&pages=466-477&issue=5&author=T.+Fukamiauthor=T.+Yokoi&title=The+emerging+role+of+human+esterases&doi=10.2133%2Fdmpk.DMPK-12-RV-042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The emerging role of human esterases</span></div><div class="casAuthors">Fukami, Tatsuki; Yokoi, Tsuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">466-477</span>CODEN:
                <span class="NLM_cas:coden">DMPRB8</span>;
        ISSN:<span class="NLM_cas:issn">1347-4367</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society for the Study of Xenobiotics</span>)
        </div><div class="casAbstract">In this review, novel aspects of the role of esterases, which contribute to the metab. of 10% of therapeutic drugs, are described.  Esterases hydrolyze the compds. that contain ester, amide, and thioester bonds, which cause prodrug activation or detoxification.  Among esterases, carboxylesterases are well known to be involved in the hydrolysis of a variety of drugs.  Addnl., other esterases have recently received attention for their pharmacol. and toxicol. roles.  Arylacetamide deacetylase (AADAC) is involved in the hydrolysis of flutamide, phenacetin, and rifamycins.  AADAC is assocd. with adverse drug reactions because the hydrolytic metabolites of flutamide and phenacetin appear to be assocd. with hepatotoxicity and nephrotoxicity/hematotoxicity, resp.  Paraoxonase and butyrylcholinesterase hydrolyze pirocarpine/simvastatin and succinylcholine/bambuterol, resp.  Although the esterases that hydrolyze the acyl-glucuronides of drugs have largely been unknown, we recently found that α/β hydrolase domain contg. 10 (ABHD10) is responsible for the hydrolysis of mycophenolic acid acyl-glucuronide in human liver.  Because acyl-glucuronides are assocd. with toxicity, ABHD10 might function as a detoxification enzyme.  Thus, various esterases, which include enzymes that have not been known to hydrolyze drugs, are involved in drug metab. with different substrate specificity.  Further esterase studies should be conducted to promote our understanding in clin. pharmacotherapy and drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDhsUJ4NrYQbVg90H21EOLACvtfcHk0ljNmPJZVpS-KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVykurzE&md5=d760b8a6a3217a4ab9716190800012b0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2133%2Fdmpk.DMPK-12-RV-042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2133%252Fdmpk.DMPK-12-RV-042%26sid%3Dliteratum%253Aachs%26aulast%3DFukami%26aufirst%3DT.%26aulast%3DYokoi%26aufirst%3DT.%26atitle%3DThe%2520emerging%2520role%2520of%2520human%2520esterases%26jtitle%3DDrug%2520Metab.%2520Pharmacokinet.%26date%3D2012%26volume%3D27%26issue%3D5%26spage%3D466%26epage%3D477%26doi%3D10.2133%2Fdmpk.DMPK-12-RV-042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berry, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollenberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span> <span> </span><span class="NLM_article-title">Esterase activities in the blood, liver and intestine of several preclinical species and humans</span>. <i>Drug Metab. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">70</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.2174/187231209788654081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.2174%2F187231209788654081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=19601867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsVGju70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2009&pages=70-77&issue=2&author=L.+M.+Berryauthor=L.+Wollenbergauthor=Z.+Zhao&title=Esterase+activities+in+the+blood%2C+liver+and+intestine+of+several+preclinical+species+and+humans&doi=10.2174%2F187231209788654081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Esterase activities in the blood, liver and intestine of several preclinical species and humans</span></div><div class="casAuthors">Berry, Loren M.; Wollenberg, Lance; Zhao, Zhiyang</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">70-77</span>CODEN:
                <span class="NLM_cas:coden">DMLRBM</span>;
        ISSN:<span class="NLM_cas:issn">1872-3128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Species and tissue differences in the activity of three major classes of esterases, carboxylesterase (CE), butyrylcholinesterase (BChE) and paraoxonase (PON), were studied.  Substantial species differences in activity of these esterases were obsd. between the mouse, rat, dog monkey and human.  Such species differences must be considered when using these preclin. species to optimize the pharmacokinetic properties of ester compds. intended for human use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDFldzEQtQKLVg90H21EOLACvtfcHk0ljNmPJZVpS-KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsVGju70%253D&md5=f480d5a0b9f54e7a34eadac588521caa</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F187231209788654081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187231209788654081%26sid%3Dliteratum%253Aachs%26aulast%3DBerry%26aufirst%3DL.%2BM.%26aulast%3DWollenberg%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DZ.%26atitle%3DEsterase%2520activities%2520in%2520the%2520blood%252C%2520liver%2520and%2520intestine%2520of%2520several%2520preclinical%2520species%2520and%2520humans%26jtitle%3DDrug%2520Metab.%2520Lett.%26date%3D2009%26volume%3D3%26issue%3D2%26spage%3D70%26epage%3D77%26doi%3D10.2174%2F187231209788654081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oesch, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oesch-Bartlomowicz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landsiedel, R.</span></span> <span> </span><span class="NLM_article-title">Drug-metabolizing enzymes in the skin of man, rat, and pig</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">659</span>– <span class="NLM_lpage">698</span>, <span class="refDoi"> DOI: 10.1080/03602530701690366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1080%2F03602530701690366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=18058329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlyitbnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2007&pages=659-698&issue=4&author=F.+Oeschauthor=E.+Fabianauthor=B.+Oesch-Bartlomowiczauthor=C.+Wernerauthor=R.+Landsiedel&title=Drug-metabolizing+enzymes+in+the+skin+of+man%2C+rat%2C+and+pig&doi=10.1080%2F03602530701690366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Metabolizing Enzymes in the Skin of Man, Rat, and Pig</span></div><div class="casAuthors">Oesch, Franz; Fabian, Eric; Oesch-Bartlomowicz, Barbara; Werner, Christoph; Landsiedel, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">659-698</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The mammalian skin has long been considered to be poor in drug metab.  However, many reports clearly show that most drug metabolizing enzymes also occur in the mammalian skin albeit at relatively low specific activities.  This review summarizes the current state of knowledge on drug metabolizing enzymes in the skin of human, rat, and pig, the latter, because it is often taken as a model for human skin on grounds of anatomical similarities.  However only little is known about drug metabolizing enzymes in pig skin.  Interestingly, some cytochromes P 450 (CYP) have been obsd. in the rat skin which are not expressed in the rat liver, such as CYP 2B12 and CYP2D4.  As far as investigated most drug metabolizing enzymes occur in the suprabasal (i.e. differentiating) layers of the epidermis, but the rat CYP1A1 rather in the basal layer and human UDP-glucuronosyltransferase rather in the stratum corneum.  The pattern of drug metabolizing enzymes and their localization will impact not only the beneficial as well as detrimental properties of drugs for the skin but also dictate whether a drug reaches the blood flow unchanged or as activated or inactivated metabolite(s).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofhs_tmoLY7bVg90H21EOLACvtfcHk0lhEf5HPzZCPjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlyitbnO&md5=43dcf77be2bd31c8a5629321f959bc10</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1080%2F03602530701690366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F03602530701690366%26sid%3Dliteratum%253Aachs%26aulast%3DOesch%26aufirst%3DF.%26aulast%3DFabian%26aufirst%3DE.%26aulast%3DOesch-Bartlomowicz%26aufirst%3DB.%26aulast%3DWerner%26aufirst%3DC.%26aulast%3DLandsiedel%26aufirst%3DR.%26atitle%3DDrug-metabolizing%2520enzymes%2520in%2520the%2520skin%2520of%2520man%252C%2520rat%252C%2520and%2520pig%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2007%26volume%3D39%26issue%3D4%26spage%3D659%26epage%3D698%26doi%3D10.1080%2F03602530701690366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Felding, J.</span>; <span class="NLM_string-name">Sørensen, M. D.</span></span> <span> </span><span class="NLM_article-title">Triazolopyridines as Phosphodiesterase Inhibitors for treatment of Dermal Diseases</span>. PTC Int. Appl. <span class="NLM_patent">WO2008/125111 A1</span>, Oct 23, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=J.+Felding&author=M.+D.+S%C3%B8rensen&title=Triazolopyridines+as+Phosphodiesterase+Inhibitors+for+treatment+of+Dermal+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFelding%26aufirst%3DJ.%26atitle%3DTriazolopyridines%2520as%2520Phosphodiesterase%2520Inhibitors%2520for%2520treatment%2520of%2520Dermal%2520Diseases%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatzelmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schudt, C.</span></span> <span> </span><span class="NLM_article-title">Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast <i>in vitro</i></span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>297</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">279</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=11259554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BD3MXisVSrsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=297&publication_year=2001&pages=267-279&issue=1&author=A.+Hatzelmannauthor=C.+Schudt&title=Anti-inflammatory+and+immunomodulatory+potential+of+the+novel+PDE4+inhibitor+roflumilast+in+vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro</span></div><div class="casAuthors">Hatzelmann, Armin; Schudt, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">297</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">267-279</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">From a series of benzamide derivs., roflumilast (3-cyclopropylmethoxy-4-difluoromethoxy-N-[3,5-di-chloropyrid-4-yl]b enzamide) was identified as a potent and selective PDE4 inhibitor.  It inhibits PDE4 activity from human neutrophils with an IC50 of 0.8 nM without affecting PDE1 (bovine brain), PDE2 (rat heart), and PDE3 and PDE5 (human platelets) even at 10,000-fold higher concns.  Roflumilast is almost equipotent to its major metabolite formed in vivo (roflumilast N-oxide) and piclamilast (RP 73401), however, more than 100-fold more potent than rolipram and Ariflo (cilomilast; SB 207499).  The anti-inflammatory and immunomodulatory potential of roflumilast and the ref. compds. was investigated in various human leukocytes using cell-specific responses: neutrophils [N-formyl-methyl-leucyl-phenylalanine (fMLP)-induced formation of LTB4 and reactive oxygen species (ROS)], eosinophils (fMLP- and C5a-induced ROS formation), monocytes, monocyte-derived macrophages, and dendritic cells (lipopolysaccharide-induced tumor necrosis factor-α synthesis), and CD4+ T cells (anti-CD3/anti-CD28 monoclonal antibody-stimulated proliferation, IL-2, IL-4, IL-5, and interferon-γ release).  Independent of the cell type and the response investigated, the corresponding IC values (for half-max. inhibition) of roflumilast were within a narrow range (2-21 nM), very similar to roflumilast N-oxide (3-40 nM) and piclamilast (2-13 nM).  In contrast, cilomilast (40-3000 nM) and rolipram (10-600 nM) showed greater differences with the highest potency for neutrophils.  Compared with neutrophils and eosinophils, representing the terminal inflammatory effector cells, the relative potency of roflumilast and its N-oxide for monocytes, CD4+ T cells, and dendritic cells is substantially higher compared with cilomilast and rolipram, probably reflecting an improved immunomodulatory potential.  The efficacy or roflumilast in vitro and in vivo (see accompanying article in this issue) suggests that roflumilast will be useful in the treatment of chronic inflammatory disorders such as asthma and chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpANJYEeXGhmLVg90H21EOLACvtfcHk0lhEf5HPzZCPjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXisVSrsbc%253D&md5=07296ba5ffb2bc94fc154627c8877bdb</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHatzelmann%26aufirst%3DA.%26aulast%3DSchudt%26aufirst%3DC.%26atitle%3DAnti-inflammatory%2520and%2520immunomodulatory%2520potential%2520of%2520the%2520novel%2520PDE4%2520inhibitor%2520roflumilast%2520in%2520vitro%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2001%26volume%3D297%26issue%3D1%26spage%3D267%26epage%3D279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, J. A.</span>; <span class="NLM_string-name">Eady, R. A. J.</span>; <span class="NLM_string-name">Pope, F. M.</span></span> <span> </span><span class="NLM_article-title">Anatomy and Organization of Human Skin</span>. In  <i>Rook’s Textbook of Dermatology</i>, <span class="NLM_edition">7</span>th ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, T.</span>, <span class="NLM_string-name">Breathnach, S.</span>, <span class="NLM_string-name">Cox, N.</span>, <span class="NLM_string-name">Griffiths, C.</span></span>, Eds.; <span class="NLM_publisher-name">Blackwell Publishing</span>: <span class="NLM_publisher-loc">Oxford, U.K.</span>, <span class="NLM_year">2004</span>; pp  <span class="NLM_fpage">4190</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1002%2F9780470750520.ch3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&pages=4190&author=J.+A.+McGrath&author=R.+A.+J.+Eady&author=F.+M.+Popeauthor=T.+Burns&author=S.+Breathnach&author=N.+Cox&author=C.+Griffiths&title=Rook%E2%80%99s+Textbook+of+Dermatology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2F9780470750520.ch3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9780470750520.ch3%26sid%3Dliteratum%253Aachs%26aulast%3DMcGrath%26aufirst%3DJ.%2BA.%26atitle%3DAnatomy%2520and%2520Organization%2520of%2520Human%2520Skin%26btitle%3DRook%25E2%2580%2599s%2520Textbook%2520of%2520Dermatology%26aulast%3DBurns%26aufirst%3DT.%26pub%3DBlackwell%2520Publishing%26date%3D2004%26spage%3D4190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Man, M. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feingold, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holleran, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elias, P. M.</span></span> <span> </span><span class="NLM_article-title">Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunological, and biochemical changes following single versus multiple oxazolone challenges</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1038/sj.jid.5701011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1038%2Fsj.jid.5701011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=17671515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVSksbvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2008&pages=79-86&author=M.+Q.+Manauthor=Y.+Hatanoauthor=S.+H.+Leeauthor=M.+Manauthor=S.+Changauthor=K.+R.+Feingoldauthor=D.+Y.+Leungauthor=W.+Holleranauthor=Y.+Uchidaauthor=P.+M.+Elias&title=Characterization+of+a+hapten-induced%2C+murine+model+with+multiple+features+of+atopic+dermatitis%3A+structural%2C+immunological%2C+and+biochemical+changes+following+single+versus+multiple+oxazolone+challenges&doi=10.1038%2Fsj.jid.5701011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a Hapten-Induced, Murine Model with Multiple Features of Atopic Dermatitis: Structural, Immunologic, and Biochemical Changes following Single Versus Multiple Oxazolone Challenges</span></div><div class="casAuthors">Man, Mao-Qiang; Hatano, Yutaka; Lee, Seung H.; Man, Mona; Chang, Sandra; Feingold, Kenneth R.; Leung, Donald Y. M.; Holleran, Walter; Uchida, Yoshikazu; Elias, Peter M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-86</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Atopic dermatitis (AD) is a chronic dermatosis bearing clin., histol., and immunol. similarities to chronic allergic contact dermatitis (ACD).  AD shows a Th2 cell-dominant inflammatory infiltrate, elevated serum IgE levels, a permeability barrier abnormality, and Staphylococcus aureas colonization.  Repeated hapten challenges reportedly produce a Th2-like hypersensitivity reaction (Th2-like HR).  Here, 9-10 challenges with oxazolone (Ox) to hairless mice also produced a chronic Th2-like HR.  Permeability barrier function and expression of differentiation proteins, filaggrin, loricrin, and involucrin, became abnormal.  CRTH-pos. Th2-dominant inflammatory infiltrate, with increased IL-4 expression, and a large increase in serum IgE levels were obsd.  The barrier abnormality was assocd. with decreased stratum corneum (SC) ceramide content and impaired lamellar body secretion, resulting in abnormal lamellar membranes, as in human AD.  Furthermore, as in human AD, epidermal serine protease activity in SC increased and expression of two lamellar body-derived antimicrobial peptides, CRAMP and mBD3, declined after Ox challenges, paralleling the decrease of their human homologs in AD.  Thus, multiple Ox challenges to normal murine skin produce a chronic Th2-like HR, with multiple features of human AD.  Because of its reproducibility, predictability, and low cost, this model could prove useful for evaluating both pathogenic mechanisms and potential therapies for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3yt_71_rf17Vg90H21EOLACvtfcHk0li6X5u8EInEuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVSksbvN&md5=105e48a210092f15687bcc60e966fdc1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fsj.jid.5701011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.jid.5701011%26sid%3Dliteratum%253Aachs%26aulast%3DMan%26aufirst%3DM.%2BQ.%26aulast%3DHatano%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DMan%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DFeingold%26aufirst%3DK.%2BR.%26aulast%3DLeung%26aufirst%3DD.%2BY.%26aulast%3DHolleran%26aufirst%3DW.%26aulast%3DUchida%26aufirst%3DY.%26aulast%3DElias%26aufirst%3DP.%2BM.%26atitle%3DCharacterization%2520of%2520a%2520hapten-induced%252C%2520murine%2520model%2520with%2520multiple%2520features%2520of%2520atopic%2520dermatitis%253A%2520structural%252C%2520immunological%252C%2520and%2520biochemical%2520changes%2520following%2520single%2520versus%2520multiple%2520oxazolone%2520challenges%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2008%26volume%3D128%26spage%3D79%26epage%3D86%26doi%3D10.1038%2Fsj.jid.5701011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walmsley, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tate, M.</span></span> <span> </span><span class="NLM_article-title">The GADD45a-GFP Green Screen HC assay</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>817</i></span>,  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1007/978-1-61779-421-6_12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1007%2F978-1-61779-421-6_12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=22147576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1OnsrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=817&publication_year=2012&pages=231-50&author=R.+M.+Walmsleyauthor=M.+Tate&title=The+GADD45a-GFP+Green+Screen+HC+assay&doi=10.1007%2F978-1-61779-421-6_12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The GADD45a-GFP GreenScreen HC assay</span></div><div class="casAuthors">Walmsley, Richard M.; Tate, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">817</span>
        (<span class="NLM_cas:issue">Genetic Toxicology</span>),
    <span class="NLM_cas:pages">231-250</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Mutagens, clastogens, and aneugens cause increased expression of the human GADD45a gene.  This has been exploited in the GreenScreen HC genotoxicity assay in which the gene's expression is linked to the expression of green fluorescent protein (GFP).  The host for the reporter construct is the human lymphoblastoid cell line TK6.  It was chosen for its growth as a cell suspension, which allows simple pipet transfers, and for its wild-type p53 competent status.  P53 is required for proper GADD45a expression, and more generally for genome stability.  TK6 is a karyotypically stable cell line.  The GreenScreen assays were designed to facilitate screening, and this is reflected in its microplate format and low compd. requirement.  Protocols are available for testing with and without S9 as a source of exogenous metabolic activation.  Data is collected either spectrophotometrically or by flow cytometry, and a simple spreadsheet converts raw data into dose-response curves, and provides a statistically significant pos. or neg. result.  Extensive validation has demonstrated that in contrast to other in vitro mammalian genotoxicity assays, the GADD45a assays have both high sensitivity and specificity - they very rarely produce misleading pos. results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD0EqM59A-NbVg90H21EOLACvtfcHk0li6X5u8EInEuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1OnsrrO&md5=5d7e9eea24272b838150333970e51ef8</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2F978-1-61779-421-6_12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-61779-421-6_12%26sid%3Dliteratum%253Aachs%26aulast%3DWalmsley%26aufirst%3DR.%2BM.%26aulast%3DTate%26aufirst%3DM.%26atitle%3DThe%2520GADD45a-GFP%2520Green%2520Screen%2520HC%2520assay%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2012%26volume%3D817%26spage%3D231%26epage%3D50%26doi%3D10.1007%2F978-1-61779-421-6_12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, S. F.</span>; <span class="NLM_string-name">Vifian, T.</span>; <span class="NLM_string-name">Horneman, A. M.</span>; <span class="NLM_string-name">Lau, J. F.</span></span> <span> </span><span class="NLM_article-title">Triazolopyridines as Phosphodiesterase Inhibitors for Treatment of Dermal Diseases</span>. PTC Int. Appl. <span class="NLM_patent">WO2010/069322 A1</span>, Jun 24, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+F.+Nielsen&author=T.+Vifian&author=A.+M.+Horneman&author=J.+F.+Lau&title=Triazolopyridines+as+Phosphodiesterase+Inhibitors+for+Treatment+of+Dermal+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNielsen%26aufirst%3DS.%2BF.%26atitle%3DTriazolopyridines%2520as%2520Phosphodiesterase%2520Inhibitors%2520for%2520Treatment%2520of%2520Dermal%2520Diseases%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, S. F.</span>; <span class="NLM_string-name">Larsen, J. C. H.</span></span> <span> </span><span class="NLM_article-title">[1,2,4]Triazolopyridines and Their Use as Phosphodiesterase Inhibitors</span>. PTC Int. Appl. <span class="NLM_patent">WO2013/092739 A1</span>, Jun 27, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=S.+F.+Nielsen&author=J.+C.+H.+Larsen&title=%5B1%2C2%2C4%5DTriazolopyridines+and+Their+Use+as+Phosphodiesterase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNielsen%26aufirst%3DS.%2BF.%26atitle%3D%255B1%252C2%252C4%255DTriazolopyridines%2520and%2520Their%2520Use%2520as%2520Phosphodiesterase%2520Inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, M.</span>; <span class="NLM_string-name">Dahl, A. C.</span>; <span class="NLM_string-name">McParland, J.</span></span> <span> </span><span class="NLM_article-title">Methods for the Preparations of Substituted [1,2,4]triazolo[1,5-a]pyridines</span>. PTC Int. Appl. <span class="NLM_patent">WO2014/206903 A1</span>, Dec 31, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=M.+Larsen&author=A.+C.+Dahl&author=J.+McParland&title=Methods+for+the+Preparations+of+Substituted+%5B1%2C2%2C4%5Dtriazolo%5B1%2C5-a%5Dpyridines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLarsen%26aufirst%3DM.%26atitle%3DMethods%2520for%2520the%2520Preparations%2520of%2520Substituted%2520%255B1%252C2%252C4%255Dtriazolo%255B1%252C5-a%255Dpyridines%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taketani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shii, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ninomiya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, T.</span></span> <span> </span><span class="NLM_article-title">Carboxylesterase in the liver and small intestine of experimental animals and human</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>81</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">924</span>– <span class="NLM_lpage">932</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2007.07.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1016%2Fj.lfs.2007.07.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=17764701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVCmur%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2007&pages=924-932&issue=11&author=M.+Taketaniauthor=M.+Shiiauthor=K.+Ohuraauthor=S.+Ninomiyaauthor=T.+Imai&title=Carboxylesterase+in+the+liver+and+small+intestine+of+experimental+animals+and+human&doi=10.1016%2Fj.lfs.2007.07.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Carboxylesterase in the liver and small intestine of experimental animals and human</span></div><div class="casAuthors">Taketani, Megumi; Shii, Mayumi; Ohura, Kayoko; Ninomiya, Shinichi; Imai, Teruko</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">924-932</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Native PAGE showed carboxylesterase (CES) to be the most abundant hydrolase in the liver and small intestine of humans, monkeys, dogs, rabbits and rats.  The liver contains both CES1 and CES2 enzymes in all these species.  The small intestine contains only enzymes from the CES2 family in humans and rats, while in rabbits and monkeys, enzymes from both CES1 and CES2 families are present.  Interestingly, no hydrolase activity at all was found in dog small intestine.  Flurbiprofen derivs. were R-preferentially hydrolyzed in the liver microsomes of all species, but hardly hydrolyzed in the small intestine microsomes of any species except rabbit.  Propranolol derivs. were hydrolyzed in the small intestine and liver microsomes of all species except dog small intestine.  Monkeys and rabbits showed R-preferential and non-enantio-selective hydrolysis, resp., for propranolol derivs. in both organs.  Human and rat liver showed R- and S-preferential hydrolysis, resp., in spite of non-enantio-selective hydrolysis in their small intestines.  The proximal-to-distal gradient of CES activity in human small intestine (1.1-1.5) was less steep than that of CYP 3A4 and 2C9 activity (three-fold difference).  These findings indicate that human small intestine and liver show extensive hydrolase activity attributed to CES, which is different from that in species commonly used as exptl. animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXCn7QUZQMsLVg90H21EOLACvtfcHk0lhc2IvpG_5zbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVCmur%252FN&md5=6f3bdd3ea26d3a8d48c25d558264832d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2007.07.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2007.07.026%26sid%3Dliteratum%253Aachs%26aulast%3DTaketani%26aufirst%3DM.%26aulast%3DShii%26aufirst%3DM.%26aulast%3DOhura%26aufirst%3DK.%26aulast%3DNinomiya%26aufirst%3DS.%26aulast%3DImai%26aufirst%3DT.%26atitle%3DCarboxylesterase%2520in%2520the%2520liver%2520and%2520small%2520intestine%2520of%2520experimental%2520animals%2520and%2520human%26jtitle%3DLife%2520Sci.%26date%3D2007%26volume%3D81%26issue%3D11%26spage%3D924%26epage%3D932%26doi%3D10.1016%2Fj.lfs.2007.07.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taketani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shii, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosokawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, K.</span></span> <span> </span><span class="NLM_article-title">Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1734</span>– <span class="NLM_lpage">1741</span>, <span class="refDoi"> DOI: 10.1124/dmd.106.009381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1124%2Fdmd.106.009381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=16837570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVCltbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=1734-1741&issue=10&author=T.+Imaiauthor=M.+Taketaniauthor=M.+Shiiauthor=M.+Hosokawaauthor=K.+Chiba&title=Substrate+specificity+of+carboxylesterase+isozymes+and+their+contribution+to+hydrolase+activity+in+human+liver+and+small+intestine&doi=10.1124%2Fdmd.106.009381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine</span></div><div class="casAuthors">Imai, Teruko; Taketani, Megumi; Shii, Mayumi; Hosokawa, Masakiyo; Chiba, Kan</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1734-1741</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Hydrolase activity from human liver and small intestine microsomes was compared with that of recombinant human carboxylesterases, hCE-1 and hCE-2.  Although both hCE-1 and hCE-2 are present in human liver, the dominant component was found to be hCE-1, whereas the hydrolase activity of the human small intestine was found to be predominantly hCE-2.  HCE-2 has a limited ability to hydrolyze large acyl compd. substrates.  Interestingly, propranolol derivs., good substrates for hCE-2, were easily hydrolyzed by substitution of the Me group on the 2-position of the acyl moiety, but were barely hydrolyzed when the Me group was substituted on the 3-position.  These findings suggest that hCE-2 does not easily form acylated intermediates because of conformational interference in its active site.  In contrast, hCE-1 could hydrolyze a variety of substrates.  The hydrolytic activity of hCE-2 increased with increasing alc. chain length in benzoic acid deriv. substrates, whereas hCE-1 preferentially catalyzed the hydrolysis of substrates with short alc. chains.  Kinetic data showed that the detg. factor for the rate of hydrolysis of p-aminobenzoic acid esters was Vmax for hCE-1 and Km for hCE-2.  Furthermore, the addn. of hydrophobic alcs. to the reaction mixt. with p-aminobenzoic acid Pr ester induced high and low levels of transesterification by hCE-1 and hCE-2, resp.  When considering the substrate specificities of hCE-1, it is necessary to consider the transesterification ability of hCE-1, in addn. to the binding structure of the substrate in the active site of the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_5Qby7_S88LVg90H21EOLACvtfcHk0lhc2IvpG_5zbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVCltbvI&md5=b2d3c1d2aee89b647e1c8030daee8c3a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1124%2Fdmd.106.009381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.106.009381%26sid%3Dliteratum%253Aachs%26aulast%3DImai%26aufirst%3DT.%26aulast%3DTaketani%26aufirst%3DM.%26aulast%3DShii%26aufirst%3DM.%26aulast%3DHosokawa%26aufirst%3DM.%26aulast%3DChiba%26aufirst%3DK.%26atitle%3DSubstrate%2520specificity%2520of%2520carboxylesterase%2520isozymes%2520and%2520their%2520contribution%2520to%2520hydrolase%2520activity%2520in%2520human%2520liver%2520and%2520small%2520intestine%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26issue%3D10%26spage%3D1734%26epage%3D1741%26doi%3D10.1124%2Fdmd.106.009381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span>An Explorative
Trial Evaluating the Effect of LEO 39652 Cream 2.5 mg/g in Adults
with Mild to Moderate Atopic Dermatitis (AD). <a href="https://clinicaltrials.gov/ct2/show/NCT02496546" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02496546</a> (accessed May 1, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=An+Explorative%0ATrial+Evaluating+the+Effect+of+LEO+39652+Cream+2.5+mg%2Fg+in+Adults%0Awith+Mild+to+Moderate+Atopic+Dermatitis+%28AD%29.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02496546+%28accessed+May+1%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eirefelt, S.</span>; <span class="NLM_string-name">Hummer, J.</span>; <span class="NLM_string-name">Basse, L. H.</span>; <span class="NLM_string-name">Bertelsen, M.</span>; <span class="NLM_string-name">Johansson, F.</span>; <span class="NLM_string-name">Birngruber, T.</span>; <span class="NLM_string-name">Sinner, F.</span>; <span class="NLM_string-name">Larsen, J.</span>; <span class="NLM_string-name">Nielsen, S. F.</span>; <span class="NLM_string-name">Lambert, M.</span></span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Eirefelt%2C+S.%3B+Hummer%2C+J.%3B+Basse%2C+L.+H.%3B+Bertelsen%2C+M.%3B+Johansson%2C+F.%3B+Birngruber%2C+T.%3B+Sinner%2C+F.%3B+Larsen%2C+J.%3B+Nielsen%2C+S.+F.%3B+Lambert%2C+M.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DEirefelt%26aufirst%3DS." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonnel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legouffe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortensen, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pamelard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, K. T.</span></span> <span> </span><span class="NLM_article-title">MALDI imaging facilitates new topical drug development process by determining quantitative skin distribution profiles</span>. <i>Anal. Bioanal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>410</i></span>,  <span class="NLM_fpage">2815</span>– <span class="NLM_lpage">2828</span>, <span class="refDoi"> DOI: 10.1007/s00216-018-0964-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1007%2Fs00216-018-0964-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=29546543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFOltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=410&publication_year=2018&pages=2815-2828&author=D.+Bonnelauthor=R.+Legouffeauthor=A.+H.+Erikssonauthor=R.+W.+Mortensenauthor=F.+Pamelardauthor=J.+Stauberauthor=K.+T.+Nielsen&title=MALDI+imaging+facilitates+new+topical+drug+development+process+by+determining+quantitative+skin+distribution+profiles&doi=10.1007%2Fs00216-018-0964-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">MALDI imaging facilitates new topical drug development process by determining quantitative skin distribution profiles</span></div><div class="casAuthors">Bonnel, David; Legouffe, Raphael; Eriksson, Andre H.; Mortensen, Rasmus W.; Pamelard, Fabien; Stauber, Jonathan; Nielsen, Kim T.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical and Bioanalytical Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">410</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2815-2828</span>CODEN:
                <span class="NLM_cas:coden">ABCNBP</span>;
        ISSN:<span class="NLM_cas:issn">1618-2642</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Generation of skin distribution profiles and reliable detn. of drug mol. concn. in the target region are crucial during the development process of topical products for treatment of skin diseases like psoriasis and atopic dermatitis.  Imaging techniques like mass spectrometric imaging (MSI) offer sufficient spatial resoln. to generate meaningful distribution profiles of a drug mol. across a skin section.  In this study, the authors use matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) to generate quant. skin distribution profiles based on tissue extinction coeff. (TEC) detns. of four different mols. in cross sections of human skin explants after topical administration.  The four drug mols.: roflumilast, tofacitinib, ruxolitinib, and LEO 29102 have different physicochem. properties.  In addn., tofacitinib was administered in two different formulations.  The study reveals that with MALDI-MSI, the authors were able to observe differences in penetration profiles for both the four drug mols. and the two formulations and thereby demonstrate its applicability as a screening tool when developing a topical drug product.  Furthermore, the study reveals that the sensitivity of the MALDI-MSI techniques appears to be inversely correlated to the drug mols.' ability to bind to the surrounding tissues, which can be estd. by their Log D values.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocPcMlQ4QHu7Vg90H21EOLACvtfcHk0ljGybeTLcu1kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFOltb8%253D&md5=b9c42c78f372eddbd9413ac3bbc5cbeb</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2Fs00216-018-0964-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00216-018-0964-3%26sid%3Dliteratum%253Aachs%26aulast%3DBonnel%26aufirst%3DD.%26aulast%3DLegouffe%26aufirst%3DR.%26aulast%3DEriksson%26aufirst%3DA.%2BH.%26aulast%3DMortensen%26aufirst%3DR.%2BW.%26aulast%3DPamelard%26aufirst%3DF.%26aulast%3DStauber%26aufirst%3DJ.%26aulast%3DNielsen%26aufirst%3DK.%2BT.%26atitle%3DMALDI%2520imaging%2520facilitates%2520new%2520topical%2520drug%2520development%2520process%2520by%2520determining%2520quantitative%2520skin%2520distribution%2520profiles%26jtitle%3DAnal.%2520Bioanal.%2520Chem.%26date%3D2018%26volume%3D410%26spage%3D2815%26epage%3D2828%26doi%3D10.1007%2Fs00216-018-0964-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bodenlenz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragatin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liebenberger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschapeller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulgaropoulos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raml, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatschelhofer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benkali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rony, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinner, F.</span></span> <span> </span><span class="NLM_article-title">Kinetics of clobetasol-17-propionate in psoriatic lesional and non-lesional skin assessed by dermal open flow microperfusion with time and space resolution</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">2229</span>– <span class="NLM_lpage">2238</span>, <span class="refDoi"> DOI: 10.1007/s11095-016-1960-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1007%2Fs11095-016-1960-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=27271272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVOnur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2016&pages=2229-2238&author=M.+Bodenlenzauthor=C.+Dragatinauthor=L.+Liebenbergerauthor=B.+Tschapellerauthor=B.+Boulgaropoulosauthor=T.+Augustinauthor=R.+Ramlauthor=C.+Gatschelhoferauthor=N.+Wagnerauthor=K.+Benkaliauthor=F.+Ronyauthor=T.+Pieberauthor=F.+Sinner&title=Kinetics+of+clobetasol-17-propionate+in+psoriatic+lesional+and+non-lesional+skin+assessed+by+dermal+open+flow+microperfusion+with+time+and+space+resolution&doi=10.1007%2Fs11095-016-1960-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetics of Clobetasol-17-Propionate in Psoriatic Lesional and Non-Lesional Skin Assessed by Dermal Open Flow Microperfusion with Time and Space Resolution</span></div><div class="casAuthors">Bodenlenz, Manfred; Dragatin, Christian; Liebenberger, Lisa; Tschapeller, Bernd; Boulgaropoulos, Beate; Augustin, Thomas; Raml, Reingard; Gatschelhofer, Christina; Wagner, Nathalie; Benkali, Khaled; Rony, Francois; Pieber, Thomas; Sinner, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2229-2238</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: To evaluate the kinetics of topically applied clobetasol-17-propionate (CP-17) in lesional and nonlesional psoriatic skin when released from a com. available low-strength cream using in vivo dermal open-flow microperfusion (dOFM).  Methods: Twelve patients received Dermovate cream (CP-17, 0.05%) on small lesional and nonlesional skin test sites for 14 days, once daily.  On day 1 and 14, dOFM samples were continuously taken in the dermis for 24 h postdose and analyzed by LC-MS/MS.  Probe depths were assessed by 50 MHz ultrasound scanning.  Results: Mixed-effects modeling identified skin condition, treatment duration and probe-depth as kinetics detg. variables.  The time- and depth-resolved intradermal data revealed (i) slower penetration of CP-17 into lesional than into nonlesional skin, (ii) normalized (faster) skin penetration after repeated dosing, and no CP-17 accumulation within the dermis independently of the skin condition.  Conclusions: Intradermal investigation of a highly lipophilic drug released from low-strength cream was successfully performed by using dOFM and timely and spatially, i.e., probe-depth dependent, resolved kinetic data were delivered.  These data support the assumption that the thickened psoriatic stratum corneum might act as trap compartment which lowers the skin penetration rate for lipophilic topical drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowrTpeyI8lrLVg90H21EOLACvtfcHk0ljGybeTLcu1kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVOnur0%253D&md5=4a3b0f91493967632ddfa3a5cd22d992</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1007%2Fs11095-016-1960-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-016-1960-y%26sid%3Dliteratum%253Aachs%26aulast%3DBodenlenz%26aufirst%3DM.%26aulast%3DDragatin%26aufirst%3DC.%26aulast%3DLiebenberger%26aufirst%3DL.%26aulast%3DTschapeller%26aufirst%3DB.%26aulast%3DBoulgaropoulos%26aufirst%3DB.%26aulast%3DAugustin%26aufirst%3DT.%26aulast%3DRaml%26aufirst%3DR.%26aulast%3DGatschelhofer%26aufirst%3DC.%26aulast%3DWagner%26aufirst%3DN.%26aulast%3DBenkali%26aufirst%3DK.%26aulast%3DRony%26aufirst%3DF.%26aulast%3DPieber%26aufirst%3DT.%26aulast%3DSinner%26aufirst%3DF.%26atitle%3DKinetics%2520of%2520clobetasol-17-propionate%2520in%2520psoriatic%2520lesional%2520and%2520non-lesional%2520skin%2520assessed%2520by%2520dermal%2520open%2520flow%2520microperfusion%2520with%2520time%2520and%2520space%2520resolution%26jtitle%3DPharm.%2520Res.%26date%3D2016%26volume%3D33%26spage%3D2229%26epage%3D2238%26doi%3D10.1007%2Fs11095-016-1960-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, G.</span></span> <span> </span><span class="NLM_article-title">Clearance concepts in pharmacokinetics</span>. <i>J. Pharmacokinet. Biopharm.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1007/BF01059626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1007%2FBF01059626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=4764426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A280%3ADyaE2c%252FmtVKisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1973&pages=123-136&author=M.+Rowlandauthor=L.+Benetauthor=G.+Graham&title=Clearance+concepts+in+pharmacokinetics&doi=10.1007%2FBF01059626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Clearance concepts in pharmacokinetics</span></div><div class="casAuthors">Rowland M; Benet L Z; Graham G G</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmacokinetics and biopharmaceutics</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-36</span>
        ISSN:<span class="NLM_cas:issn">0090-466X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSz4Zcsmz7GkKe0F5ixvZgXfW6udTcc2ebdVHDZ_lvMTbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE2c%252FmtVKisw%253D%253D&md5=bf6ffefba3dd092a61fb55bca443973a</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2FBF01059626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01059626%26sid%3Dliteratum%253Aachs%26aulast%3DRowland%26aufirst%3DM.%26aulast%3DBenet%26aufirst%3DL.%26aulast%3DGraham%26aufirst%3DG.%26atitle%3DClearance%2520concepts%2520in%2520pharmacokinetics%26jtitle%3DJ.%2520Pharmacokinet.%2520Biopharm.%26date%3D1973%26volume%3D1%26spage%3D123%26epage%3D136%26doi%3D10.1007%2FBF01059626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Card, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">England, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabrizizad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y. J.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the activity of drugs that inhibit phosphodiesterases</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2233</span>– <span class="NLM_lpage">2247</span>, <span class="refDoi"> DOI: 10.1016/j.str.2004.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=10.1016%2Fj.str.2004.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=15576036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVClur3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=2233-2247&author=G.+L.+Cardauthor=B.+P.+Englandauthor=Y.+Suzukiauthor=D.+Fongauthor=B.+Powellauthor=B.+Leeauthor=C.+Luuauthor=M.+Tabrizizadauthor=S.+Gilletteauthor=P.+N.+Ibrahimauthor=D.+R.+Artisauthor=G.+Bollagauthor=M.+V.+Milburnauthor=S.-H.+Kimauthor=J.+Schlessingerauthor=K.+Y.+J.+Zhang&title=Structural+basis+for+the+activity+of+drugs+that+inhibit+phosphodiesterases&doi=10.1016%2Fj.str.2004.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases</span></div><div class="casAuthors">Card, Graeme L.; England, Bruce P.; Suzuki, Yoshihisa; Fong, Daniel; Powell, Ben; Lee, Byunghun; Luu, Catherine; Tabrizizad, Maryam; Gillette, Sam; Ibrahim, Prabha N.; Artis, Dean R.; Bollag, Gideon; Milburn, Michael V.; Kim, Sung-Hou; Schlessinger, Joseph; Zhang, Kam Y. J.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2233-2247</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) comprise a large family of enzymes that catalyze the hydrolysis of cAMP or cGMP and are implicated in various diseases.  The authors describe the high-resoln. crystal structures of the catalytic domains of PDE4B, PDE4D, and PDE5A with ten different inhibitors, including the drug candidates cilomilast and roflumilast, for respiratory diseases.  These cocrystal structures reveal a common scheme of inhibitor binding to the PDEs: (i) a hydrophobic clamp formed by highly conserved hydrophobic residues that sandwich the inhibitor in the active site; (ii) hydrogen bonding to an invariant glutamine that controls the orientation of inhibitor binding.  A scaffold can be readily identified for any given inhibitor based on the formation of these two types of conserved interactions.  These structural insights will enable the design of isoform-selective inhibitors with improved binding affinity and should facilitate the discovery of more potent and selective PDE inhibitors for the treatment of a variety of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8l4KWCohSy7Vg90H21EOLACvtfcHk0lgHN-wKT3Oljw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVClur3K&md5=0fa91e4b9047e3df3946c526592be396</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2004.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2004.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DCard%26aufirst%3DG.%2BL.%26aulast%3DEngland%26aufirst%3DB.%2BP.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DLuu%26aufirst%3DC.%26aulast%3DTabrizizad%26aufirst%3DM.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26atitle%3DStructural%2520basis%2520for%2520the%2520activity%2520of%2520drugs%2520that%2520inhibit%2520phosphodiesterases%26jtitle%3DStructure%26date%3D2004%26volume%3D12%26spage%3D2233%26epage%3D2247%26doi%3D10.1016%2Fj.str.2004.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XOQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XOQ','PDB','1XOQ'); return false;">PDB: 1XOQ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ZBA" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ZBA','PDB','6ZBA'); return false;">PDB: 6ZBA</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i103"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00797">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_66466"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00797?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00797</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">HPLC traces of key compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00797/suppl_file/jm0c00797_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00797/suppl_file/jm0c00797_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00797/suppl_file/jm0c00797_si_001.pdf">jm0c00797_si_001.pdf (949.62 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00797/suppl_file/jm0c00797_si_002.csv">jm0c00797_si_002.csv (4.0 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The atomic coordinates of <b>40</b> (LEO 39652) bound to PDE4D has been deposited with the Protein Data Bank under the accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ZBA">6ZBA</a>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00797&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-23%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00797" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00797" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67991509feaed1b3","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
